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ABSTRACT 
 
 
 
Viral vectors based on Adeno-associated viruses (AAV) have a broad application 
spectrum including gene therapy and basic research. However, because naturally 
occurring AAV capsids are rarely sufficiently efficient and/or specific for a given 
application, techniques were developed to broaden the existing capsid repertoire. A 
prototype technology is DNA family shuffling where, in a first step, homologous cap 
genes encoding capsid subunits are fragmented and recombined, yielding a viral library 
which can then be subjected to selection in order to enrich promising variants. The aim 
of the present study was to dissect and improve four critical steps along this procedure. 
Firstly (1), two different methodologies for production of cap gene fragments were 
compared, resulting in the identification of DNase I based fragmentation as the most 
robust approach. Interestingly, cap DNA concatamer formation during nested PCR was 
observed, leading to amendment of the PCR purification protocol. Next (2), we studied 
the impact of chimerism on the essential assembly-activating protein (AAP) that is 
encoded in an alternative open reading frame within cap and is recombined as well 
during DNA family shuffling. Importantly, by performing a battery of complementary 
experiments, we were able to show that shuffling of AAP is not impairing its function, i.e. 
the support of particle assembly. Furthermore, no influence on titers was observed for 
wild-type and most chimeric vector productions, altogether relieving long-standing 
concerns about a potential rate-limiting role of AAP for AAV vector generation and 
evolution. Thirdly (3), we established a pioneering in vivo AAV library selection strategy 
in which, unlike most previously reported schemes, we selected novel capsids in specific 
cell types within an organ instead of the organ as a whole. Specifically, we were 
motivated by the facts that liver disease is wide-spread in humans and that hepatic 
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stellate cells (HSC) are known to drive liver fibrosis, thus contributing to disease 
progression. Alas, tools to genetically manipulate HSCs are limited. Therefore, a library 
encompassing 10 capsid variants was selected in HSC by AAV injection into mice, HSC 
isolation and PCR rescue using purified total DNA. Following multiple selection rounds, 
in vivo bulk validation was performed based on next-generation sequencing. In total, 157 
capsid variants were screened in parallel and again, the liver was segregated into the 
single cell types, i.e. hepatocytes, HSC, Kupffer cells and liver sinusoidal endothelial 
cells. Notably, this revealed that the selection was successful as hepatocyte-detargeted 
vectors were identified that showed a strong co-transduction of HSC and Kupffer cells. 
Intriguingly, we noted differences in vector specificity and efficiency on the DNA versus 
the RNA level. In order to even further restrict the new vectors to a given cell type, vector 
cassettes were generated bearing cell-type specific promoters and miRNA binding sites 
to suppress off-targeting in cells expressing these miRNAs. Testing of these constructs 
in vitro gave promising results especially for the miRNA-based detargeting strategy. 
Finally (4), we implemented improvements during the selection and analysis steps, 
including the use of PacBio/SMRT sequencing technology to monitor AAV sequence 
enrichments throughout the course of selection. Additionally, we managed to increase 
the stringency of the PCR rescue of cap genes, by incorporating sample-specific 
barcodes, i.e., short, unique nucleotide stretches, into the AAV library genomes. By 
using these barcodes as a primer during sample recovery, we could isolate single 
libraries out of a complex library mixture, as validated in vitro. In the future, this original 
strategy could be exploited to track individual libraries in vivo upon injection of a mixture 
of libraries, which should in turn help to accelerate the identification of top-performing 
variants for validation studies. In summary, different steps along the powerful 
methodology of DNA family shuffling were improved advancing future vector 
development and the lingering concern about AAP impairment upon shuffling was 
dispersed.   
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 ZUSAMMENFASSUNG 
 
 
Virale Vektoren, die auf dem Adeno-assoziierten Virus (AAV) basieren, haben ein breites 
Anwendungsspektrum in der Gentherapie und der Grundlagenforschung. Allerdings sind 
die natürlich vorkommenden Kapside meist nicht ausreichend effizient und/oder 
spezifisch für eine bestimmte Anwendung, was die Entwicklung von Technologien 
gefördert hat, welche das bestehende Repertoire an Kapsiden erweitern können. Ein 
bekannter Vertreter ist das sogenannte DNA „family shuffling“, bei dem homologe 
Kapsidgene (cap), welche für die Kapsiduntereinheiten kodieren, zunächst fragmentiert 
und anschließend neu rekombiniert werden. Das Ergebnis sind virale 
Kapsidbibliotheken, welche für die Anreicherung vielversprechender Varianten 
selektioniert werden können. Die vorliegende Arbeit adressiert und verbessert vier 
entscheidende Aspekte des Verfahrens. Zuerst (1) wurden zwei Methoden für die 
Herstellung von cap-Fragmenten betrachtet, wobei DNase I-basierte Fragmentierung als 
der robustere Ansatz identifiziert wurde. Interessanterweise wurde während der 
nachfolgenden nested PCR die Ausbildung von DNA-Konkatameren beobachtet, 
woraufhin eine Verbesserung des Protokolls zur PCR-Aufreinigung erfolgte. Als zweites 
(2) untersuchten wir den Einfluss von Rekombination auf das essenzielle Assembly-
activating protein (AAP), welches in einem alternativen Leserahmen des Kapsidgens 
kodiert und daher auch von DNA family shuffling betroffen ist. Mit Hilfe einer Serie 
komplementärer Experimente konnten wir zeigen, dass das „shuffling“ von AAP seine 
Funktion in der Partikelassemblierung nicht beeinträchtigt. Des Weiteren wurde kein 
Einfluss auf die Produktionseffizienz von AAV-Wildtypen und den meisten Chimären 
bestimmt. Diese Ergebnisse mindern bestehende Befürchtungen über eine potenzielle 
schädliche Wirkung von ungewolltem AAP-Shuffling auf AAV Vektorgeneration und –
evolution. Drittens (3) haben wir eine neuartige in vivo AAV Selektionsstrategie 
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entwickelt, bei der neue Kapside in speziellen Zelltypen statt wie bisher im gesamten 
Organ selektioniert wurden. Wir wurden besonders durch die weite Verbreitung von 
Lebererkrankungen im Menschen motiviert sowie durch die Rolle bestimmter Zelltypen 
wie Stellatzellen, die an Leberfibrose beteiligt sind und zum Fortschreiten der Krankheit 
beitragen. Leider sind die bestehenden Methoden zur genetischen Manipulation dieses 
Zelltyps aktuell begrenzt. Deshalb wurde eine virale Kapsidbibliothek bestehend aus 
zehn AAV Serotypen in Stellatzellen in Mäusen selektioniert. Dafür wurde die Bibliothek 
in die Mäuse injiziert, bevor die Stellatzellen isoliert und die erfolgreichen Kapside nach 
DNA-Extraktion mittels PCR amplifiziert wurden. Nach mehreren solcher 
Selektionsrunden wurde für die Validierung ein Hochdurchsatzverfahren basierend auf 
Next-Generation Sequencing gewählt, in dem 157 Kapsidvarianten parallel in Mäusen 
getestet wurden. Hierbei wurde der Anteil dieser Kapside  sowohl in Gesamt-DNA auch 
als in Gesamt-cDNA  aus Stellatzellen, Hepatozyten, Kupfferzellen und 
Lebersinusoidendothelzellen bestimmt. Dies bestätigte eine erfolgreiche Selektion hin zu 
nicht-parenchymalen Zellen, da Kapside identifiziert wurden, die keine Hepatozyten 
mehr transduzieren. Des Weiteren wurde eine starke Ko-Transduktion von Kupfferzellen 
und Stellatzellen beobachtet. Interessanterweise haben wir Unterschiede in Effizienz und 
Spezifität der Kapside auf DNA- und RNA-Ebene festgestellt. Um die Spezifität noch 
weiter zu erhöhen, wurden Vektorkassetten erstellt mit zelltypspezifischen Promotoren 
und miRNA-Bindestellen, welche eine Vektorexpression in miRNA-exprimierenden 
Zellen unterdrücken. Diese generierten Konstrukte wurden einem in vitro Test 
unterzogen, welcher insbesondere die Effizienz der miRNA-basierten Strategie belegte. 
Zuletzt (4) wurde das Potenzial von PacBio/SMRT-Sequenzierung zur umfassenden  
Analyse und Verfolgung angereicherter Kapside auf DNA-Ebene verifiziert. Zusätzlich 
konnten wir durch die Einführung einzigartiger Barcode-Sequenzen in die viralen 
Kapsidbibliotheken eine stringentere PCR-Isolierung der Kapsidgene ermöglichen. 
Barcodes sind probenspezifische Nukleotidsequenzen, die bei Verwendung als 
Bindestelle für Primer die spezifische Isolation einer bestimmten viralen Bibliothek aus 
einer Mixtur erlauben, wie in vitro bestätigt wurde. Darüber hinaus wurde diese 
innovative Strategie eingesetzt, um einzelne Bibliotheken in verschiedenen Organen in 
der Maus zu verfolgen. Dieser Ansatz könnte in zukünftigen Selektionen die 
Identifikation der besten Kandidaten für die Validierung beschleunigen. 
Zusammengefasst wurden verschiedene Schritte bei der potenten Methodik des DNA 
family shuffling verbessert und gleichzeitig die lang bestehende Befürchtung widerlegt, 
dass shuffling von AAP zur Funktionsminderung der zugehörigen Kapside führt. Vereint 
werden die Erkenntnisse und Fortschritte dieser Arbeit die zukünftige AAV 
Vektorentwicklung vereinfachen und beschleunigen.  
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1. INTRODUCTION 
Viral vectors based on Adeno-associated viruses (AAV) are nowadays a widespread tool 
with applications in gene therapy (section 1.1.3), vaccination strategies (Nieto and 
Salvetti 2014) and as a tool for genetic manipulation in basic research. However, it 
remains challenging to restrict genetic manipulation to the target cells of interest. This is 
especially the case for complex organs such as the liver, which is composed of many 
different subpopulations, e.g. stellate cells (section 1.2). In order to target AAVs to 
specific cell types, it is possible to modify the different naturally occurring variants by a 
variety of strategies (section 1.1.4) such as DNA family shuffling, thereby broadening or 
restricting the tropism further. This study aimed at the development of improved vectors 
to target distinct liver cell populations and to broaden our knowledge about aspects of 
AAV biology that might be affected by the herein applied technology of DNA family 
shuffling. 
1.1 THE ADENO-ASSOCIATED VIRUS (AAV) 
The Adeno-associated virus (AAV) was first described and named in 1965 when it was 
identified as a contaminant of an adenoviral stock (Atchison, Casto, and Hammon 1965). 
The virus belongs to the family of Parvoviridae in the genus of Dependoparvovirus 
(Adams et al. 2014). Its non-enveloped icosahedral capsid with a T=1 symmetry has a 
diameter of approximately 22-26 nm and is formed by 60 viral protein (VP) subunits 
(Nonnenmacher and Weber 2012; Goncalves 2005; Madigan and Asokan 2016). They 
are composed of VP1, VP2 and VP3 in an estimated 1:1:10 ratio (Johnson, Ozer, and 
Hoggan 1971). AAVs were initially found to be dependent on adenovirus for successful 
progeny production (Atchison, Casto, and Hammon 1965), but over the years more 
viruses were identified to support the AAV life cycle including e.g. Herpes simplex virus 
and human papilloma viruses (Geoffroy and Salvetti 2005). Most research was 
performed on the prototype serotype 2 (AAV2) which was the variant initially identified. 
To date, 13 serotypes with various tropisms (Table 1-1) and hundreds of natural isolates 
were described, which originate from a wide variety of species including mammals, birds 
and reptiles (Farkas et al. 2004; Flotte and Berns 2005). 
Although many AAV sequences have been isolated little is known about the infectious 
life cycle of wild-type viruses (Berns and Muzyczka 2017). An appropriate in vivo model 
system for studies is not available, therefore scientists are limited to in vitro studies. 
Open questions include the mode of transmission, the infectious dose required or if an 
infection could occur in the absence of a helper virus. Samples from children were 
1 Introduction 
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screened for AAV infection in order to learn more about its spread within humans (Chen 
et al. 2005). Surprisingly, none of the variants identified beared the HSPG binding motif 
(section 1.1.1.2). It was thus suggested that AAV2´s dependency on HSPG is rather a 
result from in vitro propagation and hence, adaptation to cell culture, than resembling the 
natural situation (Chen et al. 2005; Srivastava 2016). 
 
TABLE 1-1: ORIGIN OF THE 13 AAV SEROTYPES 
Serotype Species where it was isolated from Tropism in mice 
AAV1 Laboratory isolate (non-human primate) 
(Hoggan, Blacklow, and Rowe 1966) 
Skeletal muscle (Gao et al. 2002), 
liver (Zincarelli et al. 2008), CNS 
(lesser extend) (Zhang et al. 2011) 
AAV2 Laboratory isolate (human) (Hoggan, 
Blacklow, and Rowe 1966) 
liver (Zincarelli et al. 2008) (lesser 
extent) 
AAV3b Laboratory isolate (non-human primate) 
(Rutledge, Halbert, and Russell 1998) 
Liver, heart (Zincarelli et al. 2008) 
(lesser extend) 
AAV4 Laboratory isolate (non-human primate) 
(Parks et al. 1967) 
Lung, heart (Zincarelli et al. 2008) 
AAV5 Human (Bantel-Schaal and zur Hausen 
1984) 
Liver (Zincarelli et al. 2008) (lesser 
extent) 
AAV6 Laboratory isolate (Rutledge, Halbert, 
and Russell 1998) 
Liver, heart (Zincarelli et al. 2008), 
CNS (lesser extent) (Zhang et al. 
2011) 
AAV7 Non-human primate (Gao et al. 2002) Skeletal muscle (Gao et al. 2002), 
liver, heart (Zincarelli et al. 2008), 
CNS (Zhang et al. 2011) 
AAV8 Non-human primate (Gao et al. 2002)  Liver, heart (Gao et al. 2002) 
AAV9 Human (Gao et al. 2004) ubiquitous (Zincarelli et al. 2008), 
CNS (very efficient) (Zhang et al. 
2011) 
AAVrh10 Non-human primate(Gao et al. 2003) CNS (very efficient) (Zhang et al. 
2011) 
AAV11 Non-human primate (Mori et al. 2004) Muscle, kidney, spleen, lung, heart, 
and stomach (Mori et al. 2004) 
AAV12 Laboratory isolate (non-human primate) 
(Schmidt, Voutetakis, et al. 2008) 
Muscle (intramuscular injection), 
salivary glands (injected directly) 
(Schmidt, Voutetakis, et al. 2008) 
AAV13 Laboratory isolate (non-human primate) 
(Schmidt, Govindasamy, et al. 2008) 
Unknown 
PhD thesis, Anne-Kathrin Herrmann 
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1.1.1.THE BIOLOGY OF THE VIRUS 
 
1.1.1.1. GENOME ORGANIZATION 
AAVs package a single-stranded DNA genome with a size of 4.7 kb (Figure 1-1) 
(Srivastava, Lusby, and Berns 1983). The genome is flanked by inverted terminal 
repeats (ITR) which have a length of 145 bp each of which 125 bp are palindromic and 
form a hairpin structure (Lusby, Fife, and Berns 1980). The remaining single-stranded 
20 bp are designated as the D-sequence (Flotte and Berns 2005). The terminal 
resolution site (TRS) plays an important role during replication and is situated at the 
junction of the hairpin and the D-sequence. The first open reading frame (ORF) rep 
encodes four transcripts resulting in the four nonstructural proteins. The longest version, 
Rep78, is transcribed from the p5 promoter, and the second transcript from this promoter 
results in Rep68 upon alternative splicing. 
 
 
FIGURE 1-1: GENOME ORGANIZATION  
This schematic depicts the genome organization of AAV2. The double-stranded loop at both ends 
and the single-stranded D-sequence belong to the ITR. The genome contains three promoters, 
namely p5, p19 and p40, and two major ORFs, rep and cap. rep yields the non-structural proteins 
Rep78, Rep68, Rep52 and Rep40. Two of these transcripts are directly generated, while the other 
two are the result of splicing as indicated by the diagonal lines. From cap two transcripts are 
produced by using alternative splice acceptor sites, translating into VP1, VP2 and VP3. Within 
cap there is an alternative ORF encoding AAP. 
D Drep cap
p5 p19 p40
Rep78
Rep52
AAP
Rep68
VP2/3
VP1
Rep40
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The two remaining transcripts are transcribed from the p19 promoter that is situated 
within rep. Again, there is an unspliced transcript encoding Rep52 and a shorter, spliced, 
version encoding Rep40. The VPs are transcribed from the second ORF, cap, driven by 
the p40 promoter. Alternative splicing of the p40 transcript, using the same 5´splice 
donor sites but different 3´splice acceptor sites, yields two mRNAs (Trempe and Carter 
1988; Becerra et al. 1988). The mRNA encoding VP1 is generated using a weaker 
acceptor site resulting in fewer transcripts. The second mRNA is derived from the use of 
a strong acceptor site and is therefore present in higher numbers (Flotte and Berns 
2005). This mRNA encodes the remaining two VPs, which are translated using different 
start codons. VP2 uses the alternative start codon ACG whereas VP3 translation starts 
with ATG (Becerra et al. 1985). In 2010, an alternative ORF was identified within cap 
encoding the assembly-activating protein (AAP) which was found to be essential in many 
variants for capsid formation (section 1.1.1.5) (Sonntag, Schmidt, and Kleinschmidt 
2010). 
 
1.1.1.2. INITIAL ATTACHMENT AND INTERNALIZATION 
As for many viruses, initial attachment to the cell is the first major step for AAV infection. 
Usually this is achieved by a local increase of virus concentration at the cell surface by 
attachment to mostly negatively charged glycans or glycoconjugates (Huang, Halder, 
and Agbandje-McKenna 2014). For example, heparan sulfate proteoglycans (HSPG) 
were identified as a glycan moiety for AAV2 (Summerford and Samulski 1998). HSPGs 
are widely expressed which might explain the broad tropism observed for AAV2. Over 
the years, a number of additional co-receptors have been identified for AAV2 such as 
human fibroblast growth factor receptor 1 (FGFR1), αVβ5/α5β1 integrin, hepatocyte 
growth factor receptor (HGFR), and laminin receptor (LamR) (Srivastava 2016). 
Additionally a variety of glycans and co-receptors have been identified for some of the 
other serotypes (Table 1-2) but there are still unidentified interaction partners. For 
instance, the glycan usage for serotypes 7, 8, rh10, 11 and 12 is unknown (Huang, 
Halder, and Agbandje-McKenna 2014). Recently, a more universal receptor named AAV 
receptor (AAVR) has been described (Pillay et al. 2016). Curiously, the first evidence for 
this receptor was found in 1996 when AAV2 particles were incubated with membrane 
fractions identifying a 150 kDa large protein where particles bound to (Mizukami, Young, 
and Brown 1996). Nearly 20 years later, AAVR was rediscovered as an essential 
receptor for AAV2 as a knockout prevented transduction and was confirmed to be the 
previously identified 150 kDa large interaction partner (Pillay et al. 2016; Pillay et al. 
2017). 
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TABLE 1-2: IDENTIFIED RECEPTORS AND CO-RECEPTORS FOR DIFFERENT 
AAV SEROTYPES 
 
co-receptor glycan receptor 
 "universal" 
receptor 
Serotype FGFR1 integrin HGFR PDGFR EGFR LamR HSPG SIA GAL AAVR 
AAV1 
       
α2-3/α2-6 
N-linked  
X 
AAV2 X 
αVβ5/ 
α5β1 
X 
  
x x 
  
X 
AAV3 X 
 
X 
  
x x 
  
X 
AAV4 
       
α2-3 O-
linked  
independent 
AAV5 
   
X 
   
α2-3 N-
linked  
X 
AAV6 
    
X 
 
x 
α2-3/α2-6 
N-linked  
X 
AAV8 
     
x 
   
X 
AAV9 
 
Putative 
   
x 
  
x X 
AAV13 
      
X 
   
AAVR, Adeno-associated virus receptor; EGFR, epidermal growth factor receptor; FGFR1, fibroblast growth 
factor receptor-1; GAL, galactose (terminal N-linked); HGFR, hepatocyte growth factor receptor; HSPG, 
heparin sulfate proteoglycans; LamR, Laminin receptor; PDGFR, platelet-derived growth factor receptor; 
SIA, sialic acids. The table was modified from (Herrmann and Grimm 2018). 
 
 
This receptor is used by a variety of serotypes and variants, e.g. AAVs 1, 3, 5, 6, 8 and 
9. Yet, AAVR is not required for infection with AAV4 and the closely related variant 
AAVrh32.33, indicating the existence of another entry mechanism (Dudek et al. 2018).  
After attachment to the cell, AAVs are internalized by a variety of mechanisms. To date, 
clathrin-mediated endocytosis as well as clathrin-independent pathways and 
macropinocytosis were described, directing the particles to either an infectious or non-
infectious pathway (Berry and Asokan 2016).  
 
1.1.1.3. INTRACELLULAR TRAFFICKING AND NUCLEAR ENTRY 
After internalization, the virus particles traffic in vesicles presumably to early endosomes 
and further towards the trans-Golgi network (TGN) (Berry and Asokan 2016). The 
transfer towards the TGN was found to be essential for successful transgene expression 
(Nonnenmacher, Cintrat, et al. 2015). Interestingly, the previously identified AAVR 
receptor localizes intracellularly to the Golgi apparatus which implies a potential role of 
AAVR for this trafficking pathway (Pillay and Carette 2017). Additionally, a role of 
autophagy in intracellular trafficking in hepatocytes was discovered as yet another 
important mechanism (Hosel et al. 2017).  
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The escape into the cytosol is mediated by the phospholipase A2 (PLA2) domain found 
at the N-terminus of VP1 (Girod et al. 2002; Stahnke et al. 2011). Usually this domain is 
buried within the capsid but upon trafficking through the endosomes the N-termini of VP1 
and VP2 are exposed (Sonntag et al. 2006). These structural changes of the capsid are 
probably partially mediated by the action of cellular proteases, as acidification of the 
compartments alone is required but not sufficient to prepare the capsid for subsequent 
trafficking steps (Nonnenmacher and Weber 2012). For example, the inhibition of the 
endosomal cathepsins B and L led to a reduction in transgene expression for AAVs 2 
and 8 but not for AAV5 (Akache et al. 2007). The journey of the AAV via the endosomal 
pathway and thus, subsequent conformational changes in the capsid, is essential for 
infectivity as virions microinjected into the cytoplasm or nucleus failed to support 
infection (Sonntag et al. 2006; Nonnenmacher and Weber 2012). 
Once the virions are in the cytosol, they gather in the perinuclear region (Bartlett, 
Wilcher, and Samulski 2000). Curiously, only a subfraction of the particles 
(approximately 30%) actually enter the nucleus (Xiao et al. 2012). For entry, a potential 
role of the nuclear pore complex (NPC) was suggested (Kelich et al. 2015; Nicolson and 
Samulski 2014). Furthermore, the VPs themselves play an important role. Within the 
capsid, four so-called basic regions (BR) are found, three of which (BR1-3) have been 
implied in nuclear entry. Mutations in BR1-3 reduce transduction rates and there is 
evidence that BR1-3 can act as nuclear localization signals (Sonntag et al. 2006; 
Johnson et al. 2010; Berry and Asokan 2016). Furthermore, an interaction of BR2 and 
BR3 with Importin-beta, a protein known to shuttle cargo through the NPC, was 
confirmed in varying extents across different serotypes (Nicolson and Samulski 2014). 
Finally, upon reaching the nucleus AAV2 virions enter the nucleoli as intact particles 
(Sonntag et al. 2006; Johnson and Samulski 2009). 
 
1.1.1.4. CAPSID DISASSEMBLY AND REPLICATION 
In order to release the viral genome, AAV2 needs to exit the nucleolus into the 
nucleoplasm (Johnson and Samulski 2009). The rate-limiting step is now the conversion 
of a single-stranded genome into double-stranded DNA. Once freed from the virion shell, 
the minus and plus strand may anneal thereby forming a double-stranded genome and 
thus, second strand synthesis is circumvented (McCarty 2008). Replication of the 
genome is initiated at the ITR on the 5´end as it already offers a free hydroxyl group 
which can be used for transcription initiation by the host replication machinery (Chandler 
et al. 2013). A second strand will be synthesized including replication of the 3´ITR 
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(Figure 1-2). In order to replicate the 5´ITR, a nick is generated by the Rep proteins at 
the terminal resolution site in the parental strand resulting in yet another 3´hydroxyl 
group which allows replication of the 5´ITR. Finally, the ITRs refold, leading to separation 
of the two strands, and during this process, the sequence of the ITRs flips. This would be 
a simplified model and still some aspects remain enigmatic. For instance, it seems that 
the capsid does not fully disassemble and a role for the capsid proteins themselves for 
second-strand synthesis and subsequent transcription was implied (Berry and Asokan 
2016). Furthermore, the kinetics seem to differ among serotypes and cell type 
(Nonnenmacher and Weber 2012).  
The replication of the genome and subsequent progeny production can only occur in the 
presence of a helper virus. If such a helper is not available, only a small quantity of the 
two larger Rep proteins Rep78/68 will be expressed from the p5 promoter (Weitzman 
and Linden 2011). The residual expression of Rep78/68 allows binding and redirecting 
the genome to a certain locus in the human genome to mediate integration (Surosky et 
al. 1997). This locus situated on chromosome 19 is called AAVS1 and is regarded as a 
safe harbor for genetic engineering (Kotin et al. 1990; Samulski et al. 1991; Buning and 
Schmidt 2015). Whereas the replication of the genome takes place in the nucleoplasm, 
the capsids for AAV2 will preform in the nucleolus (Goncalves 2005; Wistuba et al. 
1997). Once the capsids translocate into the nucleoplasm, the minus- and plus-stranded 
genomes are packaged with equal efficiencies (McCarty 2008). Another essential factor 
for capsid assembly is the recently discovered assembly-activating protein (section 
1.1.1.5). 
 
 
FIGURE 1-2: REPLICATION OF THE AAV GENOME 
The schematic depicts the replication of the AAV genome. The free hydroxyl group of the 5´ITR is 
used to initiate replication (indicated by the dotted line). Replication proceeds through the 3´ITR. 
A nick is generated within the terminal resolution site (TRS) thereby generating yet another 
3´hydroxyl which can be used to copy the 5´ITR. Finally, the strands will displace from each other. 
Newly synthesized DNA is shown in red.  
 
TRS
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1.1.1.5. THE ASSEMBLY-ACTIVATING PROTEIN (AAP) 
AAP was identified in 2010, nearly 45 years after the initial discovery of AAV (Sonntag, 
Schmidt, and Kleinschmidt 2010). This study shed light on contradicting findings which 
were present in the field back then. There were attempts to assemble AAV2 capsids with 
VP3 only which was pursued by two different strategies. If only VP3 was subcloned into 
an expression plasmid, no capsids assembled (Ruffing, Zentgraf, and Kleinschmidt 
1992). However, if the full-length cap gene with mutated VP1 and VP2 start codons was 
used, capsid formation could be observed (Rabinowitz, Xiao, and Samulski 1999). 
Subsequently, the study identified a protein in the second ORF whose translation is 
initiated by a non-conventional CTG start codon (Sonntag, Schmidt, and Kleinschmidt 
2010). Furthermore, the authors designed a battery of cap mutants and found some of 
them were defective in capsid assembly. This phenotype could be rescued by trans-
complementation with this alternative protein. Hence, it was dubbed assembly-activating 
protein. Soon after, a role of AAP for AAV variants other than AAV2 was confirmed, 
namely, AAV1, AAV5, AAV8 and AAV9 (Sonntag et al. 2011).  
The exact mechanism by which AAP promotes capsid assembly is still not completely 
understood. An interaction of the N-terminus of AAP with the C-terminus of VP was 
suggested (Naumer et al. 2012). AAP2 localizes to the nucleolus and a role for 
transporting VPs to the nucleolei was implied initially (Sonntag, Schmidt, and 
Kleinschmidt 2010). However, when the nuclear and nucleolar localization signals were 
identified at the C-terminus of AAV2, the notion was raised that localization is a 
coincidence (Earley et al. 2015). Bioinformatical analysis of AAP5 revealed a possible 
absence of nucleolar targeting and led to the hypothesis that AAV5 might be excluded 
from the nucleolus. Nonetheless, the necessity of nucleolar localization might be at least 
valid for AAV2. Recently, the localization of AAPs from different serotypes was studied 
and indeed, they were found in different compartments (Grosse et al. 2017).  
In the same study, another assay system was presented to study AAP knockouts. 
Instead of using constructs solely expressing VP3, the full-length cap gene was mutated. 
The CTG start codon was changed and an early stop codon was introduced (Grosse et 
al. 2017). Thereby a more natural system was designed to study the role of AAP for 
capsid assembly. Curiously, the AAP2 mutant still showed low VP level expression which 
could be stabilized to wild-type levels by inhibition of the proteasome. Although VPs were 
protected from degradation capsid assembly was not observed. Possibly, AAP protects 
the VPs from degradation, by fostering capsid assembly, and a role as scaffold or 
chaperone was suggested. 
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1.1.2. THE USE OF AAVS AS RECOMBINANT VECTORS 
The generation of plasmids containing all viral elements paved the way for the in vitro 
production of AAVs. These initial plasmids contained the ITRs, AAV2 rep and cap and 
gave rise to viral progeny in the presence of adenovirus (Laughlin et al. 1983; Samulski 
et al. 1982) (Figure 1-3 A). Soon after, the ITRs were identified to be the viral element 
sufficient for genome packaging, and the viral genes could be easily replaced by a gene 
of interest (McLaughlin et al. 1988; Samulski, Chang, and Shenk 1989). For production 
of such recombinant AAV (rAAV) particles, the presence of a helper virus and the 
expression of the AAV genes in trans was required. The production system was 
improved when adenoviral proteins required for AAV replication were identified and 
subcloned into a plasmid (Grimm et al. 1998; Xiao, Li, and Samulski 1998; Matsushita et 
al. 1998) (Figure 1-3 B). This strategy required no co-infection with the cytopathic 
helpervirus and AAV stocks were free of adenoviral contamination.  
Within the cell, the recombinant vector genomes will persist episomally as long as the 
cells do not divide (Duan et al. 1998). One limitation of conventional single-stranded 
vectors is the requirement of second-strand synthesis for transgene expression 
(Ferrari et al. 1996; Fisher et al. 1996). This process requires time and is potentially 
inefficient (Wang et al. 2003). As a solution, self-complementary vectors were 
developed that were shown to mediate more efficient transduction than their single-
stranded counterparts (McCarty, Monahan, and Samulski 2001). This was achieved 
by introducing a mutation into the terminal resolution site in one of the ITRs. As a 
consequence, the strands cannot be displaced from each other during vector 
replication (Wang et al. 2003; McCarty et al. 2003) (Figure 1-3 C). Instead replication 
proceeds through the mutated ITR until the intact ITR is reached again and 
resolution can occur. However, self-complementary vectors can only package half 
the size of wild-type AAV, i.e., approximately 2.2 kb.  
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FIGURE 1-3: VECTORSYSTEM 
This schematic depicts the two kinds of vector systems. (A) In case of the wild-type virus, the viral 
genes (rep and cap) are flanked by inverted terminal repeats (ITRs) that mediate packaging. For 
successful wild-type progeny production, the functions supplied by a helper are essential. Either 
they are supplied by the helper virus itself or encoded by a plasmid (Adh). (B) For production of 
recombinant vectors, the viral genes are replaced by a transgene and transfected into HEK293T 
cells along with the Adh plasmid and a plasmid encoding rep and cap in trans. (C) For the 
generation of rAAVs, two genome configurations are available. Single-stranded vector genomes 
package cargo resembling the size of the natural genome whereas self-complementary vectors 
bear a mutated ITR (in red) that prevents resolution during replication. Therefore, the vector 
genome will be double-stranded and, hence, half of the size can be packaged. 
 
1.1.3. GENE THERAPY 
If a disease is the result of a genetic disorder, usually only the symptoms can be treated 
without curing the patient. This constitutes a life-long burden for the patient and the 
health system. The possibility of targeted manipulation of patient DNA, i.e. gene therapy, 
raised the hope for a curative treatment. This is achieved by introducing nucleic acids 
into the human cells to correct a mutated gene, introduce a functional copy of the 
Self-
complementary
A
B
ITR ITRrep2 cap
Adh
Adenovirus
e.g. HEK293T
ITR ITRtransgene
Adh
e.g. HEK293T
rep2, cap
in trans
C
Single-
stranded
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dysfunctional version or to knock out a malfunctioning gene (Kay 2011). Next to the 
treatment of inherited diseases, gene therapy is investigated as well to cure cancer. 
Viruses are the vehicle of choice since they naturally evolved to infect a cell by delivering 
its genetic cargo. 
To date, two gene therapies based on AAV vectors have been already approved in the 
Western world and many more are in clinical trials. In 2012, Glybera was the first gene 
therapy approved in Europe. An AAV1-based vector was injected intramuscularly to treat 
lipoprotein lipase deficiency (Bryant et al. 2013). Very recently, the second AAV based 
therapy was approved in the US. Luxturna treats inherited retinal disease and is 
delivered by AAV2 (Ameri 2018).  
There are several advantages of the use of AAVs as vehicles for gene transfer in 
therapeutic applications compared to other viral vectors, such as integrating retro- or 
lentiviruses. AAV exhibits a low immunogenic profile and is not associated with any 
human disease (Boutin et al. 2010). On the contrary, it is even believed to have a 
protective effect against certain diseases (Flotte and Berns 2005; Berns and Muzyczka 
2017). For example, women seropositive for AAV were less likely to develop cervix 
carcinoma caused by human papilloma virus (Smith et al. 2001).  
In contrast to e.g. lentiviruses that integrate into the human genome, AAVs mainly persist 
episomally and thus have a greatly reduced carcinogenic potential (Buchholz, Friedel, 
and Buning 2015). When integration profiles were analyzed from patients receiving 
Glybera, a random integration pattern was observed, which most likely occurred during 
repair of double-strand breaks by non-homologous end-joining (Kaeppel et al. 2013; 
Miller et al. 2005). However, the integration frequency was much lower compared to 
vectors derived from integration-competent retroviruses (Kaeppel et al. 2013). The high 
risk associated with integrating viral vectors has been seen with retroviral treatment of X-
linked severe combined immunodeficiency (SCID) when five out of 20 patients 
developed leukemia (Kay 2011). While the AAV episome persists in non-dividing cells, it 
will eventually be lost in dividing cells, as the vector genome will not be replicated along 
and be diluted out. Another advantage is their small capsid size in comparison to 
lentiviruses which is believed to lead to a deeper tissue penetration (Buchholz, Friedel, 
and Buning 2015).  
One downside of the use of AAV as vectors for gene therapy is the existence of 
neutralizing antibodies within the human population that might limit the efficacy of the 
treatment. For example, the seroprevalence for AAV2 ranges from 30% in the US to 60% 
in Africa (Calcedo et al. 2009). Another study conducted with samples from France 
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observed the highest prevalence of neutralizing antibodies against AAV2 (59%) followed 
by AAV1 (50.5%) (Boutin et al. 2010). Surprisingly, neutralizing antibodies against AAV6 
were less common (37%) although it shares 96% homology with AAV1. The other 
serotypes tested showed a low incidence of neutralizing antibodies, namely, AAV5 
(3.2%), AAV8 (19%) and AAV9 (33.5%), making them attractive choices for gene 
therapy.  
 
1.1.4. CAPSID MODIFICATIONS 
Nature has already provided scientists with a great repertoire of naturally occurring 
variants that infect a variety of different cells. However, these do not always fulfill the 
requirements needed in a certain situation due to a lack in cell tropism or efficiency. For 
successful vector transgene expression, delivery is the first important step. A variety of 
technologies have been developed to alter the capsid, thereby broadening the tropism 
further. Modification of the capsid also overcomes one drawback of natural isolates, 
especially for therapeutic approaches: the presence of neutralizing antibodies within the 
population. There are two main strategies for capsid modification, namely, rational 
design (section 1.1.4.1) and directed evolution (section 1.1.4.2) of randomized capsid 
libraries. Recently, a third strategy identified in silico novel ancestral AAV variants based 
on the reconstruction of the evolutionary lineage of present AAV sequences (Zinn et al. 
2015). 
 
1.1.4.1. RATIONAL DESIGN 
There are two approaches to rationally redirect the capsids to a given target: chemical 
modification or genetical alteration. One example for chemical modification is the 
coupling of receptorspecific antibodies to the capsid after production (Bartlett et al. 
1999). However, thermal instability and uncertainties about in vivo applications make this 
strategy less favorable (Daya and Berns 2008). In another scenario, the ligand 
recognizing the receptor was coupled to streptavidin and the capsids were biotinylated 
(Ponnazhagan et al. 2002).  
In genetic modification strategies, the cap gene itself is altered to encode the redirecting 
element. There are certain peptides known that specifically bind to a given cell type, and 
the AAV capsid tolerates the insertion of small peptides into the capsid. In an early 
attempt, the L14 peptide binding to integrin receptors was inserted into the AAV2 capsid 
at different positions (Girod et al. 1999). All mutants were able to produce particles, and 
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one of them was successfully retargeted to cell lines which were refractory to AAV2 wild-
type infection but bore receptors recognized by L14. 
In another study, designed ankyrin repeat proteins (DARPINs) specific for the protein 
Her2/neu were fused to the N-terminus of VP2 (Munch et al. 2013). Her2/neu is broadly 
expressed on tumor cells. AAVs were successfully targeted to these cells, and tumor 
growth in a mouse model was reduced by delivery of a suicide gene. One potential 
drawback observed was the generation of particles devoid of VP2-DARPIN incorporation 
resulting in unwanted off-targeting. This could be resolved by adapting the purification 
process for capsids with incorporated DARPINs (Munch et al. 2015). 
Next to the insertion of small peptides and DARPINs, another option to redirect capsids 
is the specific mutation of amino acids. For example, the basic patch encompassing 
arginines at positions 484, 487, 585 and 588 and lysine at position 532 is necessary to 
mediate HSPG binding of AAV2 (Kern et al. 2003; Opie et al. 2003). Residues R484, 
R487 and K532 are located on one capsid subunit whereas R585 and R588 are present 
on another. Mutation of R585 and R588 abolishes the HSPG binding capability. Vice 
versa, this loop can also be introduced into non-HSPG-binding variants, such as AAV5, 
enabling heparin binding (Opie et al. 2003).  
Although the strategy of rational design yielded some success stories, it has the inherent 
drawback that prior knowledge of capsid structures is required which is not always 
available. Furthermore, in some cases, redirecting peptides act differently in different 
serotypes, as shown with the peptide 7m8. In the context of AAV2, it was shown to 
mediate efficient transduction of mouse retina (Dalkara et al. 2013). However, upon 
engraftment into other serotypes the tropism differed in some cases (Khabou et al. 
2016). This suggests that the peptide itself is not the sole mediator of this effect but that 
the surrounding capsid structure is important, too. Therefore, screening methods based 
on capsid libraries constitute a feasible alternative. 
 
1.1.4.2. DIRECTED EVOLUTION 
Directed evolution is based on screening of a library containing a large amount of 
different AAV variants on the cell type of interest and selecting for variants that are able 
to transduce the target cells efficiently. The first step requires the creation of a plasmid 
library which then can be used for the preparation of a viral library (Grimm and 
Zolotukhin 2015). The viruses are then subjected to a selection pressure by e.g. infecting 
a cell of interest or a target organ. The cap sequences of the variants that successfully 
entered the target are recovered and used for subsequent production of secondary 
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libraries. After iterative selection on the target, single candidates are selected and further 
characterized. Ideally, they will have gained novel characteristics as compared to the 
wild-type. There are three widely used strategies to produce the viral libraries: error-
prone PCR, insertion of a peptide library and DNA family shuffling. In principle, all of 
these techniques can be combined (Figure 1-4). 
In error-prone PCR, the cap gene is mutated during the PCR amplification step thereby 
creating libraries based on one serotype (Perabo et al. 2006; Maheshri et al. 2006). 
However, only a few point mutations per gene will be introduced and some of them might 
be deleterious. Perabo et al. observed that their average rate of 5.7 mutations per clone 
dropped to 0.9 after production (Perabo et al. 2006). Still, this approach can be powerful 
as exemplified with the variant EP1.9 which originated from a library generated by error-
prone PCR (Asuri et al. 2012). In this variant, a single amino acid (R459G) was mutated 
in comparison to AAV2. Interestingly, several libraries generated by shuffling, error prone 
PCR and peptide display were screened in this study in human embryonic stem cells in 
parallel and EP1.9 was the most efficient capsid variant. 
In the case of peptide display libraries, randomized small peptides are inserted into a 
tolerated position within the capsid and the resulting library is selected on the target of 
interest (Muller et al. 2003; Perabo et al. 2003). One successful example for selecting a 
new variant based on peptide display libraries was the already mentioned identification 
of the peptide 7m8 in the AAV2 context, which transduces retinal cells (Dalkara et al. 
2013).  
 
FIGURE 1-4: TECHNIQUES TO GENERATE AAV CAPSID LIBRARIES 
The schematic depicts the different methods to generate viral libraries. Error-prone PCR 
introduces random mutations into the cap gene (depicted by asterisks). Additionally, randomized 
peptides can be integrated into tolerated regions of the capsid. Furthermore, based on homology, 
DNA family shuffling can yield chimeric capsids. A combination of all strategies can be applied as 
well. 
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FIGURE 1-5: DNA FAMILY SHUFFLING 
The schematic depicts the different steps for the generation of shuffled libraries by DNA family 
shuffling. Initially, full-length genes are fragmented and used as templates for a first primer-less 
PCR. Based on homology, fragments will self-prime forming chimeric variants. In a second PCR, 
the chimeras will be amplified and, in the case of AAV cap genes, subcloned into an acceptor 
plasmid by PacI/AscI digestion. Upon ligation and transformation, a plasmid library is produced 
that can be used for virus production. The asterisks indicate steps that were dissected 
experimentally in this work. 
 
The latter approach only yields a diversification at the C-terminal part of the VPs, where 
the peptide was inserted. However, since N-terminal elements are required for e.g. 
intracellular trafficking, it might be favorable to diversify these positions as well. Towards 
this aim, DNA family shuffling is an intriguing approach (Stemmer 1994b, 1994a). Here, 
DNA of closely related proteins can be fragmented and used in a primer-less PCR 
(Figure 1-5). Due to homology, complementary ends will partially anneal and will be filled 
up by the polymerase. This yields chimeric sequences consisting of stretches from the 
parental sequences. DNA family shuffling was introduced into the AAV field in 2008, 
resulting in the identification of the chimera DJ (Grimm et al. 2008). A library 
encompassing eight wild-type viruses was subjected to five rounds of selection. In one 
selection scheme the viral library was incubated with intravenous immunoglobulins 
(IVIG) prior to infection thereby eliminating immunoprevalent variants. The resultant 
variant DJ is a recombinant of AAV2, AAV8 and AAV9 and was found to have an 
immune evasion phenotype compared to its parents. DJ transduces a variety of cell lines 
in vitro but retained liver tropism in mice in vivo (Grimm et al. 2008; Liu and Moon 2016). 
Independently, two more groups published the DNA family shuffling approach soon after 
(Koerber, Jang, and Schaffer 2008; Li et al. 2008). Since then, a number of groups have 
performed shuffling on the AAV cap gene and have selected the resulting libraries in 
different targets. In the beginning, most studies focused on cell lines or organs in vivo of 
which a selection can be seen in Table 1-3.  
In recent years, selection strategies no longer solely focused on the complete organ but 
instead attempted to enrich capsids in specific cellular subpopulations. One study made 
use of a Cre recombinase specifically expressed in astrocytes within the brain. At the 
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ligation
Fragmentation Primerless
PCR
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PCR
Plasmid 
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3´end of the cap gene, a sequence was inserted that was flipped upon Cre treatment. 
This reverted sequence was used as primer binding site during the PCR rescue for 
capsid variants that successfully entered Cre-positive target cells. This led to the 
identification of the AAV9-based peptide variant PHP.B (Deverman et al. 2016). In 
another recent example, a comparable strategy was applied to enrich variants for 
efficient gene transfer in murine neuronal stem cells in the subventricular zone of the 
brain (Ojala et al. 2018). 
 
TABLE 1-3: CHIMERAS ACQUIRED BY DNA FAMILY SHUFFLING 
Chimera Derived from Selection on Details Reference 
DJ AAV2, AAV8, AAV9 Human hepatoma 
cell line 
Adenovirus 
coinfection 
(Grimm et al. 
2008) 
LK03 Parental library composed 
of AAV1-4, AAV6, AAV8-9 
(mostly AAV3b)  
Human hepatocytes 
(xenograft mouse 
model) 
Adenovirus 
coinfection 
(Lisowski et al. 
2014) 
M41 AAV1, AAV6-8 Muscle (mouse) PCR rescue (Yang et al. 
2009) 
B1 Parental library composed 
of AAV1-2, AAV4-6, AAV8-
9, AAVrh.8, AAVrh.10, 
AAVrh.39,  AAVrh.43, no 
clear assignment possible 
(mostly AAV8)  
Brain (mouse) PCR rescue (Choudhury et 
al. 2016) 
HAE-1/ 
HAE-2 
AAV1, AAV6, AAV9 (HAE-2 
only) 
Human airway 
epithelium 
Adenovirus 
coinfection 
(Li et al. 2009) 
AAV2.5T AAV2, AAV5 in 
combination with error 
prone PCR 
Human airway 
epithelium 
Adenovirus 
coinfection 
(Excoffon et 
al. 2009) 
Chimeric-
1829 
AAV1-2, AAV8-9 CS1 (hamster 
melanoma) cell line 
Adenovirus 
coinfection 
(Li et al. 2008) 
AAV-
U87R7-
C5 
AAV1-2, AAVrh.8, 
AAVrh.10 with additional 
mutations 
U87 (human glioma 
cell line) 
Adenovirus 
coinfection 
(Maguire et al. 
2010) 
32/ 83 Parental library composed 
of AAV1-6, AAV8 (E531K) 
and AAV9 (no clear 
assignment possible at 
some positions) 
Neuron enriched 
regions 
PCR rescue (Gray et al. 
2010) 
Olig001 AAV1-2, AAV6, AAV8-9 Striatal cells (rat) PCR rescue (Powell et al. 
2016) 
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1.2. THE LIVER 
The liver is a vital organ that fulfills a variety of functions such as glycogen storage, 
production of hormones, xenobiotic transformation and protein synthesis (LeCluyse et al. 
2012). Additionally, at any given moment it receives approximately 25-30% of the total 
blood within the human body. Furthermore, immune tolerance is generated there and, 
due to the abundance of cells with antigen-presenting capability, the liver is important for 
an immune response (Doherty 2016). 
 
1.2.1. ORGANIZATION OF THE LIVER 
Hepatocytes are executing most functions associated with the liver and constitute 80% of 
the total liver mass (Godoy et al. 2013). Whereas the hepatocytes are referred to as 
parenchymal cells, the remaining cell fraction are the non-parenchymal cells (NPCs). 
Within the total cell population, 60% are the parenchymal cells and the remaining 40% 
the NPCs (LeCluyse et al. 2012). The NPCs only constitute 6.5% of the total liver volume 
and next to Kupffer cells, hepatic stellate cells and liver sinusoidal endothelial cells 
(LSEC), other cell types are present. For example, cholangiocytes build the biliary ducts 
and oval cells represent a reservoir of stem cell-like cells.   
 
 
FIGURE 1-6: ARCHITECTURE OF THE LIVER  
 (A) The hexagonally shaped lobule is the structural unit of the liver and characterized by the 
central vein (CV) in the middle and the portal triad (PT) at the corners. The PT consists of the 
portal vein (PV), the bile duct (BD) and a hepatic artery (A). The functional unit is the acinus 
created by zonation of hepatocyte function due to an oxygen gradient indicated by the blue arrow. 
(B) The cell types of the liver encompass hepatocytes and the non-parenchymal cell fraction: liver 
sinusoidal endothelial cells (LSECs), Kupffer cells and stellate cells. 
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The liver´s structural unit is the hexagonally shaped lobule (Godoy et al. 2013) (Figure 
1-6 A). The portal triad is situated at the corners of the hexagon and is composed of the 
portal vein, a hepatic artery and a bile duct. In the center, the central vein can be found 
where hepatocytes radiate to the periphery of the hexagon. Usually such a cord is one 
hepatocyte thick, and blood is flowing from the artery and the portal vein along the 
sinusoids to the central vein (LeCluyse et al. 2012). As a consequence, an oxygen 
gradient is generated and this describes the functional unit of the lobule namely the 
acinus.   
The major cell types within the NPC fraction are Kupffer cells, stellate cells and LSECs 
(Figure 1-6 B). The sinusoids are lined by LSECs and constitute approximately 20% of 
the liver cell population (Kmiec 2001). These endothelial cells have openings in their 
plasma membrane called fenestrae (Godoy et al. 2013). They allow the diffusion of small 
molecules such as hormones, proteins and toxicants from the blood to the hepatocytes.  
Furthermore, they bear scavenger receptors for the uptake of supposed antigens and 
can act as antigen-presenting cells to T-cells, which might play a role for immunological 
tolerance.  
The space of Disse is located between hepatocytes and LSECs (LeCluyse et al. 2012). 
Stellate cells can be found there and they constitute around 6% of the liver cell 
population. In a quiescent state, stellate cells are a storage place for vitamin A and they 
participate in regeneration. Kupffer cells are liver-resident macrophages situated in the 
sinusoids where they screen the incoming blood derived from the digestive tract for 
pathogens (Godoy et al. 2013). They contribute 15% of the liver cell population. Upon 
recognition, they can launch an immune response by secretion of e.g. cytokines thereby 
involving the other cells in the liver in the inflammatory response.   
 
1.2.2. DISEASE DEVELOPMENT AND PROGRESSION 
Approximately one million people die per year from chronic liver disease caused by e.g. 
viral hepatitis and alcohol abuse (Fernandez-Iglesias and Gracia-Sancho 2017). Upon 
liver injury stellate cells can convert into an activated state where they replicate and 
deposit excess extracellular matrix (LeCluyse et al. 2012). It is thought that this 
contributes to liver fibrosis and disease progression possibly leading to liver cirrhosis. 
Usually, pathogens are cleared from the blood but there are some which can 
successfully establish their infection in the liver, such as the hepatitis viruses and 
subspecies from the malaria-causing parasite Plasmodium. There are two possibilities 
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how the pathogen reaches the hepatocytes (Protzer, Maini, and Knolle 2012). In one 
scenario, they leave the blood stream through the fenestrae of LSECs and diffuse 
through the space of Disse to their target. Alternatively, the pathogens might traverse 
through other cells such as LSECs and Kupffer cells. Indeed, it was shown for 
Plasmodium that the transfer through Kupffer cells actually increases infection efficiency 
(Prudencio, Rodriguez, and Mota 2006). 
1.3. AIMS OF THE THESIS 
Viral vectors based on AAVs have a wide range of applications including gene therapy 
and basic research. However, most of the naturally occurring variants have the drawback 
that they are not directly applicable due to e.g. pre-existing immunity or a lack of 
efficiency and/or specificity. Therefore, methods to broaden the AAV repertoire are both 
promising and urgently needed to overcome existing hurdles and to foster clinical AAV 
application. One of these techniques is DNA family shuffling, whereby complex viral 
capsid libraries are first generated out of a pool of capsid gene fragments and then 
selected in a given target cell. In this study, we sought to address, improve and 
standardize different aspects of the AAV DNA shuffling protocol, by optimizing the 
fragmentation, nested PCR and purification methodologies, altogether aiming to 
streamline the existing workflow and make it more accessible to interested researchers.  
Another important question related to DNA family shuffling concerns the alternative ORF 
aap within the cap gene, which is essential for AAV particle assembly. The AAP ORF will 
be recombined as well during shuffling, raising concerns in the field that this might impair 
its function. We therefore wanted to study the functionality of chimeric AAPs further and 
assess whether providing excess AAP during production would overcome possible 
restrictions.  
Additionally, the fate of a viral library was followed up after its generation. One aim here 
was to develop vectors that are specific for the different liver cell types, i.e. hepatocytes, 
LSECs, Kupffer cells and stellate cells. As mentioned above, stellate cells are particularly 
interesting for the research of liver disease but their study is hampered due to limited 
tools for genetic manipulation. Existing methods include carbon tetrachloride injection 
into mice to induce liver fibrosis and mouse models where the Cre recombinase is under 
the control of a stellate cell-specific promoter  (Mederacke et al. 2013). As it would be 
highly beneficial if knockdown or overexpression studies could be conducted, we aimed 
to fill in this gap by trying to isolate stellate cell-specific AAV vectors. To this end, an AAV 
library was selected in stellate cells in mice and after four rounds of selection, single 
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candidates were further validated yielding promising variants. At last, improvements 
were implemented into the selection and analysis workflow. These include novel 
PacBio/SMRT sequencing technologies that allow an in-depth analysis of AAV sequence 
enrichments and an increase in stringency during the PCR rescue of AAV genomes by 
the usage of barcodes, i.e. unique nucleotide stretches.   
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2. RESULTS 
 
2.1. OPTIMIZATION OF DNA FAMILY SHUFFLING 
The generation of viral libraries by DNA family shuffling is an efficient method to diversify 
AAV capsid genes and a prerequisite for the selection and discovery of AAV variants 
with novel features, including cellular tropisms or immune evasion. This technique was in 
the center of the present study, whose aim it was to dissect the biology underlying 
selected steps in the protocol and to harness the enhanced understanding in order to 
optimize the library generation and selection workflows. In the following, the results will 
be described, while technical details are supplied in section 4.2.4. 
 
2.1.1. FRAGMENTATION METHODS 
The initial steps of DNA family shuffling comprise the amplification of genes of interest, 
i.e., AAV cap genes, and their subsequent fragmentation into smaller pieces for ensuing 
recombination into recombinant chimeric sequences. In this work, two different methods 
of fragmentation were compared: Covaris-based ultrasonication (physical fragmentation) 
versus DNase I digestion (enzymatic fragmentation) (Figure 2-1 A). The rationale behind 
the selection of ultrasonication was that it should allow, in principle, to standardize the 
fragmentation procedure as it enables the generation of fragments of a defined size 
range. In fact, the inability to fully control the conventional DNase I fragmentation 
reaction and the size of the resulting DNA pieces is one of the bottlenecks of the current 
DNA family shuffling protocol. In a pilot experiment, the Covaris S2 device was set to 
generate fragments of 150 bp, 300 bp and 800 bp in size. Indeed, when resolved on a 
1% agarose gel, different fragment sizes were observed that roughly met the 
expectations (Figure 2-1 B). This was most pronounced for the 150 bp setting, which 
was the smallest setting and yielded a distinct band of a size between 100 and 200 bp. 
The medium setting (300 bp) generated a fragment pool rather than a specific band in 
the range of 100 to 300 bp. For the largest setting (800 bp) a smear between 200 bp and 
800 bp was observed.  
Next, all samples (highlighted by boxes in Figure 2-1) were purified from the gel and 
used for subsequent PCR steps. In all cases, the 800 bp sample produced the full-length 
cap genes (2.2 kb) but with varying efficiencies between the replicates (Figure 2-1 D). 
The samples with a smaller fragment size failed to yield full-length cap, with the 
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exception of the second replicate (#2) where a recovery of the 2.2 kb cap band was 
observed for the 300 bp input sample.  
The second fragmentation method used was DNase I digestion. As seen in Figure 2-1 C, 
the longer the DNA is digested the smaller the fragments become. For example, 
digestion for 0.5 min (#2) yielded an even looking smear whereas digestion for 1.5 min 
(#1) produced a strong signal with a peak at approximately 150 bp. In all cases, the 
smear ranging from 100 bp to 1 kb was extracted and purified for subsequent PCR 
steps. All samples were able to recover the full-length cap gene to a similar extent 
(Figure 2-1 E).  
 
FIGURE 2-1: FRAGMENTATION METHODS 
Ultrasonication and DNase I digestion were compared for the generation of capsid libraries. (A) 
Fragmentation is the initial step for DNA family shuffling. (B) DNA was fragmented by 
ultrasonication with settings generating fragments of 150 bp, 300 bp and 800 bp and resolved on 
a 1% agarose gel. A representative image from three independent fragmentations is shown and 
the boxes highlight the region which was excised and purified. The fragment pool C1 was used for 
further subcloning. (C) A number of different DNase I digestions were performed and the boxes 
indicate the regions which were used for excision and subsequent DNA purification. The 
digestions occurred over a course of 0.5 to 2 min and were resolved on a 1% agarose gel. 
Fragment pools D1, D2 and D3 were used for further subcloning. (D, E) All samples were used to 
perform the subsequent PCR steps to reassemble full-length cap genes. For comparison, equal 
volumes were separated on a 1% agarose gel. Adapted from (Herrmann et al. manuscript in 
preparation). 
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As shown above, the DNase I digestions produced varying results on the gels (band or 
smear) indicative of different size distributions. To study whether all products would yield 
comparable chimeric clones, selected fragment pools highlighted in Figure 2-1 (fragment 
pools C1, D1-3) were subcloned and single chimeras were sequenced and analyzed by 
the Shuffling-ALignment ANalysis Tool (Salanto) from our laboratory (Schurmann et al. 
2013).  
 
FIGURE 2-2: SEQUENCE ANALYSIS OF LIBRARIES C1 AND D1-3 
(A) The in-house tool Salanto compares the sequence of a shuffled clone (chimera) to the 
parental references (e.g. AAV1 and AAV9). The sequence is assigned to a certain parent until 
there is a change in sequence. From there on, the next parental reference will be assigned. The 
arrow indicates the position where a crossover from AAV1 to AAV9 occurs. Nucleotides that differ 
between the parental serotypes are underlined. (B) A color code is implemented to visualize the 
parental distribution among the different chimeric clones. Mutated nucleotides are referred to as 
“mut”. In case a sequence stretch is ambiguous, it will be assigned as “indet”. (C) Ten clones from 
each library (C1, D1-3) were analyzed with respect to the distribution of parental serotypes and 
colored accordingly. One bar represents the complete cap gene of a single clone in 5´-
3´orientation. Additionally, the average sum (∑) of fragments per serotype is depicted below each 
block and the average fragment length (L) in bp is shown. Adapted from (Herrmann et al. 
manuscript in preparation). 
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Of note, one sequencing reaction would not be able to cover the complete 2.2 kb cap 
gene and therefore, three primers were used (#822, #36 and #823) and the complete 
cap sequence was assembled manually. In a first step, all chimeric sequences were 
aligned to their parental references, i.e., AAV1, AAV7, AAV8, AAV9 and AAVrh10 
(Figure 2-2 B). This alignment can then be fed into the Salanto tool. After definition of the 
parental sequences, the software assigns now the chimeric sequences to their 
respective parents. The option “type assignment” was chosen for analysis. Here, a 
nucleotide specific of a given parent is recognized and from there on the chimera is 
assigned to this reference (Figure 2-2 A). As soon as there is a change in the sequence 
which is not in accordance with the selected parental reference, a crossover will occur to 
another parental sequence. This is exemplified by the change in color in Figure 2-2 C. If 
several options exist for a sequence stretch, it will be assigned as undetermined and 
labeled “indet”. Furthermore, Salanto recognizes positions where none of the parental 
references fit as mutations (assigned “mut”). 
To compare the libraries generated by the two fragmentation methods, 10 clones each 
were sequenced and analyzed with Salanto with the abovementioned type assignment. 
For depiction, the complete nucleotide sequence of the chimeras is depicted and the 
respective parental serotype was colored according to the legend (Figure 2-2 B, C). 
Additional features of Salanto were used to assess the library composition. Firstly, the 
number of fragments derived from each serotype was counted and the mean sum of 
fragments is depicted. Similarly, the average fragment length was determined. The mean 
was chosen as the serotypes are not equally distributed among the libraries. For 
instance, AAV9 represented by dark blue seems to be less abundant in library C1. The 
analysis for the individual serotypes can be found in the supplementary section in Figure 
6-1.  
A correlation between the sum of fragments and the length can be observed, namely, the 
longer the fragment length becomes the number of fragments decreases. Covaris-based 
fragmentation yielded less (18.1) but larger fragments (161.6 bp). In contrast, libraries 
based on DNase I digestion, i.e., D1, D2 and D3, yielded more fragments (27, 23.6 and 
24.5, respectively) of a shorter average length (117.4 bp, 136.8 bp and 133.1 bp, 
respectively). All tested DNase I-based libraries gave comparable results despite the 
differences in the fragment pools resulting from the initial digestions (Figure 2-1 C). This 
finding in combination with the observation that all samples originating from DNase I-
based fragmentation efficiently produced full-length cap, highlights the robustness of 
enzymatic fragmentation for DNA family shuffling.  
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2.1.2. LIBRARY AMPLIFICATION AND SUBCLONING 
Next to the different fragmentation methods, the PCR setup was modified with the aim to 
improve the resulting DNA yields for more efficient subcloning (Figure 2-3 A). 
Fragmentation is the initial step for DNA family shuffling and the fragment pools are 
allowed to re-anneal in a first PCR which is primerless. Based on homology fragments 
will partially anneal and become filled up by the polymerase. This is then followed by a 
second nested PCR step which amplifies full-length cap genes (section 1.1.4.2, Figure 
1-5). Firstly, the elongation step for the second, nested PCR was varied from 1 to 6 min 
and equal volumes of the PCR reactions were separated on a 1% agarose gel. This 
showed that an elongation time in the range of 2 to 3 min was optimal to recover full-
length cap, which can be observed as the band running slightly above the 2 kb marker 
band (indicated by arrows in Figure 2-3 B). Longer time points (5 to 6 min elongation 
time) failed to recover cap efficiently. Curiously, bands with larger sizes than 2.2 kb occur 
e.g. between 4 and 5 kb (2-4 min elongation time) and at roughly 6 kb (3-4 min 
elongation time). One possible explanation is the formation of concatamers during PCR 
amplification that become more prominent upon an increase in elongation time. The 
nature of the band is highly intriguing as the standard protocol within the lab for DNA 
purification after PCR in the context of DNA family shuffling specifically recommends the 
recovery of the 2.2 kb band from the gel (Große 2016). In order to study the composition 
of the band between 4 and 5 kb, it was separately excised, purified and digested with 
PacI/ AscI restriction enzymes which flank the cap genes. If concatamer formation 
occurred, the restriction sites should be still present and hence, the concatamer should 
be resolved upon restriction enzyme digestion. Indeed, after PacI/AscI digestion the 
extracted large band with a size between 4 and 5 kb became the same size as the full-
length 2.2 kb cap band (Figure 2-3 C).  
Based on these observations the possibility to improve DNA yields by purification 
method was investigated. To this end, a large-scale PCR was set up, pooled and half of 
the volume was loaded on a gel for subsequent excision of the 2.2 kb band and 
purification. The other half was directly processed for column purification. Both samples 
were digested according to the protocol (section 4.2.4.4) and were resolved side-by-side 
on an agarose gel. As seen in Figure 2-1 D the signal intensity is much stronger for the 
sample that was initially column-purified indicative of a higher yield. We thus conclude 
that it is beneficial for future library generations to initially purify the large-scale PCR over 
a column and to then extract the DNA from a gel after digestion with the restriction 
enzymes required for cloning.   
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FIGURE 2-3: IMPROVEMENT OF LIBRARY PURIFICATION 
(A) The schematic depicts the steps of DNA family shuffling which were studied further. (B) The 
elongation time of the second PCR was varied ranging from 1 to 6 min. Equal volumes of the 
PCR reactions were visualized on a 1% agarose gel and full-length cap genes are indicated by 
the arrows. (C) Next to the band of interest at 2.2 kb, bands with larger sizes were observed when 
the elongation time was increased. To address the possibility of concatamer formation, both 
bands, at 2.2 (1) and the one between 4 and 5 kb (2), were separately excised, purified and 
digested with PacI/AscI. After digestion, both of them ran at a size of approximately 2.2 kb. (D) 
Comparison of two purification methods. After library generation by the second PCR, the DNA 
was either run on a gel, excised and purified or directly purified over a column. After PacI/AscI 
digestion, the samples were again run on a gel, illustrating the higher yields from the direct 
column purification. Adapted from (Herrmann et al. manuscript in preparation). 
 
2.2. INADVERTENT SHUFFLING OF AAP 
During DNA family shuffling for the generation of novel cap libraries, the ORF of AAP is 
shuffled along. One concern that has lingered in the field since the initial publication of 
AAP (Sonntag, Schmidt, and Kleinschmidt 2010) was that this inadvertent shuffling of 
AAP might turn out to be detrimental for production of AAV particles and/or during 
subsequent selection steps. To address this question, we made use of a series of AAP 
knockout mutants that had been generated previously in our laboratory (Große 2016; 
Grosse et al. 2017). For most of these knockout mutants, the unconventional AAP start 
codon CTG was altered within the context of an AAV helper plasmid encoding AAV rep, 
cap and AAP. Additionally, a stop codon was introduced as early as possible in the AAP 
ORF without changing the overlapping VP frame. In the same study, the DNA sequences 
of the AAV4 and AAV5 cap genes were adapted to AAV2 in order to increase sequence 
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homology and thus shuffling efficiency. Thereby, the VP frame was kept intact but, 
accidentally, the AAP frame was altered, leading to the introduction of various stop 
codons. These versions were used as AAV4 and AAV5 AAP knockout constructs. 
Additionally, a trans-complementation assay had been established in which so-called 
crude lysates were produced by transfection of four plasmids. Usually, one plasmid 
encodes the transgene flanked by ITRs, one plasmid provides AAV rep and cap and the 
third plasmid provides helper virus functions which are required for successful AAV 
progeny production (compare sections 1.1.2, 4.2.5.2). Two days after transfection in 
HEK293T cells, the cells are harvested and subjected to iterative cycles of freezing and 
thawing in order to break the cells apart. Finally, the samples are spun down and the 
AAV containing supernatant is referred to as crude lysate. In the trans-complementation 
assay either the wild-type constructs with endogenous AAP or the AAP knockout 
constructs were used and were additionally supplemented with exogenous AAP or 
stuffer (Figure 2-5 B). For supplementation with exogenous AAP, the wild-type AAPs 
were subcloned under the control of the strong CMV promoter on an expression plasmid 
additionally bearing an HA-tag laboratory (Große 2016; Grosse et al. 2017). Previous 
results showed that the constructs with mutated AAP failed to produce rAAV vectors 
packaging an eGFP reporter as no cells expressed the transgene upon transduction 
(Große 2016; Grosse et al. 2017). However, supplementation with exogenous AAP could 
potently recover vector production and subsequent cell transduction to wild-type levels.  
 
2.2.1. INTERCHANGABILITY OF AAPS BETWEEN WILD-TYPE AAVS 
The aforementioned AAP knockout constructs had been generated by a former PhD 
student in the laboratory (Stefanie Große) who also obtained the first evidence that AAP 
depletion diminishes rAAV particle yields. Here, two important related questions were 
addressed, i.e., whether the genetic AAP knockouts would also be reflected on the 
protein level and whether the drop in rAAV transduction efficiency was a result of 
unsuccessful particle assembly. Therefore, three exemplary knockout AAP versions, 
namely those derived from AAV2, AAV8 and AAV9, were cloned into the expression 
plasmid as described in section 4.2.3.2. In order to assess the AAP expression from the 
resulting plasmids, they were transfected into HEK293T cells, the cells were harvested 
and a Western blot was performed (section 4.2.6.2).  
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FIGURE 2-4: AAP EXPRESSION AND CAPSID ASSEMBLY MONITORED ON 
THE PROTEIN LEVEL 
(A) AAP expression from the AAP expression plasmids was assessed by Western blot. Each 
plasmid was transfected into HEK293T cells and the cell pellet was lysed 48 h after transfection. 
Equal volumes were loaded and stained for actin (housekeeper) or HA (AAP). The label “mut” 
refers to the knockout versions. (B) A trans-complementation assay was performed during 
production of rAAV particles and particle assembly was assessed. The wild-type capsid, the AAP 
knockout mutant or the mutant co-transfected with AAP were used to package a GFP reporter-
encoding vector plasmid in HEK293T cells. After 48 h the cells were harvested, cracked open by 
freeze/ thaw cycles and the supernatant acquired after centrifugation was used for native dot blot 
analysis. (C) Equal volumes of untreated or heated sample were spotted and either free VPs were 
detected with the monoclonal B1 antibody (or polyclonal anti-VP serum in the case for AAV4 
which is not recognized by B1), or assembled particles were detected with the A20/ ADK 
antibodies. Structures recognized in the AAP deficient sample are indicated by the arrow (native 
condition) and the arrowhead (heat treatment). The experiment was performed three times and 
representative blots are shown. This figure was published and adapted from (Grosse et al. 2017). 
 
cap
A
C
95 C--- 95 C--- 95 C---
wild-type mutant mutant + AAP 
AAV1
B1
ADK1
AAV3
B1
ADK8
AAV4
VP
ADK4
AAV2
B1
A20
B1
ADK5
AAV5
B1
ADK6
AAV6
B1
ADK8
AAV8
B1
ADK9
AAV9
95 C--- 95 C--- 95 C---
wild-type mutant mutant + AAP 
36
28
kDa
AAP
actin
HA / AAP
1 2 3 4 5 6 7 8 9
rh
10 2 8 9
mut
B
AdhGFP
cap
x AAP mut
/
 
AAP
48 h
PhD thesis, Anne-Kathrin Herrmann 
29 
 
Actin served as a loading control (housekeeper) and the AAPs were detected by their HA 
tag which is present in all expression plasmids. As expected, AAP was successfully 
expressed from all plasmids encoding the wild-type AAPs and the signal was absent for 
the knockout versions (Figure 2-4 A). Additionally, varying sizes for the different AAP 
variants were observed. 
Once the presence or absence of expression of AAP had been successfully confirmed, 
the trans-complementation assay mentioned above was recapitulated on the protein 
level as well. To this end, so-called crude rAAV lysates (section 4.2.5.2) were produced 
using 10 wild-type capsids with endogenous AAP or AAP knockout mutants 
supplemented with stuffer DNA and, in the case of the mutant, with an AAP expression 
plasmid (Figure 2-4 B). An Adenoviral helper (Adh) plasmid provided the factors required 
for AAV progeny production and an eGFP expression cassette flanked by AAV ITRs was 
chosen as a reporter. Two days after transfection of the different components, the cells 
were harvested, lysed by iterative cycles of freezing and thawing and, finally, the cell 
debris was spun down. The supernatant containing the rAAV particles is referred to as 
crude lysate.  
In order to assess particle assembly non-denaturing conditions are required to maintain 
the capsid structure. To this end a dot blot under native, non-denaturing conditions was 
performed by loading equal amounts of crude lysate on a membrane (section 4.2.6.3). In 
addition, the samples were heated at 95°C to promote disassembly of the capsids into 
VP subunits. Antibodies were used which specifically detect the assembled capsids, 
namely, A20 (AAV2), ADK1 (AAV1), ADK4-6 (AAV4-6), ADK8 (AAV3 and AAV8) and 
ADK9 (AAV9) (Table 4-17). In order to detect free VP, the B1 antibody was applied 
which recognizes VP1-3 from most serotypes except for AAV4. For the latter a polyclonal 
anti-VP serum was used which recognizes free VPs and possibly assembled capsids of 
many AAV serotypes including AAV4 (Sonntag et al. 2011). As expected for the wild-
type AAV helper plasmids encoding the intact, endogenous AAP, assembled particles 
were detected under native conditions and VP subunits were detected when promoting 
disassembly by high temperature (Figure 2-4 B). Neither free VP nor assembled particles 
were detected for most of the AAP knockout variants, i.e. AAV2, AAV3, AAV6, AAV8 and 
AAV9. Upon trans-complementation of the knockout versions with AAP, however, 
assembly could be readily detected again comparable to the wild-types. Curiously, for 
the AAP knockouts in AAV1, AAV4 and AAV5 signals were detected with their respective 
ADK antibodies despite the absence or very weak detection of free VP (highlighted by 
arrows in Figure 2-4 B). 
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Next, trans-complementation assays were performed to assess the rescue potential of 
different wild-type AAPs for a given knockout mutant. In this assay, crude lysates are 
produced and the ability to mediate eGFP transduction is used as a surrogate marker of 
successful particle formation (Figure 2-5 A) (section 4.2.6.1). Specifically, we tested the 
ability of 10 different wild-type AAPs to rescue the indicated AAP knockout versions by 
monitoring the transduction efficiency via FACS analysis. In order to avoid saturation, a 
dilution of the crude lysate was chosen where no saturation was observed, i.e. where 
percentages of GFP-positive cells remained below 95%. All results were compared 
relative to the cognate wild-type control and allowed us to make several interesting 
observations (Figure 2-5 B). Generally, all serotypes tested exhibit a dependency on 
AAP as the knockout versions (second row) barely gave rise to infectious particles, as 
evidenced by the dark color indicating low to no infection. An exception were the AAV4 
and AAV5 AAP mutants which exhibited transduction efficiencies of 8.9 % and 3.2 %, 
respectively. Upon trans-complementation with AAP, a high interchangeability between 
AAPs from different serotypes could be observed. The exceptions were again AAP4 and 
AAP5 which failed to support most serotypes other than their own (exemplified by a 
darker color). In terms of homology AAP4 and AAP5 are more divergent from the 
remaining wild-types (Figure 2-5 C). In contrast, the AAV4 and AAV5 knockouts were 
rescued by a range of other AAP variants. Curiously, the AAV3 mutant supplemented 
with AAP2, 3, 7 and rh10 exceeded the transduction efficiency of wild-type AAV3. 
Furthermore, the AAV7 and rh10 mutants are rescued more efficiently than the AAV4 
and AAV5 mutants but not to the same extent as the remaining variants AAV1-3, AAV6 
and AAV8-9.  
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FIGURE 2-5: WILD-TYPE AAP INTERCHANGEABILITY 
(A) Schematic depicting the experimental setting for the trans-complementation assay. 
Recombinant AAV particles are generated by transfection of an adenoviral helper plasmid (Adh), 
a transgene (GFP reporter), the capsid (wild-type or AAP mutant) and either stuffer DNA or AAP 
into HEK293T cells. After 48 h, the cells are harvested and exposed to freeze/thaw cycles for 
lysis. The cell debris is pelleted and the AAV supernatant is used to transduce cells. FACS 
analysis is performed 48 h later to determine percentages of GFP-positive cells. (B) Different cell 
lines were used for transduction and for analysis the ones were chosen where no saturation was 
observed, i.e. MCF7 (AAV2-6) and SF539 (AAV1, AAV7-rh10). All values were compared relative 
to the wild-type which was set to 100% and the result is depicted as a heatmap ranging from no 
infectivity (black) to 110% (white). In some cases, the efficiency exceeded the cognate wild-type 
(‡). The mean of n=3 are depicted. (C) The homology of the wild-type AAPs is presented as a 
heatmap. The scale ranges from no difference in homology (0%, white) to a difference of 
maximally 42.8% (black). This figure was published and adapted from (Grosse et al. 2017).   
 
2.2.2. FUNCTIONALITY OF CHIMERIC AAPS 
As described above, a high degree of AAP interchangeability was observed in this work 
among the wild-types. This encouraged us to investigate further whether chimeric AAPs 
could mediate this effect as well. AAV DJ was the first chimera published when the 
method of DNA family shuffling was introduced into the AAV field (Grimm et al. 2008). 
Therefore, the AAP from the chimera AAV DJ, referred to as AAP DJ, was studied 
whose parental sequences are derived from AAV2, 8 and 9 (Figure 2-6 A).  
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FIGURE 2-6: RESCUE ABILITY OF AAP DJ 
(A) The nucleotide sequence of AAP DJ was aligned and assigned to the parental sequences of 
AAP2, 8 and 9. The respective parental sequence stretches were colored accordingly. (B) The 
Western blot analysis from Figure 2-4 A was extended to include expression from AAP DJ. (C) 
The rescue of AAP mutants from AAV2, 8 and 9 was tested by monitoring the percentage of GFP-
positive cells relative to the respective wild-type. HEK293T cells (AAV2) and SF539 (AAV8 and 
AAV9) were used. Depicted are the means and standard deviation of three independent 
transfections. A one-way ANOVA with Bonferroni´s multiple comparison test was performed and 
the significance is depicted above the graphs (n.s., not significant; *, p<0.01; ***, p<0.0001). (D) 
The dataset from Figure 2-5 B was extended to include the results of trans-complementation with 
AAP DJ. Part of this figure (panels B-D) was adapted from (Herrmann, Grosse, et al. 2018).  
 
Initially, successful AAP expression was confirmed by Western blotting where, similar to 
AAP8, AAP from AAV DJ ran as a double band (Figure 2-6 B). As before, a trans-
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complementation assay was performed with the parental knockout versions, comparing 
the rescue potential of parental AAPs with chimeric AAP DJ. In the case of the AAP 
knockout versions for AAV8 and 9, all AAPs tested including AAP DJ were capable of 
restoring the efficiency back to wild-type level (Figure 2-6 C). In contrast, rescue of the 
AAP2 knockout mutant was only achieved with its cognate AAP and with AAP DJ, 
whereas trans-complementation with either AAP8 or AAP9 was inefficient.  
Subsequently, the assay was extended to include all wild-type knockout versions tested 
before. Notably, AAP DJ rescued most knockouts and, comparable to AAP2, trans-
complementation of the AAV3 mutant with AAP DJ led to transduction efficiencies even 
exceeding wild-type AAV3 levels (Figure 2-6 D).  
Having established the functionality of one chimeric AAP originating from a successfully 
selected variant, the experiment was expanded to larger numbers of shuffled AAPs from 
unselected libraries. Therefore, a total of 60 chimeric AAPs were subcloned into 
expression plasmids. The AAPs originated from five different libraries and 12 arbitrarily 
chosen clones per library were assessed for their capability to rescue the AAV2 mutant 
in the trans-complementation assay performed before (Figure 2-5 A). The parental origin 
of the chimeric sequences is depicted elsewhere (Figure 6-2). The 1-10O library was 
generated during this study using the sequence-adapted AAV4 and AAV5 variants with 
repaired AAP start codons (Große 2016).  
Of note, the vast majority of chimeric AAPs successfully rescued the AAV2 mutant back 
to wild-type levels. In total, 54 clones rescued the AAV2 mutant and only six clones failed 
to support infectious particle formation (Figure 2-7). These six clones (12, 16, 18, 21, 22 
and 45) along with three of the variants that barely crossed the 5% threshold (19, 39 and 
51) were tested again with AAP knockout mutants of their respective parental serotypes 
(Table 6-1). All the variants tested could rescue at least one of their parental mutants 
above the threshold level of 5%. Remarkably, some clones achieved a rescue efficiency 
of more than 80% (clones 12, 19, 21, 45).  
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FIGURE 2-7: RESCUE ABILITY OF UNSELECTED AAPS 
AAP sequences from 60 arbitrarily chosen chimeras were subcloned and used to trans-
complement the AAV2 AAP knockout mutant. The library origin is denoted above the bars and 12 
clones per library were analyzed. The amount of GFP-positive cells is depicted relative to the 
wild-type and the means are shown from at least two independent transductions. The light gray 
box indicates intermediate performers achieving rescue efficiencies of 5-50% and the triangles 
denote variants that failed to rescue the AAV2 mutant but succeeded with at least one parental 
knockout. The colored numbers describe the performance of the cognate capsid (Figure 2-8 C), 
i.e., transduction-competent (green) or not (red). This data set is an expansion of Figure 3.10 
(Große 2016) and was taken from (Herrmann, Grosse, et al. 2018). 
 
As all chimeric AAPs tested were functional, the questions arose whether AAP addition 
during production has an effect on vector yield and whether the cognate capsids are 
functional. Therefore, the experimental setup was adapted to use wild-type capsids 
instead of the AAP knockout mutants and to supplement a mixture of AAPs instead of a 
single one (Figure 2-8 A).  
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FIGURE 2-8: ADDITION OF AAP DURING RAAV PRODUCTION DOES NOT 
INCREASE TRANSDUCTION EFFICIENCY 
(A) A trans-complementation assay was performed using the wild-type capsids and either a 
cocktail of wild-type AAPs (+) or stuffer DNA (-) was supplemented during vector production. 
Initially, the wild-types were tested on HEK293T (B) and MCF7 (C) cells. The mean of the 
transduction efficiency of three independent transfections is depicted as a heatmap. The bar 
graphs below show the mean and standard deviation and represent the fold difference of AAP 
supplementation relative to the stuffer control. The dotted line indicates no change (1). (D) The 
same experimental setup was expanded to five capsid chimeras per library and the indicated cell 
lines were tested. The bar graph below represents the same analysis as in (B, C) for HEK293T 
cells. nd, not determined. This data set was adapted from (Herrmann, Grosse, et al. 2018). 
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In this setup, the endogenous AAP will be expressed from the capsids. Firstly, the wild-
types were studied and a mixture of all wild-type AAPs, i.e., AAP1-10 was supplied. Two 
cell lines were tested, HEK293T cells (Figure 2-8 B) and MCF7 cells (Figure 2-8 C). 
AAV4 is unable to transduce HEK293T cells and, therefore, the two cell lines were 
chosen to include this AAV serotype. When comparing the results of AAP 
supplementation during production relative to the stuffer control, a ratio around one can 
be found indicating that no increase in transduction efficiency occurred. Additionally, five 
cognate capsids whose AAPs were tested before (Figure 2-7 B), were subcloned into a 
helper context to allow for their use for vector packaging. During production, an AAP 
mixture representing the AAPs from the parental library was supplemented, such as 
AAP2, AAP8 and AAP9 for capsids originating from the 289 library. Three different cell 
lines were screened as the tropism is unknown for these novel capsid variants. Out of 25 
capsids, 19 were able to transduce at least one of the cell lines tested. In most cases, 
the ratio of transduction efficiencies for the AAP-supplemented to stuffer control-
supplemented samples ranged around one.  
However, the chimeric capsid 18 is a curious exception as its transduction efficiency 
increased approximately 10-fold by the addition of the AAP24589 mixture. To further 
dissect this interesting result, the experiment was repeated but now single AAPs were 
added during production. This revealed that AAP5 and AAP2 were the AAP variants 
predominantly contributing to this phenotype (Figure 2-9).  
 
 
FIGURE 2-9: CONTRIBUTION OF AAPS FOR CAPSID 18 PRODUCTION 
The observed increase in transduction efficiency upon AAP addition in clone 18 was further 
dissected. A trans-complementation assay was performed using the chimeric capsid from variant 
18 and the indicated AAPs were supplemented. The resulting crude lysates were tested in 
different cell lines as before. The mean transduction efficiency from two independent transfections 
is shown. This data set was adapted from (Herrmann, Grosse, et al. 2018). 
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Finally, of note is that four out of six capsid variants that gave no transduction originated 
from the 24589 library, although, all six cognate AAPs were functional (compare colored 
numbers in Figure 2-7 B). 
In summary, AAP is an essential factor for assembly of the wild-types tested and only the 
AAV4 and AAV5 AAP knockout mutants retained partial activity. The concern that the 
recombination of the AAP frame during DNA family shuffling would impair its function 
could be relieved as all chimeric AAPs were capable of trans-complementing at least one 
of their parental AAP knockout mutant versions. 
   
2.3. AAV SELECTION ON HEPATIC STELLATE CELLS 
So far, early steps of DNA family shuffling were studied with the aim to improve existing 
shuffling protocols and to understand an important underlying biological question, i.e., 
the impact of recombination on the AAP frame. Next, the selection step itself was studied 
further by performing iterative rounds of selection on a target cell. Our laboratory has a 
long-standing interest in liver diseases as a variety of pathologies are associated with it. 
For instance, the Malaria causative agents from the Plasmodium spp. are transmitted by 
a mosquito bite and travel with the blood stream towards the liver where they establish 
their infection in hepatocytes. Recently, our laboratory in collaboration with the group of 
Ann-Kristin Mueller (Heidelberg University Hospital, Germany) showed a protective effect 
by over-expression of miRNA-155 against repeated challenge with the parasite 
(Hentzschel et al. 2014). In order to mediate sterile immunity, usually three injections of a 
genetically attenuated parasite were required, however, only one injection was 
necessary when miRNA-155 was overexpressed. The underlying biological mechanisms 
are not yet elucidated but a role of the non-parenchymal cell (NPC) fraction, and 
especially Kupffer cells, was identified. The lack of cell-type specific vectors limits further 
studies to e.g. overexpress this miRNA only in a specific cell type, such as Kupffer cells. 
In addition, in collaboration with the laboratory of Holger Willenbring (University of 
California, San Francisco [UCSF], CA, USA), we have an interest in the study of liver 
fibrosis and specifically, in stellate cells which contribute to disease progression. 
Recently, AAV6 wild-type vectors were found to target activated stellate cells in a mouse 
model of liver fibrosis achieved by injection of carbon tetrachloride (CCl4) (Rezvani et al. 
2016). In order to study early steps of fibrosis, viral vectors targeting the quiescent 
stellate cells would be highly beneficial for distinct genetic manipulation in this cell 
population.  
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2.3.1. LIBRARY GENERATION AND SELECTION 
To generate an AAV library by DNA family shuffling for subsequent selection in stellate 
cells, a variety of serotypes was incorporated. In detail, the serotypes 1-9 and rh10 were 
chosen. As noted before, AAV4 and AAV5 are less homologous than the remaining 
serotypes within the library. Hence, to increase their abundance the sequence optimized 
versions of the corresponding capsid genes were used, named 4O and 5O, respectively 
(sections 2.2, 2.2.2.).  
All cap variants were mixed in equal amounts and enzymatic fragmentation was chosen 
as we found it to be the most robust approach for DNA family shuffling (section 2.1.1). 
Upon DNase I treatment an even looking smear was acquired and, as before, the range 
from 100 bp to 1 kb was excised, purified and used for subsequent PCRs (Figure 2-10 
A). After cloning, the library was transformed into electrocompetent bacteria and an 
efficiency of 1.2.x106 colonies was achieved (section 4.2.2.2). In order to get an 
impression about the shuffling efficiency, 12 clones were sequenced and analyzed by 
Salanto as before (section 2.1.1). As hoped for, stretches of AAV4O and AAV5O were 
incorporated in, e.g., clones 7 and 8. Furthermore, all serotypes used for DNA family 
shuffling were present and on average 13.6 crossovers occurred per clone indicative of 
successful shuffling. At the N-terminal end, more crossover events can be observed than 
at the C-terminal end where the stretches tend to get larger. This is in line with the fact 
that AAV capsid genes display the lowest degree of homology at the C terminus that 
encodes the variable surface of the capsid (Figure 6-3 B, C). 
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FIGURE 2-10: GENERATION AND SELECTION OF A 1-10O LIBRARY 
(A) A DNase I digest was performed on serotypes 1-9 and rh10 and the box indicates the region 
purified for subsequent PCR steps. (B) The complete cap gene was sequenced from 12 clones. 
Each bar represents the nucleotide sequence of one clone. A type assignment using Salanto was 
performed and parental stretches were colored accordingly. To increase shuffling efficiency, the 
sequences of AAV4 and 5 were adapted to AAV2 (“O”). (C) Schematic depicting the selection 
strategy. A viral library was injected into a mouse and 24 h later, the stellate cells were isolated 
from the liver. A PCR rescue was performed using total stellate cell DNA as template and used for 
production of secondary libraries. In total, four rounds of selection were performed. The cartoon of 
the mouse was taken from the servier medical art collection (https://smart.servier.com/). (D) 
Representative image of the PCR rescue. As a first step, a small-scale test PCR was performed 
using different template volumes as input material. Equal volumes of the PCR reactions were 
loaded and the condition yielding the highest intensity was used for large-scale PCRs.  
 
Having confirmed successful DNA family shuffling, the selection in stellate cells was 
initiated in collaboration with the laboratory of Holger Willenbring (Figure 2-10 C). The 
library was purified by cesium chloride gradient density centrifugation (section 4.2.5.5) to 
remove empty particles and 5x1011 vector genomes (vg) were injected into one mouse 
expressing GFP specifically in stellate cells (section 4.2.7.1). After 24 h, the liver was 
perfused and stellate cells were sorted by FACS. In a quiescent state, stellate cells store 
Vitamin A in fat droplets which can be excited by UV light (Mederacke et al. 2015). 
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Therefore, cells which were double-positive for GFP and Vitamin A were used for further 
DNA isolation and production of secondary libraries. Prior to setting up a large-scale 
PCR, a test PCR was performed. Here, different template volumes were tested in the 
PCR reaction rather than specific ng amounts to determine the condition achieving the 
highest product yield. The rationale behind this strategy is that total DNA is isolated from 
the cells and the portion of AAV genomes is unknown. A low portion of AAV genomes 
could require higher template volumes and vice versa, high portions of AAV genome 
could lead to template inhibition during PCR and hence, lower template volumes are 
required. As seen in Figure 2-10 D a reduction in template leads to higher AAV cap 
recovery and thereby, the best PCR condition was identified. 
In total, four rounds of selection were performed and 64 clones originating from the 
different selection rounds were sequenced. The sequences were sorted according to 
their C-terminal parental assignment (see below). When considering the individual 
selection rounds, enrichment at the C-terminus of AAV1 and AAV6 was observed during 
the first three selection rounds (Figure 6-4). Unexpectedly, the fourth round yielded 
chimeras with a C-terminal enrichment for AAV7 and this observation was recapitulated 
upon repetition of the fourth round with two more mice.  
 
2.3.2. VALIDATION OF SINGLE CHIMERAS 
In order to choose the most promising variants for individual experimental validation all 
clones were sorted into different groups based on their C-terminal parts (Figure 2-11). 
The groups identified were mostly derived from AAVrh10 (10-stretch), AAV7 (7-stretch) 
or AAV1 (1-stretch). Additionally, we specified groups that contained combinations. One 
showed a pronounced crossover from AAV7 to AAVrh10 and then back again to AAV7 
(7-rh10-7). The other two were mixes of AAV1, AAV6 and AAV7 (1/6/7 mix) or AAV1 and 
AAV6 (1/6 mix). Only five out of 64 sequences did not fit to any of the groups identified. 
Next, at least two representatives from each group were chosen for further in vivo 
validation. Therefore, the candidate capsids were transferred from the replication-
competent background into a helper context which allowed for packaging of an eYFP 
reporter. The vectors were produced in small-scale and purified by Iodixanol gradient 
density centrifugation (section 4.2.5.4).    
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FIGURE 2-11: AMINO ACID SEQUENCE OF SELECTED VARIANTS 
Each colored bar represents the complete amino acid sequence of a single chimeric capsid. The 
color code for the parental references is depicted at the top. The 1-10O library was subjected to 
an iterative in vivo selection in mice and AAV cap sequences were recovered from isolated 
stellate cells. After each round, chimeric amino acid sequences were isolated (eight from the first 
and second round, 18 from the third, 30 from the fourth) and finally sorted according to their C-
terminal domain. Single chimeras (indicated by the arrow) from each identified group were 
randomly chosen for further in vivo validation. Capsid 3-5 is highlighted as it became the lead 
candidate in later analyses. 
 
2.3.2.1. HIGH PRODUCTION CAPACITY UPON SELECTION 
Interestingly, when the clones selected for validation were produced individually, we 
noted titers comparable or even higher to the parental wild-types (Figure 2-12). The latter 
(shown in white) were at the lower end with titers in the range of 5x1011 vg/ ml. Three 
chimeric variants produced also at a lower titer (4-8, 4b2-08, 4-5) and six achieved a titer 
at wild-type level (4-10 to 3-10). Eight chimeric capsids yielded titers in the range of 1012 
to 1013, i.e., over ten-fold higher than all wild-types. 
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FIGURE 2-12: TITERS OF CHIMERIC CAPSIDS 
The indicated capsid variants were produced by transfection of 15 plates and Iodixanol density 
centrifugation purification. The chosen color code refers to the group shown in Figure 2-11. 
 
From these observations, the question arose whether this increase in production 
capacity might be linked to novel properties of the AAPs, as previously observed with 
AAP DJ (section 2.2.2). Therefore, AAPs derived from low- and high-producing chimeras 
(4-8, 4b2-08, 4-5 and 3-5, 3-17, 3-18, 3-21, 4-3, 4-6, 4-7), as well as AAPs from 
chimeras producing comparable to the wild-types (3-3, 3-9), were cloned into the 
expression construct and their rescue potential was tested with the AAP knockout 
mutants of the most abundant parental serotypes, i.e. AAV1, AAV6, AAV7 and AAVrh10. 
The full AAP sequences are depicted in the supplements in Figure 6-2. All selected AAP 
variants were able to rescue at least one of the AAP knockout mutants (Figure 2-13). In 
almost all cases, AAV1 and AAV6 could be rescued back to wild-type levels whereas 
AAV7 and AAVrh10 were less efficiently rescued. Exceptions were the AAP variants 
derived from 3-3, 3-17, 4-3 and 4-7 that potently rescued the AAV7 and AAVrh10 AAP 
mutants. However, no striking differences between the different AAPs were observed 
such as an increase in transduction efficiency seen for the AAV3 AAP knockout mutant 
(section 2.2.1). In conclusion, the increase in production efficiency was most likely not 
mediated by AAP.    
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FIGURE 2-13: RESCUE ABILITY OF AAPS WHICH UNDERWENT SELECTION 
(A). Different AAPs (Figure 2-12) subcloned from chimeras which underwent selection in stellate 
cells were tested for their potential to rescue the indicated AAP knockout plasmids. (B) The 
amount of GFP-positive cells was compared relative to the respective wild-type control (set to 
one) and the means with standard deviation from three independent transfections are depicted. 
Comparable to Figure 2-7 the intermediate performers with a rescue efficiency of 5 to 50% is 
indicated by the grey box. This data set adapted from (Herrmann, Grosse, et al. 2018). 
 
2.3.2.2. INITIAL VALIDATION ON SINGLE CANDIDATE LEVEL 
The produced variants were injected into mice at a dose of 1x1011 vg per mouse. Ten 
days later, the mice were sacrificed and liver slices were processed for immunostainings. 
The vector delivered an eYFP reporter and stellate cells were stained for desmin, which 
is a commonly used marker for this cell type. The wild-types, AAV1 and AAV6 mostly 
transduced hepatocytes (Figure 2-14 A). In contrast, the tested chimeras showed 
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different transduction profiles and most notably novel tropisms were identified. This 
indicates that the applied selection pressure lead to enrichment of promising variants. 
 
FIGURE 2-14: IMMUNOSTAININGS OF LIVER SLICES 
Different AAV vectors enriched during selection in stellate cells were validated in vivo. (A) The 
indicated wild-types or chimeras were injected into mice and the livers were processed for 
immunostainings. Shown are representative images of the transduction efficiency for some of the 
vectors tested. The first number indicates the round of selection and the second number refers to 
the clone. The reporter (green) and stellate cell marker desmin (red) were stained. (B) Two more 
variants are shown in a higher magnification. Additionally, the nuclei were stained with DAPI. (C) 
For the variant 3-5 a different tropism was observed in another mouse. The brightness was 
increased by 20% for all pictures. The images were acquired by Regina Espanol-Suner 
(Willenbring lab). 
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In detail, a couple of variants efficiently transduced hepatocytes, such as 3-9 and 4-3. 
Others were low transducers in general, e.g., as seen with 3-18 and 4-7. Most 
interestingly, some capsids developed novel tropisms, namely, 4-6, 3-10, 3-5 and 4b-10 
(Figure 2-14 A, B). In these cases, a low rate of hepatocytes was transduced and cells 
were targeted which closely localized with the desmin staining.  
It has to be noted, however, that the liver is a complex organ and that the cells are in 
close proximity, which together complicated the identification and quantification of vector-
targeted cells. Accordingly, the staining was not always distinct enough to determine 
whether the signals co-localized or whether a nearby cell had been transduced. 
Additionally, we observed variations in tropism between mice as exemplified with variant 
3-5, which targeted stellate cells in one mouse but mostly hepatocytes in another (Figure 
2-14 C). 
For this reason, an alternative strategy was followed in collaboration with Steven Dooley 
(University hospital Mannheim, Germany). The AAV variant 3-5 was injected into mice 
and, instead of staining liver slices, the liver was perfused and single cell types were 
cultivated upon isolation. The cultured cells were then stained for the reporter and for a 
cell-specific marker. The identity of hepatocytes was confirmed by HNF4A staining, 
stellate cells were identified by desmin staining. Kupffer cells were recognized by F4/80 
and, lastly, LSECs were stained with LYVE1. Notably, the cell isolations appeared 
homogenous as most nuclei (column 3, Draq5) localized with the cell-specific marker 
(column 2) (Figure 2-15 A). Interestingly, while barely any hepatocytes and LSECs were 
transduced by the 3-5 vector, the vast majority of stellate cells and Kupffer cells were 
transduced (Figure 2-15 A, B). This finding independently confirmed the promising result 
from the immunostainings (Figure 2-14). 
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FIGURE 2-15: CELL SEPARATION AND STAINING 
Determination of transduced cell types after AAV3-5 application in mice. (A, B) The variant 3-5 
was injected into mice and the four cell types were isolated. The cells were taken into culture and 
stained for the reporter (green), a cell-type specific marker (red) and the nucleus (DRAQ5). An 
overlay of all channels is depicted in column "merge". (A) In the overlays for stellate cells and 
Kupffer cells, part of the image is highlighted by a box. In (B) this section was enlarged for a 
better visualization of the different stainings. The pictures were acquired by Christof Dormann 
(Dooley lab). 
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2.3.2.3. POOLED APPROACH BY NEXT-GENERATION SEQUENCING 
So far, the novel tropism displayed by AAV 3-5 was confirmed by an alternative 
approach and from the immunostainings three more variants are potentially interesting 
(4-6, 3-10 and 4b-10) (Figure 2-14). However, the validation on single-capsid level 
requires high numbers of mice and time. In order to cover more variants in parallel a bulk 
validation approach was developed based on next-generation sequencing (NGS) 
(section 4.2.7.2).  
Previously, another member of the Grimm laboratory – Jonas Weinmann - has 
established a screening protocol where multiple barcoded, AAV capsid variants are 
injected into a mouse and the distribution of the capsids is determined on the DNA and 
RNA levels by NGS analysis. The barcode is a small, unique nucleotide stretch 
incorporated into the 3´untranslated region (UTR) of the eYFP reporter (Figure 2-16).  
Here, all variants of interest were separately produced and equal virus amounts were 
pooled. Of note, a primary library existed in the laboratory containing 82 variants 
representing wild-type capsids and peptide insertion variants thereof. A secondary library 
was generated where 28 chimeras derived from the in vivo HSC selection of this screen 
(denoted AH) were chosen including variants that were already tested in vivo (Figure 
2-14) and variants which were newly sequenced (Figure 6-5). Additionally, chimeras 
from an unrelated selection performed by a different lab member (denoted JEA) and 
additional published capsid variants were included.  
 
 
FIGURE 2-16: BULK VALIDATION BY NEXT-GENERATION SEQUENCING 
Each capsid variant tested contained a unique barcoded vector genome. All variants were mixed 
in equal amounts and injected into mice. Ultimately, the livers were perfused and single cell types 
were isolated, namely, hepatocytes, stellate cells, LSECs and stellate cells. From each sample, 
the genomic DNA and RNA was isolated followed by qualitative and quantitative NGS analysis of 
barcode distribution. The cartoon of the mouse was taken from the servier medical art collection 
(https://smart.servier.com/). 
YFP YFP
NGS
- Efficiency & biodistribution
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To resolve the tropism of these capsids within the liver, four cell types were isolated from 
each individual mouse, namely, hepatocytes, stellate cells, LSECs and Kupffer cells. The 
two libraries were mixed and injected into mice at a total dose of 1.57x1012 vector 
genomes. Theoretically, each of the resulting 157 variants injected is represented with 
1x1010 particles. Genomic DNA (gDNA) as well as RNA were isolated and the latter was 
processed for cDNA synthesis. Importantly, the vector-encoded barcode will be co-
transcribed due to its positioning within the 3´UTR, thus allowing for monitoring of actual 
transgene expression on the RNA level and comparison with vector genome delivery on 
the DNA level. All samples including the input library were then processed for NGS and 
the recovered values were normalized to the abundance of a given variant in the input 
library. 
 
FIGURE 2-17: CDNA PROFILES FOR LIVER CELL SUBTYPES 
Capsids were ranked by ransgene expression (cDNA) and the top 15 hits are shown. Within a 
given cell type, the sum of all barcode read counts was set to 1.0 and the proportion of each 
variant determined. The bars were colored according to their origin: wild-types (WT) are colored in 
black, variants originating from an unrelated screen (JEA) in green, chimeras originating from this 
study (AH) in purple and all other variants in white. HSC, hepatic stellate cell; Hep, hepatocyte; 
KC, Kupffer cell 
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Within a given cell type, the proportion of each variant contributing to the transgene 
expression on the RNA/cDNA level was determined (Figure 2-17). Surprisingly, none of 
the chimeras selected in the in vivo HSC screen appear in the top 15 ranking in stellate 
cells. Instead, the chimeras originating from an unrelated screen in muscle (JEA) 
showed pronounced off-targeting to the different liver cell types. The two serotypes 
AAV7 and AAVrh10 were most effective among all wild-types in stellate cells and were 
found as well in the other fractions. There were two variants identified in this study which 
appeared in the top 15 of other cell types, namely, 4N9 (Hep, KC) and 4N7 (LSEC).  
 
 
FIGURE 2-18: GDNA PROFILES FOR LIVER CELL SUBTYPES 
Vector-encoded barcodes were ranked on the gDNA level. Shown are the top 15 hits. Variants 
that showed up in the top 15 list on the expression level (cDNA) as well are marked by an asterisk 
(*). Note that the scale of the Y axis for the hepatocytes differs from the others. More details are 
found in the legends of Figure 2-17. Additionally, a version was included where AAV5 wild-type 
was excluded from the graphs for a better visualization (Figure 6-6). 
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In addition to cDNA expression, the capsids were ranked on the gDNA level as well. 
Notably, whereas the graphs looked comparable among the various cell types for cDNA, 
this was different for the gDNA ranking. Within the non-parenchymal cells (NPC), i.e., 
stellate cells, Kupffer cells and LSECs, a large proportion of AAV5 can be found which is 
absent from hepatocytes (Figure 2-18). In stellate cells, a high number of the in vivo HSC 
selected variants now appear in the top 15 rank. In total, there are three wild-types 
(AAV1, AAV5, and AAV7), four originate from the unrelated screen (JEA), and eight were 
selected variants from this study.  
Intriguingly, the ranking is highly similar among the different NPCs and six of the eight 
top hits appear in both, LSECs and Kupffer cells (4b-10, 3-18, 3-5, 4-6, 3-10 and 4N11). 
As the gDNA and cDNA graphs resembled each other for hepatocytes, the variants were 
indicated which occur on both, gDNA and cDNA level (compare the asterisks in Figure 
2-18). Curiously, hepatocytes displayed a good correlation between gDNA and cDNA 
(13/15) and LSECs were intermediate (7/15). In contrast, stellate cells (3/15) and Kupffer 
cells (1/15) had a very low coupling of gDNA with cDNA. 
To assess this observation further, a higher sample size was used. Hence, the gDNA 
rank was assigned to the cDNA rank of the top 50 hits on the transgene expression level. 
If one would assume a perfect transcription of gDNA into mRNA/cDNA, a line with the 
slope of 1.0 would be expected. The data for a higher sample size was plotted and 
analyzed by linear regression. Of note, the linear regression analysis considers the 
ranking only and the top 50 were chosen thereby excluding the last ranks where a very 
low amount to no read counts were determined. In addition, the analysis does not 
account for the differences in abundance. For example, AAV5 was the most abundant 
wild-type in the NPCs with a fair amount of distance to the second rank, yet the graphs 
do not contain this vital information. Nonetheless, this particular type of data depiction 
provides a mechanistic explanation for the unique performance of the tested chimeras.  
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FIGURE 2-19: COMPARISON OF THE CDNA WITH THE GDNA RANK 
The correlation of the cDNA rank with the gDNA rank was investigated. The top 50 in the cDNA 
ranking were studied more closely (plotted on the X-axis). The accompying gDNA ranks of the 
single variants were plotted on the Y-axis. Each dot represents the cDNA and associated gDNA 
rank of a single variant. A linear regression was fit into the data points and the slope with its 
standard deviation was determined (indicated by the numbers at the top right of each graph). 
 
 
The slopes for hepatocytes and LSECs were close to 1.0, namely 0.984 and 1.057, 
respectively (Figure 2-19). In contrast, stellate cells have a linear regression with a slope 
of 0.917 which becomes even flatter in Kupffer cells (0.569). This confirms the previous 
observation that hepatocytes and also LSECs have a coupling of gDNA presence to 
RNA expression. Whereas Kupffer cells and to a lesser extent, stellate cells, are 
uncoupled and high gDNA amounts do not automatically translate into high transgene 
expression.    
At last, the amino acid sequences of the chimeras selected in stellate cells and used in 
the NGS screen were studied (Figure 6-5). Curiously, on the gDNA level, these variants 
showed an enrichment of AAV1 and AAV6 at the C-terminus. This was strikingly different 
on the cDNA level where the C-terminus was predominantly derived from AAV7. 
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So far, the distribution of the different variants within a specific cell type was analyzed.  
By application of an alternative normalization strategy, the distribution of a given variant 
among the different cell types can be analyzed, too. Here, the normalization strategy 
considers the vector genomes present in one cell and, therefore, the analysis compares 
the efficiency of a variant per cell and does not account for the complete cell population.  
The biodistribution of the top 15 lead candidates on cDNA level for HSC are depicted in 
Figure 2-20 A. Of note, the variants originating from an unrelated screen (JEA) occurred 
in most cell types thereby exhibiting a broad transduction profile (e.g. 3D4 and 2D4). In 
addition, enrichment in a certain cell type can be observed, such as in Kupffer cells/HSC 
(6_P4 and 1_A2) or in hepatocytes (B1 and 8_A1). Next, the biodistribution of in vivo 
HSC selected chimeras was studied further to see if enrichment for HSC can be 
observed. As observed before, some of the variants showed a broad transduction profile 
(e.g. 4N6 and 4N7) (Figure 2-20 B). Interestingly, these chimeras were derived from 
AAV7/AAVrh10 and likewise, these parental wild-types exhibited a broad distribution 
among the different cell types, too. Most importantly, there were variants, such as 3-5, 
4N1 and 4b-10, which displayed off-targeting from hepatocytes and were more abundant 
in Kupffer cells/HSC. Of note, whereas 3-5 and 4b-10 had a higher preference for 
Kupffer cells than for HSC, the chimera 4N1 showed an increased tropism for HSC than 
for Kupffer cells. The corresponding wild-types, AAV1 and AAV6, showed a comparable 
biodistribution. Curiously, vectors that targeted HSC expressed in a highly similar 
efficiency in Kupffer cells as well. 
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FIGURE 2-20: BIODISTRIBUTION WITHIN THE LIVER 
(A) The biodistribution of the top 15 lead candidates on cDNA level in stellate cells is depicted as 
a stacked bar graph. The four cell types analyzed were stellate cells (HSC), Kupffer cells (KC), 
hepatocytes (Hep) and LSECs. (B) The selected variants along with the respective wild-type 
controls were sorted according to their cDNA rank. More information about the exact rank is 
provided in Figure 6-5.  
 
The variants which will be considered for future in vivo validation studies are summarized 
in Figure 2-21 A. For hepatocytes, the chimeric capsid AAV DJ turned out to be highly 
specific and was the best candidate identified. In previous in vivo validation experiments 
AAV 3-5 mediated efficient transduction of both, Kupffer cells and HSC (Figure 2-14, 
Figure 2-15), and this was recapitulated in the biodistribution analysis. Additionally, the 
chimera 4N1 is of interest due to its preference for HSC over Kupffer cells. The 
corresponding wild-types were included as appropriate controls. For LSECs the overall 
efficiency was rather low and a vector with higher specificity for this cell type could not be 
identified. Another benefit from selection is the increase in production efficiency (Figure 
2-12).  
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FIGURE 2-21: DETAILS ON THE MOST PROMISING VARIANTS 
The NGS screen resulted in the identification of interesting variants for further validation. (A) The 
biodistribution of the variants is shown in a side-by-side comparison. (B) Likewise, their 
production efficiency was compared based on the particle amount produced per plate during 
transfection. The data originate from a database in the Grimm lab collecting the details of all virus 
productions. (C) The two lead candidates 3-5 and 4N1 share the highest homology on the protein 
level with AAV1. For a better comparison AAV6 is included as well. The approximate amino acid 
positions differing from AAV1 are indicated within the grey bars by the stars and arrows. The 
specific changes are noted below using the color code indicated above AAV1. The arrows in the 
bar representing AAV1 indicate the approximate translation start sites for the different VPs. 
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The AAV variant 3-5 has a difference of nine amino acids compared to AAV1 and 
produces 16 times better, with an average particle yield per plate of 4.17x1010 (AAV1) 
and 6.71x1011 (3-5), respectively (Figure 2-21 B, C). Of note, five of the amino acids are 
located near to the N-terminus and are buried within the capsid. The second candidate 
4N1 is more diverse and has a difference of 13 different amino acids compared to AAV1. 
Finally, the aim was the identification of promising AAV variants for the use as cell-type 
specific vectors. The in vivo HSC selection yielded promising variants (3-5 and 4N1) 
which showed hepatocyte detargeting and a preference for HSC and Kupffer cells. The 
NGS bulk validation provided many interesting observations and allowed to dissect the 
tropisms and efficiencies of the different AAV variants tested.  
 
2.3.2.4. ENHANCING SPECIFICITY BY VECTOR DESIGN 
The NGS screen has yielded interesting variants for further validation, but most vectors 
still exhibited off-targeting. While the selection process had reduced the targeting to 
hepatocytes, vectors entering stellate cells also transduced Kupffer cells. For this 
reason, we reckoned that the vector cassette itself needs to be improved as well in order 
to obtain the required specificity. As described below, this was achieved by pursuing two 
complementary strategies. 
The first element that we aimed to improve is the promoter that drives transgene 
expression. Cell-type specific promoters have the advantage that expression is limited to 
the cell type where the promoter is active. For stellate cells, the periostin promoter was 
acquired during the collaboration with Holger Willenbring. Likewise, collaboration with 
Antonia Follenzi (Università del Piemonte Orientale, Italy) provided the cd11b and VEC 
promoters that are active in Kupffer cells or LSECs, respectively. All promoters were 
cloned into an AAV vector encoding an eGFP reporter (section 4.2.3.4). Single-stranded 
vectors were chosen due to the size of the promoters that are incompatible with self-
complementary vectors. However, the use of conventional single-stranded AAV 
genomes comes at the cost of a slower onset of transgene expression. 
Therefore, an alternative strategy was pursued in parallel where a self-complementary 
vector with a ubiquitous CMV promoter was adapted. Here, microRNA (miRNA) binding 
sites (bs) were incorporated into the 3´UTR of the eGFP reporter. To achieve detargeting 
from hepatocytes, four miR-122 bs were incorporated. Additionally, a combinatorial 
vector cassette was generated where next to the miR-122 bs, two bs for miR142-3p 
were inserted. This miRNA is expressed in cells of hematopoietic origin and should 
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mediate off-targeting from between Kupffer cells (Merlin et al. 2017). An overview over 
the different constructs and the expected expression profile is depicted in Figure 2-22 A. 
Next, the vector cassettes were tested for functionality in vitro. The chimeric capsid 3-5 
was chosen for production of crude lysates and different cell lines were transduced. Two 
days later, the amount of GFP-positive cells was determined by FACS analysis. The cell 
lines were chosen to model the different cell types found in the liver. Huh7 cells are 
derived from a hepatic carcinoma and served as a surrogate for hepatocytes. As 
expected, reporter expression was abolished from constructs bearing the miR-122 bs 
(Figure 2-22 B). Similarly, the miR142-3pbs diminished expression in RAW264.7 cells 
which are derived from macrophages. Thereby, detargeting from Kupffer cells and 
hepatocytes should be achievable. The other cells included were LX-2 which originated 
from human stellate cells and human umbilical vein endothelial cells (HUVEC) which 
model endothelial cells, i.e., LSECs. The miRNA bs tested had no effect on transgene 
expression in these two cell lines.  
 
 
FIGURE 2-22: ADAPTATION OF THE VECTOR CASSETTE 
Increase of vector cassette specificity by using different promoters and incorporing miRNA 
binding sites. (A) Scheme depicting the expected performance of the listed vector elements (left) 
in different liver cell subtypes (top). Successful transgene expression is colored green and 
inactive elements are shown in red. The arrows indicate the expected miRNA-dependent down-
regulation of transgene expression. (B) All elements were packaged into the chimera 3-5 in small 
scale. The resulting crude lysates were used to transduce a variety of cell lines (indicated at the 
top) and the amount of reporter (eGFP) positive cells was determined 48 h later by FACS. The 
mean of n=3 is depicted as a heat map ranging from no infection (0%) to 100%. The color scale is 
indicated below. Hep, hepatocytes; HSC, hepatic stellate cells; KC, Kupffer cell; bs, miRNA 
binding site 
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The cell-type specific promoters were not as efficient in mediating specificity as the 
miRNA bs. The cd11b promoter was acquired for Kupffer cells and is inactive in most cell 
types, albeit HUVECs to a small extent. Periostin was chosen for stellate cells and the 
promoter is active in all cell lines except for RAW264.7. In contrast, the VEC promoter 
specifically conveyed expression in HUVECs and thereby limited transgene expression 
to the endothelial cell line. 
Overall, the generated vector cassettes were capable of restricting the transgene 
expression to specific cell types by application of miRNA bs and the VEC promoter. The 
results from the in vitro experiment are promising for future in vivo validations. 
 
2.4.OPTIMIZATION OF THE SELECTION PROCESS 
While the selection was performed, ideas for improvement arose to advance future 
selections. When many samples are processed in parallel, there is a risk of cross-
contamination during PCR rescues. Similarly to the abovementioned NGS approach, a 
novel barcoding strategy was thus implemented to increase the stringency during 
selection and to prevent possible cross-contaminations. Furthermore, it can serve as an 
indicator of enrichment during selection. Additionally, an alternative sequencing 
approach by SMRT sequencing (PacBio) was assessed. 
 
2.4.1. BARCODE MEDIATED PCR RESCUE 
In order to increase the stringency of the PCR rescue during selection, a novel barcoding 
strategy should be implemented. Therefore, the replication-competent backbone used for 
the selection of AAVs required adjustments for the insertion of the barcodes (Figure 2-23 
A). Therefore, an additional restriction site was introduced after the 3´end of cap. The 
NdeI restriction site was chosen as it was neither present in the acceptor backbone nor 
in the 10 serotypes used in this study and was transferred by oligo annealing between 
the AscI site and the SpeI site (Figure 2-23 A, section 4.2.3.3). Thereby two positions 
were created where the barcodes can be inserted. Eventually, a reverse primer covering 
the barcode sequence can be used for a specific PCR rescue. The idea was to tag 
individual libraries by use of one barcode at the AscI/ NdeI interface (see section 2.4.2). 
Additionally, the second barcode at the NdeI/ SpeI interface could be then used to 
separate the PCR rescues between single selection rounds or organs by introduction of 
a new barcode sequence for every sample.    
2 Results 
58 
 
Initially, a proof-of-principle for the selectivity of the barcodes was performed in an in 
vitro setting (section 4.2.8.1). Therefore, three different libraries were tagged with a 
barcode, namely, libraries composed of serotypes 2, 8 and 9 (289); 1, 7-9 and rh10 
(1789rh10); and 1-rh10 with shuffling optimized versions of AAV4 and 5 (1-10O). The 
individual libraries were produced in small scale as crude lysates. Next, HEK293T cells 
were infected for subsequent PCR rescue. The libraries were either used separately 
(conditions 1-3 in Figure 2-23 B) or as a mixture where each library is present at the 
same volume (condition 4 in Figure 2-23 B). The next day, the cells were harvested and 
lysed by Proteinase K digestion. A PCR was performed on all four samples (single and 
mixed infections) with either library-specific primers (lib) or a general primer (G) common 
in all libraries.  
As expected, the general primer could rescue cap in all samples (Figure 2-23 C). The 
library-specific primers cover the corresponding unique barcode and, hence, sample-
specific amplification was expected. Indeed, this specificity was observed as in the 
single-infection samples, only the respective barcodes serving as reverse primer binding 
site could perform the rescue (highlighted by arrows). Next, the samples were 
sequenced to confirm the identity of the rescued cap variants. Initially, PCRs using the 
common primer “G” were performed on conditions 1-3 (Figure 2-23 B) followed by 
subcloning and sequencing. The clones recovered originated from the expected library 
exemplified by Salanto analysis which correlated with the parents from the input library 
(Figure 6-7) and the presence of the expected library-specific barcode.  
Next, the sample containing a mixture of libraries (condition 4) was analyzed. By using 
the common primer “G”, a mixture of clones can be isolated evidenced by the numbers 
and the type assignment (Figure 2-23 D). Clones from all three input libraries were 
observed. However, a majority originated from the 289 library (6 out of 10). If the library-
specific barcodes were used for the PCR step, only clones originating from the 
respective library were recovered, once again confirming the specificity. 
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FIGURE 2-23: BARCODED PCR RESCUE 
(A) The altered backbone design is depicted. The NdeI site was introduced between the existing 
AscI and SpeI site allowing for the insertion of two different barcodes at the same time. One can 
be used to tag a library (lib) and the other can specify e.g. a given organ or selection round. For a 
proof-of-principle, three different libraries were tagged with a unique lib barcode and, additionally, 
a general (G) barcode common for all was inserted. (B) Crude lysates were produced and 50 µl 
were used to infect HEK293T cells either separately (1-3) or as a mixture (4). After 24 h, the cells 
were harvested and a PCR rescue was performed. (C) For the PCR, all samples were tested with 
different combinations of reverse primer and equal volumes were analyzed on a 1% agarose gel. 
Sample numbering correlates with the conditions in (B). The barcode exploited as reverse primer 
binding site is depicted above the gel image and expected bands are highlighted with the arrow. 
(D) The products from the PCR rescues for condition 4 were subcloned for further analysis. The 
approximately last 800 bp of cap were sequenced with a reverse primer and single clones were 
analyzed with Salanto. The color code is depicted above the image and below. Numbers indicate 
the identified barcodes from all clones tested. Adapted from (Herrmann et al. manuscript in 
preparation). 
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2.4.2. LIBRARY TRACKING IN VIVO 
During the course of the study, a 1-10O library was generated by DNA family shuffling 
and selected in stellate cells in vivo (section 2.3.1). This library is referred to as “original” 
(ori). Although enrichment of certain C-terminal domains was observed, the initial library 
had a certain bias towards AAV1, AAV6 and AAV7. For future selections, a more evenly 
distributed library representing a higher variety at the C-terminus should be beneficial. 
Therefore, another 1-10O library was shuffled under the same conditions originally used. 
This library (“new”) again showed a large proportion of AAV1 and AAV6, exemplified by 
the grey and pink color at the 3´end in Figure 2-24 A. In order to circumvent this bias, the 
shuffling was repeated once more but this time, AAV1 and AAV6 were counted as one 
serotype in the DNase I digestion. This resulted in a third library (“red”) with a reduced 
amount of these serotypes and an increased proportion of AAVrh10.  
To test the hypothesis that a mixture of AAV libraries could be beneficial for selection 
due to the presence of a higher C-terminal diversity, an in vivo pilot study was performed 
to obtain proof-of-principle. Therefore, four shuffled libraries (289, 1-10O ori/red/new) 
were tagged with a unique barcode and produced separately by cesium chloride gradient 
density centrifugation (section 4.2.8.2). After titration, equal virus amounts were mixed 
and injected intravenously into two female mice. Two days later, they were sacrificed and 
selected organs were extracted followed by DNA isolation (Figure 2-24 A). For the PCR 
rescue, a common primer was used for the amplification of cap. The recovered variants 
were subcloned and single clones were sequenced from the 3´end. Then, the present 
barcodes were identified, counted and the relative percentage was determined (Figure 
2-24 B). For all organs from the first selection round, 96 sequences were recovered. A 
second round of selection was performed with the libraries recovered from heart, liver 
and kidney and here, 48 clones were sequenced. 
After the first round of selection, the distribution among organs looked similar for the 1-
10O libraries. The 289 library was less abundant in most organs except for kidney where 
it occupied approximately a quarter of the reads. However, after another round of 
selection, changes could be observed. The 289 library was now less abundant in the 
kidney, comparable to the other organs after the first round of selection. Instead, an 
increase of the libraries 1-10O “ori” and “new” could be observed.  
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FIGURE 2-24: LIBRARY TRACKING IN VIVO 
Validation of the library barcoding strategy in mice in vivo. (A) Scheme of the experimental 
setting. Four different libraries were tagged with a specific barcode and a mixture was injected 
into mice. After 48 h, the indicated organs were isolated and processed for DNA isolation. The 
color code represents the parental serotypes of the libraries. Full-length cap genes are shown on 
the nucleotide level. (B) The isolated DNA was used for PCR rescues with a common primer and 
the last 800 bp of the cap gene were sequenced. From the first selection round, 96 clones were 
analyzed and 48 from the second. The percentage of individual barcodes is depicted as a stacked 
bar graph. Lu, lung; M, muscle; K, kidney; Li, liver; H, heart; #2, round 2. The cartoon of the 
mouse was taken from the servier medical art collection (https://smart.servier.com/). Adapted 
from (Herrmann et al. manuscript in preparation). 
 
In contrast, these two libraries became less abundant in the liver upon another selection 
round. Instead, an enrichment of the 1-10O “red” library and the 289 library was 
observed. The liver is the only organ where the 289 library was further enriched upon 
selection. In the heart, an enrichment of the 1-10O “new” library can be observed at the 
cost of the “red” library. Overall, differences in the distribution of individual libraries were 
observed indicative of enrichments. 
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In summary, we showed that the barcoding approach was capable to mediate a more 
stringent PCR rescue, even when a mixture of libraries was present. Furthermore, future 
selection studies could benefit from using a mixture of libraries instead of an individual 
one, and the presented strategy could also be applied to track the library origin.  
 
2.4.3. MONITORING LIBRARY ENRICHMENT BY SMRT SEQUENCING 
Last but not least, yet another aspect that needs to be improved during generation and 
selection of AAV capsid libraries is the sequencing method. To date, the standard 
procedure is Sanger sequencing of single clones. This method is cheap, simple and fast, 
but, it is also very low-throughput especially since three sequencing reactions are 
required to cover the complete cap gene (section 2.1.1). Thus, only a fraction of the 
whole clone population within a capsid library is covered. PacBio/SMRT is an alternative 
sequencing method that bears the seminal advantage that it reads on average 10 to 
15 kb with a coverage of 3.5–7.5x104 reads  (Rhoads and Au 2015).  
During the selection in stellate cells performed in this work (section 2.3.1), a presumable 
shift from AAV1 and AAV6 towards AAV7 was observed by Sanger sequencing. To 
independently validate this result, the PCR rescue product obtained after the third round 
was sent for PacBio/SMRT sequencing. A more detailed analysis of the data is found in 
the Bachelor thesis of Niklas Beumer (also performed in the Grimm laboratory), who 
kindly isolated the sequences of 200 random clones. These sequences were aligned and 
assigned, using another pivotal feature of the Salanto suite. Briefly, at each nucleotide 
position the proportion of each reference sequence, undetermined (indet) and mutated 
(mut) was determined. This finally reflects the likeliness of a certain serotype to occur at 
a given position and the data was depicted as a line graph as seen in Figure 2-25. The 
lines for Sanger sequencing appear like a staircase (Figure 2-25 A) whereas, in stark 
contrast, the PacBio/SMRT-derived analysis appears much smoother (Figure 2-25 B). 
The reason for the latter is the difference in the number of analyzed sequences, which is 
approximately 10-fold higher in the case of the PacBio/SMRT strategy.  
Moreover, in the analysis based on Sanger sequencing of 18 clones, an enrichment of 
AAV1 and AAV6 was observed at the C-terminal part. Interestingly, there seemed to be 
a preference of AAV1 over AAV6 at certain positions (indicated by the arrows). Similarly, 
this trend can be observed in the sequences derived from PacBio/SMRT sequencing. 
However, here, an overall high abundance of AAV7 became visible which was missed in 
the Sanger sequencing-based analysis. 
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FIGURE 2-25: SEQUENCE ANALYSIS BASED ON DIFFERENT METHODS 
The positionwise distribution of the parental sequences revealed a higher accuracy of 
PacBio/SMRT sequencing. The complete nucleotide sequence was analyzed by Salanto. The 
probability (Y-axis) of a given parental serotype at a certain position (X-axis) is depicted and 
colored according to the color scheme. The arrows indicate a preference of AAV1 over AAV6 at a 
certain position. (A) The analysis is based on the analysis of 18 clones by Sanger sequencing. (B) 
The analysis is the result of 200 sequences originating from a PacBio/SMRT sequencing run. 
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3.DISCUSSION 
Over the last few decades, viral vectors based on AAVs have become increasingly 
popular for a variety of biological or medical applications. Their attractiveness and 
potential are best exemplified by the fact that the first two gene therapies approved in the 
Western World are based on AAV vectors (section 1.1.3). The development of clinical 
AAV gene therapies is additionally fostered by basic research and our resulting, steadily 
improving knowledge about disease initiation and progression. A major example that was 
in the center of the present work is the liver, a vital organ exerting multiple functions in 
physiology and disease that is composed of different cell types. Of these, stellate cells 
play an important role for the progression of liver fibrosis, a potentially fatal disease 
lacking options for curative treatment (section 1.2.2). Accordingly, viral vectors that are 
specific for these or other liver cell types would be of great value for the biomedical 
community. A most promising strategy to achieve this vital aim is the molecular 
engineering of novel viral capsids and genomes that mediate cell type-specific 
expression of therapeutic transgenes, ideally from a non-invasive peripheral infusion. To 
this end, the present work pursued two complementary goals: (i) to dissect and optimize 
seminal steps in the workflow for AAV capsid evolution by DNA family shuffling, and (ii) 
to apply this technology in order to enrich novel, liver cell type-specific AAV capsids 
through iterative selection in adult mice in vivo. 
 
3.1. TECHNICAL IMPROVEMENTS 
The first major aim of this work was to broaden our current understanding of the 
molecular processes underlying DNA family shuffling of AAV capsid genes, and to then 
use the newly gained knowledge to improve and simplify the protocol for future users of 
this powerful technology. As described above and discussed in more detail below, the 
steps that were investigated comprise (i) fragmentation of input capsid genes, (ii) 
purification of products from the re-assembly PCR, (iii) DNA barcoding as a novel means 
for library multiplexing and tracking, and (iv) use of PacBio/SMRT instead of Sanger 
sequencing for analysis of shuffled full-length capsid genes.  
Initially, we studied one of the very early steps in DNA family shuffling, namely, the 
fragmentation of full-length cap genes into smaller pieces for subsequent re-assembly in 
a primer-less PCR. To date, the vast majority of previous studies comprising the 
pioneering work from Grimm and colleagues (Koerber, Jang, and Schaffer 2008; Li et al. 
2008; Grimm et al. 2008) has used enzymatic fragmentation with DNase I as method of 
3 Discussion 
66 
 
choice. However, this procedure is difficult to standardize because the digestion 
efficiency is influenced by multiple parameters, including the age of the enzyme and the 
experience of the operator. We therefore evaluated the possibility to overcome this 
bottleneck by replacing the DNase I reaction with physical fragmentation by Covaris-
based ultrasonication.  
Our results show that when using the Covaris machine for fragmentation, only the pool 
with the largest fragments (800 bp) was capable of producing full-length cap (Figure 2-1). 
This confirms and extends previous data from our group, and it supports the hypothesis 
that DNA family shuffling is dependent on longer fragments above a certain threshold 
(Große 2016). Interestingly, when DNA family shuffling was modeled by another group in 
silico, it was found that small fragments of 100 bp would convey a four times higher 
crossover rate as compared to larger fragments of 400 bp (Maheshri et al. 2006). 
Concurrently, however, the overall yield would be decreased by a factor of over six-fold. 
Additionally, when modeling the reassembly frequency, the best result was obtained for 
fragments of 400 bp in size as compared to 100 bp and 200 bp fragments. Taken 
together, this model suggests that a minimal fragment size of 400 bp yields the best 
trade-off of between crossover frequency and reassembly efficiency. Of note, this former 
theroretical prediction is fully congruent with the new experimental data obtained in the 
present work, as the pool of 300 bp fragments obtained by Covaris ultrasonication failed 
to recover cap in most cases.  
Furthermore, our sequencing analyses show that the C1 library created through 
ultrasonication was composed of fewer fragments with an overall larger fragment size, in 
contrast to libraries derived from DNase I digestion that contained shorter fragments with 
a higher abundance (Figure 2-2). Also this correlation is in line with previous data from 
our group (Große 2016).  
Finally, we compared different conditions for DNase I digestion, in particular varying 
reaction times, to assess their influence on the overall efficiency of the DNA family 
shuffling protocol. Importantly, our data suggest that all of them worked comparably well, 
based on our analysis of average fragment size and abundance of fragments.   
In conclusion of this part, our thorough comparison of two fragmentation methods, 
enzymatic or physical, provided compelling evidence that DNase I digestion is the more 
robust approach. This was supported by the observations that (i) all DNase I digests 
tested recovered cap, and that (ii) the reproducibility of full-length cap assembly is higher 
for DNase I (6/6 samples recovered cap) as compared to Covaris (only 4/9 reactions 
recovered cap). Furthermore, the robustness is illustrated by the finding that (iii) the 
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sequence analysis gave comparable results among individual DNase I digests, despite 
different appearances of the digests on the gel in terms of fragment size distributions. As 
a whole, our results allow us to conclude that DNase I digestion is in fact much more 
robust and reproducible than originally anticipated, and we thus continue to recommend 
this method as the preferred option for initial DNA fragmentation during AAV DNA family 
shuffling. 
Additionally, we were able to improve the yields of the recovered full-length cap PCR 
product, which was urgently needed as roughly 1.3 µg of digested PCR product are 
required for standard library generation. This improvement was made possible by 
showing that bands generated during nested PCR steps with a size between 4 to 5 kb 
could be resolved into the 2.2 kb cap band upon digestion with appropriate restriction 
enzymes (Figure 2-3). Our interpretation of this finding is that the restriction sites flanking 
cap serve as a linker sequence, leading to concatamer formation and permitting 
resolution into single molecules through enzymatic digestion. Accordingly, the PCR 
purification protocol was changed from the standard gel purification to column 
purification, which, as shown above (Figure 2-3), resulted in a substantial increase in 
final yields of PCR product for subsequent cloning. This optimization is highly beneficial 
for future library productions as it additionally saves time, work and materials.   
Next to the steps for library production, we also succeeded at optimizing the downstream 
selection process of shuffled AAV capsid libraries. A first improvement was the 
incorporation of specific barcodes into the library backbones, fueled by our motivation to 
increase the stringency of the PCR rescue for secondary library generation. This was 
urgently implied by observations in our group and many others working with AAV 
libraries (D. Grimm, personal communication) of occasional contamination with unrelated 
cap sequences during PCR reactions. To decrease this risk, we came up with the idea 
that incorporation of a barcode specific for e.g. a given target organ or a particular 
selection round can be used as a reverse binding primer site during PCR rescue. 
Because this barcode can be designed to be unique for each scenario, it will serve as a 
unanimous identifier for a specific library and will thus largely reduce or eliminate the risk 
of cross-contamination. This expectation was clearly validated by our results from the in 
vitro experiments, proving that it is indeed possible to deliberately isolate individual 
libraries or clones from a mixture (Figure 2-23).  
Based on these encouraging first data, we can readily envision a second benefit of our 
new library barcoding strategy next to the reduction of contaminations, namely, the ability 
to use a mixture of different libraries for selection instead of only one (Figure 2-24). 
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Thereby, the complexity and variability of the input library, or rather the pool thereof, can 
be expanded even further, while the barcodes can be exploited to track the origin of each 
individual library within the pool at any time. This ability to multiplex and deconvolve 
libraries, respectively, is essential because if enrichment of a certain library in a pool is 
observed early during the selection, this will indicate that candidates originating from this 
library are most relevant. Hence, subsequent selection rounds can focus on this subset 
of libraries and thus continuously increase the stringency and chances of overall 
success. This strategy of co-infecting with multiple different libraries at once was applied 
in the past (albeit lacking the additional benefit of the barcodes) and yielded the 
promising variant EP1.9 (section 1.1.4.2, (Asuri et al. 2012)). In this previous example, 
libraries created by different technologies were chosen, i.e. shuffling, peptide insertion 
and error-prone PCR, which ultimately enabled the identification of the library origin. As 
an important advance, our novel barcoding strategy will now also allow to mix and 
disentangle several shuffled libraries, whose identification would otherwise be difficult, 
especially when libraries with a similar parental composition are used.  
Finally, we have made first attempts to improve yet another critical step in the AAV DNA 
family shuffling protocol, which is the sequencing-based analysis of the starting libraries 
or of selected clones. This was motivated by the fact that the current standard - Sanger 
sequencing - requires three different sequencing reactions to cover the complete cap 
gene, the results of which are then manually assembled into the full-length sequence. 
This labor-, time- and cost-intensive work load limits the amount of clones which can be 
analyzed in parallel and therefore necessitates the implementation of alternative, more 
powerful and high-throughput-compatible sequencing methods. One such option could 
be Illumina sequencing, but the maximum read length of this technology is limited to 
approximately 250 bp (Rhoads and Au 2015), which makes it unsuitable for  sequencing 
of full-length shuffled AAV genomes in a single run due to their size of 2.2 kb (i.e., in 
principle, the same problem as with Sanger sequencing). Fortunately, in recent years, 
the SMRT technology of Pacific Biosciences (thus also called PacBio sequencing) has 
become affordable and thus very attractive as a novel means for sequencing of shuffled 
AAVs. The latter is owing to the facts that PacBio/SMRT sequencing can easily cover the 
entire cap gene in one run, and that the read depth is still in a range (typically >15.000) 
that is orders of magnitude above that of conventional Sanger sequencing. Here, the 
power and potential of this new approach were exemplified and the sample after the third 
selection round was sequenced. Sanger sequencing predicted enrichment for AAV1 and 
AAV6 but unexpectedly, the picture changed after the fourth round where enrichment of 
AAV7 was found in three independent mice (Figure 6-4). The complete PacBio 
PhD thesis, Anne-Kathrin Herrmann 
69 
 
sequencing run encompassed approximately 13600 reads providing approximately 103 
more reads than Sanger sequencing. Analysis of 200 clones retrieved from PacBio 
sequencing revealed that AAV7 was already the most abundant serotype after the third 
round and the same interesting enrichment of AAV6 over AAV1 was identified seen in 
Sanger sequencing (Figure 2-25). For future studies this sequencing technology is highly 
promising as much more clones can be covered and, ideally, the most abundant variants 
can be thereby identified.  
 
3.2. THE SHUFFLING OF AAP IS NOT DETRIMENTAL 
When AAP was first reported in 2010, the authors immediately raised the concern that 
during shuffling of cap, the overlapping AAP frame will be shuffled along which might in 
turn be detrimental for production of viral libraries and selection (Sonntag, Schmidt, and 
Kleinschmidt 2010). In earlier studies the fact was exploited that VP3 alone can 
assemble particles as long as AAP is present. By using VP3 only expression constructs 
the AAP frame is not complete and as a consequence particle assembly is diminished. In 
contrast, the experimental system established by or group is in a more natural context as 
the whole VP frame is used where AAP was endogenously knocked out (Große 2016). 
This allowed us to assess the functionality of AAP - wild-type or shuffled - in a trans-
complementation assay. Briefly, endogenous AAP was knocked out in AAV helper 
plasmids of various serotypes so that during production of recombinant particles, either 
stuffer DNA or AAP could be supplemented in trans. Subsequently, expression of a 
vector-encoded GFP reporter in cells transduced with the resulting crude rAAV lysates 
was monitored as a surrogate marker of infectious particle production. However, this 
assay is indirect, and neither AAP expression nor the generation of assembled AAV 
particles has been confirmed more directly on the protein level to date. During this study, 
these critical gaps were filled by, firstly, confirming the functionality of the AAP 
expression plasmids by Western blotting. As hoped for, this analysis showed the 
complete absence of residual AAP expression in case of the knockout AAP versions, 
thereby verifying our combinatorial strategy to disrupt the AAP start codon and to 
concurrently introduce a stop codon (Figure 2-4 A). Intriguingly, the different AAPs ran at 
varying sizes in the gel although a similar size would be expected based on their 
sequences. Of note, while this study was conducted, another group presented a similar 
system and our observation is in accordance with their results (Earley et al. 2017). Taken 
together, this implies that AAP may be post-translationally modified in a serotype-specific 
manner, which is an interesting hypothesis for future work. 
3 Discussion 
70 
 
Secondly, in this study, we analyzed the outcome of the trans-complementation assay 
more directly on the AAV protein/capsid level as well. Therefore, native dot blots using 
capsid-specific antibodies were performed under non-denaturing conditions, in order to 
detect assembled AAV particles in the presence or absence of AAP. As an important 
control, the samples were additionally heated to promote capsid disassembly. This 
confirmed that the impaired transduction originates from a lack of assembled particles 
(Figure 2-4 B). Curiously, in the case of the AAV1, 4 and 5 AAP knockout mutants, the 
ADK antibodies detected a structure which failed to reveal the B1 epitope (hidden inside 
the assembled particle) upon heating. A possible explanation is that the VP subunits 
form stable aggregates in the absence of AAP that are recognized by the ADK 
antibodies and that are largely resistant to treatment with heat. 
Next, the dependency of a given AAV variant on its own cognate AAP was assessed by 
testing different AAP variants. Therefore, an experimental array was designed where 
each AAV variant was rescued with all different wild-type AAPs, followed by 
measurement of transduction activity (Figure 2-5 B). A major finding was that most of the 
serotypes tested highly depend on AAP. Notable exceptions were the AAV4 and AAV5 
mutants that maintained residual transduction activity even in the absence of AAP, which 
might reflect the aforementioned structures detected in the dot blot. Furthermore, a high 
degree of interchangeability was observed with most AAPs, which is in agreement with, 
and substantially expands, previously published data (Sonntag et al. 2011). This follow-
up study reported the assembly of AAV1, AAV2, AAV8 and AAV9 VP3-only particles 
through trans-complementation with AAP2.  
Additionally, AAP4 was only able to rescue its own knockout and the one derived from 
AAV5. Likewise, AAP5 failed to rescue a variety of AAP knockout mutants derived from 
multiple AAV serotypes, expanding results of a recent study that used VP3-only particles 
(Earley et al. 2017). These two AAPs, which are inefficient with most serotypes, have the 
most divergent sequence (Figure 2-5 C), prompting the conclusion that the compatibility 
of capsid variants with (exogenous) AAP is determined by the degree of homology. In 
this respect, it is curious that the AAV5 mutant tolerated a variety of other AAPs to 
mediate an intermediate rescue.  
Another interesting observation was made for AAV3, as some AAPs even increased the 
rescue of the AAP3 knockout mutant over wild-type level. This may indicate a stronger 
AAP dependency of AAV3 and hence a beneficial effect of AAP supplementation during 
production. Furthermore, the mutants derived from AAV7 and AAVrh10 were also unique 
by displaying an intermediate rescue efficiency as compared to the other AAP 
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knockouts. In conclusion, we found that most of the wild-type AAPs are readily 
interchangeable but there are exceptions that are worthy of further investigation. 
Motivated by these results, we next investigated shuffled AAPs and started with AAP 
from AAV DJ, denoted as AAP DJ, as this capsid was one of the first shuffled chimeras 
reported and was available in the laboratory (Grimm et al. 2008). Because it is 
composed of serotypes AAV2, 8 and 9, we tested the ability of AAP DJ to rescue these 
three parental capsids. Indeed, AAP DJ potently rescued the corresponding parental 
AAP knockout mutants to wild-type levels and, interestingly, a more efficient rescue of 
the AAV2 mutant was mediated in comparison to AAP8 and AAP9 (Figure 2-6 C). Akin to 
AAV2, it potently rescued AAV3 beyond wild-type levels as well (Figure 2-6 D) but in the 
Western blot two bands appeared for AAPDJ in the Western blot, similar to AAP8 (Figure 
2-6 B). Intriguingly, these observations imply that this chimeric AAP has acquired 
characteristics from its multiple different parents.  
When our laboratory has recently studied the localization of these different AAPs, we 
found AAP2 to be present in the nucleolei, whereas AAP8 and AAP9 were situated in the 
nucleoplasm (Grosse et al. 2017). AAPDJ was observed in the nucleoplasm as well and 
therefore resembled two of its three parents (Herrmann, Große, et al. 2018). This further 
exemplifies the chimeric functionality that AAV/P DJ has acquired during shuffling and 
molecular evolution.  
Besides, these different AAP localization patterns that we and others (Grosse et al. 
2017) (Earley et al. 2017) observed fuel questions about the exact mechanism of AAP 
during capsid assembly. For instance, it is known that AAV2 assembly occurs in the 
nucleolei but some AAPs are actually excluded from this compartment based on our data 
and could still rescue the AAV2 AAP knockout mutant upon trans-complementation.  
AAV DJ originally resulted from a combination of positive and negative selection 
pressure (Grimm et al. 2008), leaving open the possibility that shuffling of AAP might still 
be detrimental during the early steps of library generation by DNA shuffling. Therefore, 
we next analyzed additional shuffled AAPs that we arbitrarily selected from five different 
unselected libraries. When juxtaposed with the AAV2 mutant, 54 out of 60 (90%) shuffled 
AAPs were able to rescue the AAP2 knockout above the 5% threshold level, with most of 
them restoring the transduction levels back to wild-type (Figure 2-7 B). The six AAP 
clones initially classified as dysfunctional could rescue at least one of their wild-type 
parents. Of note, three more AAP variants (19, 39 and 51) were tested with their 
respective wild-type AAP knockout mutants as well as they barely passed the 5% 
threshold in the original assay with AAV2 and for these, robust rescue could be observed 
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with non-AAV2 serotypes (Table 6-1). In conclusion, all of the 60 chimeric AAPs tested 
were capable of promoting assembly of at least one of the AAP knockout versions.  
The rescue efficiencies of chimeric AAPs varied depending on the parental wild-type 
mutant rescued, which led us to the question whether AAP supplementation would result 
in increased rAAV particle yields. When the wild-type serotypes, which endogenously 
express their cognate AAP already, were produced in the presence of a mixture 
containing all 10 AAPs, the transduction efficiency of the AAP-supplemented samples 
relative to the stuffer control was around one in all cases (Figure 2-8 B, C). This indicates 
that the extra AAP supplied during production had no effect on the yields of infectious 
particles. This experiment was subsequently expanded to chimeric capsids as well. Five 
cognate capsids of the previously tested chimeric AAP variants were chosen for 
production of recombinant particles and depending on the library origin, the 
corresponding wild-type AAP variants were supplied. Out of 25 chosen capsids, 19 were 
capable of transducing at least one of the cell lines tested and comparable to the wild-
types the supplementation with extra AAP had no influence on particle yields in most 
cases (Figure 2-8 D). This is in accordance with recently published data from our group, 
showing that AAP overexpression in a baculovirus system likewise did not result in 
increased titers (Grosse et al. 2017). Taken together this suggests that excess AAP 
supplementation during library production has no effect, either positively or negatively,   
on particle production. Furthermore, this supports our conclusion that chimerism of AAP 
is not disadvantageous. 
There was one exception, namely, capsid 18 whose own AAP failed to support the 
production of transduction-competent particles, albeit it was present in this assay. A 
remarkable increase in efficiency was observed upon exogenous AAP supplementation, 
however, mostly mediated by AAP5 and to a lesser extent by AAP2 (Figure 2-9). Six 
chimeric capsids failed to achieve transduction, which might be a consequence of either 
a defect in assembly or the development of novel tropisms incompatible with the cell 
lines tested. Strikingly, four of these six capsids originated from the 24589 library, 
including variant 18. Additionally, four AAP representatives of this library were not 
efficient at rescuing the AAV2 mutant (Figure 2-7 B). From the six variants which failed to 
support the AAV2 mutant, five contain an N-terminus derived from either AAV4 or AAV5 
(supplements, Figure 6-2). As noted before, AAV4 and AAV5 are more divergent from 
the other serotypes, implying that sequence homology especially within the N-terminus 
might play a crucial role for the compatibility of a capsid with AAP. Congruent with this 
hypothesis, Tse et al. have very recently reported a series of AAP deletion and 
substitution mutants and showed that the AAP N-terminus is crucial for VP recognition 
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(Tse et al. 2018). In one particularly noteworthy experiment, they replaced part of the N-
terminus of AAP1 with AAP5 and observed a drop in AAV1 vector yield. This supports 
our aforementioned data and conclusion, that the AAP N-terminus is most important for 
conveying compatibility with a given AAV capsid.  
Furthermore, we studied the functionality of AAPs which had undergone co-selection 
with their cognate capsids. The underlying rationale was our interesting observation that 
after selection, some chimeric vectors produced better in comparison to the wild-types 
with which they shared a large proportion of the AAP C-terminus. One ensuing 
hypothesis was that an extra supply of AAP might increase particle yields, akin to what 
we had observed for the AAV3 mutant that was boosted beyond wild-type level with 
certain AAP variants. Therefore, we hypothesized that the observed increase in 
production efficiency was mediated by AAP. However, our data from the trans-
complementation assay showed that in most cases, the evolved AAPs mediated a 
rescue back to wild-type levels, but not further (Figure 2-13 B). This was especially true 
for AAV1 and AAV6. The other two mutant versions of AAV7 and AAVrh10 were not so 
readily rescued which is in accordance with previous data (Figure 2-5 B). This implies 
that the increase in production efficiency is most likely not associated with AAP itself but 
rather a result from other factors, such as capsid stability as intermediate production and 
purification steps were involved, which are in turn prone to favoring variants that produce 
at high titers and/or are more stable during density gradient centrifugation. Most 
importantly, the chimeric AAPs resulting from the selection were functional and, hence, 
not limiting for the selection.  
When AAP was initially reported, there was a concern in the field that the inadvertent 
shuffling of AAP might be detrimental for the generation of viral libraries by DNA family 
shuffling. Luckily, recently published first results from our group already indicate that this 
risk may have been over-estimated (Große 2016). In the study presented here, previous 
experiments (Figure 2-7 B) were expanded to a higher sample size and additional 
information was gathered on the effect of DNA shuffling on AAP functionality.  
The overall conclusion is that inadvertent shuffling of AAP is not as detrimental as 
thought of, supported by our findings that (i) an AAV2 mutant could be rescued by 90% 
of chimeric AAPs tested and that the remaining variants rescued at least one other 
parental serotype. This, in combination with the high interchangeability of wild-type 
AAPs, indicates a substantial compatibility between AAP and capsid variants and thus a 
high degree of compatibility. Furthermore, (ii) the supplementation of AAP during 
production of already AAP-expressing rAAV had negligible influence on transduction 
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efficiency, suggesting that the particle yields were not increased by the extra AAP. In 
addition, we studied evolved AAP variants and showed that (iii) AAP DJ combines 
characteristics from several parents. Lastly, (iv) 12 additional evolved AAPs also 
displayed broad trans-complementation ability. 
Of note, the high degree of compatibility seemed to be dependent on homology as 
incorporation of the more divergent serotypes AAV4 and AAV5 lead to reduced 
interchangeability. We therefore conclude that it should be beneficial for future studies to 
identify crucial domains in AAP that govern its function. In this context, the recent study 
identifying the AAV N-terminal part as particularly important for VP recognition is highly 
interesting (Tse et al. 2018). Consequently, this region could be kept conserved to 
prevent adverse shuffling at this position and thus disruption of AAP activity. Alternatively 
or in addition, supplying extra AAP during production might turn out to be beneficial for 
some capsids variants (such as clone 18). Concurrently, it is tempting to study the 
domains important for AAP functionality by applying DNA family shuffling directly to AAP. 
For instance, the AAPs from highly compatible AAPs, such as AAP2 or AAPrh10, could 
be shuffled with a more divergent AAP, such as AAP5. This fundamental approach, i.e., 
the use of DNA family shuffling to dissect sequence-function relationships, has recently 
been exploited to identify the determinants of the AAVrh10 capsid that mediate crossing 
of the blood-brain barrier (Albright et al. 2018). In this study, the authors shuffled AAV1, 
which is non-permissive to the brain, with AAVrh10 and then validated several variants in 
vivo. Eventually, they identified an eight amino acid long “footprint”, which upon 
engraftment into AAV1 led to brain transduction. Likewise, DNA family shuffling was 
used to study the domains of the human Argonaute (Ago) proteins Ago1-4 which are 
involved in the RNA interference pathway (Schurmann et al. 2013). In this example, the 
biological mechanisms underlying RNA cleavage were further unraveled by shuffling of 
the slicing competent Ago2 with the slicing deficient Ago proteins, such as Ago3 and 
Ago4.  
From the data obtained in this work, one can imagine different phenotypes which might 
occur during production of viral libraries (depicted in Figure 3-1). Simply put, a shuffled 
capsid is either capable to assemble particles (P1, P2) or not (P4). The latter could have 
several reasons, including premature stop codons in the AAP or VP sequence, or sterical 
hindrance of amino acids preventing capsid formation. Based on the high 
interchangeability of AAPs to trans-complement capsid variants, phenotype P3 is 
another option as well. In this scenario, the cognate AAP is incompatible with the own 
VP proteins and thus fails to support capsid assembly, as it was the case for capsid 
variant 18 in this work. Yet, the presence of an AAP originating from another shuffled 
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variant might rescue this AAP-dependent defect in capsid assembly. Concerning this 
phenotype, two considerations should be kept in mind. Firstly, the data presented here 
indicates that albeit this phenotype is possible, it is rather rare and predominantly 
occurred upon shuffling of less homologous parental sequences. A supplementation of 
AAPs during production might therefore be considered whenever divergent sequences 
are shuffled and incompatibility issues are more likely to arise. This should stabilize 
variants that would otherwise be lost although they might have had interesting properties 
for a certain selection strategy or downstream application, respectively.  
The second and most important consideration concerns the phenomenon of genotype-
phenotype linkage, i.e., encapsidation of a genome into the capsid that it encodes 
among a myriad of possible candidates in the same cell. Until recently it was not clear if 
such a linkage exists at all. One strategy to prevent packaging of a genome into an 
unrelated capsid is to transfect minimal amounts of capsid-encoding library DNA into the 
cells, to yield a low plasmid copy number per cell (e.g. (Maheshri et al. 2006)). Strikingly, 
however, other groups transfected much higher amounts of DNA and still succeeded at 
identifying functional chimeras (e.g. (Grimm et al. 2008)). Notably, a recent study 
reported an astonishingly high correlation of packaged genomes upon co-transfection in 
a replication- and packaging-competent AAV context, that was relieved as soon as the 
ITRs were removed from the cap-encoding plasmid (Nonnenmacher, van Bakel, et al. 
2015). Two possible explanations for this unexpected observation are a cis-packaging 
mechanism and a pioneer plasmid which outgrows other present plasmid variants. The 
authors hypothesized that the initial rescue of the viral genome from the plasmid is rather 
inefficient, yet as soon as this genome has been excised, it will replicate and outgrow the 
others. The resulting excess amounts of this particular variant in the cell automatically 
results in an abundance of the encoded capsid and thus increases the likelihood of 
correct genotype-phenotype linkage. In order to rescue a capsid with an incompatible 
cognate AAP (P3) trans-complementation with a compatible AAP must occur within the 
same cell, i.e., both must be expressed at the same time. In case the pioneer plasmid 
hypothesis fosters the observed phenotype-genotype linkage, residual translational 
activity of AAP for the remaining, outgrown, plasmids is necessary.  
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FIGURE 3-1: POSSIBLE PHENOTYPES DURING LIBRARY PRODUCTION 
The model depicts different phenotypes (P) which might occur during particle production. In the 
best case, the VPs are compatible with the cognate AAP and capsids are assembled (P1, 2). 
However, it is also possible that the VPs have a sterical defect and cannot assemble, or that a 
premature stop codon has been introduced by the shuffling procedure (P4). Finally, it is 
coneivable that the VPs are incompatible with their respective AAP (P3) but can be rescued by 
AAP originating from another capsid (P2). 
 
3.3. SELECTION IN STELLATE CELLS 
Stellate cells belong to the non-parenchymal cell fraction in the liver and are highly 
relevant for liver disease progression as they, for example, participate in liver fibrosis. 
Because tools for targeted genetic manipulation of these cells remain limited, a major 
goal of this work was to identify synthetic AAV variants from a library of shuffled capsids 
that can fill in this gap.   
In order to identify promising AAV variants efficient at stellate cell targeting, four rounds 
of in vivo selection were performed by peripheral injection of an AAV library into adult 
mice, followed by stellate cell isolation, total DNA purification and subsequent PCR-
based cap rescue of AAV genomes that had entered the cells. 
Sanger sequencing of single clones, performed to monitor and track library composition, 
revealed a number of interesting changes particularly in the C-terminus. Typically, the N-
terminus is buried within the capsid and is important for intracellular trafficking steps 
(section 1.1.1.3), whereas the C-terminus forms the capsid surface and is involved in cell 
binding. Therefore, the C-terminal part was sorted according to the respective parental 
serotypes, resulting in the identification of different groups that were named according to 
XX
VP
AAP
P1 P2 P3 P4
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the most abundant parental reference, i.e., 1-stretch, 7-stretch, 10-stretch, 7-rh10-7, 1/6 
mix and 1/6/7 mix. From each group, single variants were further validated in vivo by 
immunostainings of liver slices (Figure 2-14).  
Intriguingly, a variety of different phenotypes were observed. While some variants 
transduced a low number of cells overall (3-18 and 4-7), others exhibited a pronounced 
tropism towards hepatocytes (3-9 and 4-3). In addition, several capsid chimeras had 
developed a novel tropism, as best seen for 4-6, 3-10, 3-5 and 4b-10. With these 
capsids, fewer to no hepatocytes were expressing the reporter and most positive cells 
were phenotypically different from hepatocytes. Instead, reporter eGFP expression co-
localized with desmin staining, i.e., a marker for stellate cells.  
As the liver is a complex organ composed of different cell types in very close proximity, 
the method of analysis was changed from studying liver slices to separated cell 
populations. As a pilot, the 3-5 vector was injected into mice and different cell types were 
isolated from each mouse (Figure 2-15), taken into primary cell culture and stained for 
different markers. Now that single cell types could be assessed more readily and more 
unanimously, it became evident that both, stellate cells and Kupffer cells were targeted 
efficiently by capsid 3-5.  
Curiously, 3-5 exhibited different tropisms in the liver slices (Figure 2-14), namely, 
activity in either NPCs or hepatocytes. This observation was not confirmed when single 
cell types were analyzed, either by single-cell type staining (Figure 2-13) or by NGS 
analysis. It needs to be tested whether this is related to mouse strain or the method. The 
latter could be tested by performing a partial hepatectomy for immuno stainings of liver 
slices and perfusion of the remaining liver for single-cell type isolation. 
One inherent drawback for the single-capsid validation approach is the limited amount of 
variants which can be screened due to the high number of animals and the manpower 
required. Therefore, an alternative vector barcoding and NGS strategy was pursued with 
the aim to validate 28 interesting chimeras in parallel (section 2.3.2.3). Firstly, all variants 
within one cell type were ranked by their efficiencies of transgene expression, as 
measured on the RNA/cDNA level. This revealed a similar overall picture for stellate cells 
and the other cell types, namely, hepatocytes, LSECs and Kupffer cells (Figure 2-17). 
Unexpectedly, though, none of the capsid variants selected in stellate cells appeared in 
the top 15 ranking on the cDNA level. Instead, several variants from an unrelated screen 
performed by another group member were enriched, next to peptide insertion variants 
and the wild-types AAV7 and AAVrh10.  
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Interestingly, the picture looks drastically different for the ranking on the gDNA level 
(Figure 2-18). In stellate cells, the majority of variants ranking high in this list are now 
indeed derived from the in vivo screen performed in this work. This indicates that the 
applied selection procedure was actually successful at enriching variants that could enter 
the target cell population, i.e., stellate cells. A most likely explanation for the striking 
discrepancy of the results of the cDNA and gDNA ranking lies in the selection strategy 
itself. As described above, whole cells were taken for total DNA isolation as well as for 
PCR amplification and subcloning of enriched AAV capsid genes. Consequently, there is 
a high probability that variants were isolated that had delivered their genetic cargo into 
the cell (or had remained attached to the outside), but had failed to traffic to and/or enter 
the nucleus and mediate transgene expression. (Grimm and Zolotukhin 2015). 
Alternatively, it is conceivable that some capsid structures are very stable and thus 
prevent disassembly, which is a prerequisite for vector genome release and transgene 
expression. In fact, the observed increase in titer for selected clones might correlate with 
such an increase in capsid stability. Also of note in this context, when Thomas et al. 
investigated the reason for AAV8´s superior transduction profile over AAV2 in the mouse 
liver (Thomas et al. 2004), they found capsid stability and uncoating kinetics to be key to 
the rapid onset of transgene expression. While AAV8 uncoats and thus releases vector 
genomes very rapidly in the mouse liver, the AAV2 capsid is stable for a longer period of 
time and therefore takes longer to form double-stranded, transcription-competent vector 
DNA in the nucleus. 
Generally, the gDNA profile of the other NPCs shared similarities with the one from 
stellate cells. Particularly surprising was the high abundance of AAV5 wild-type gDNA in 
all NPCs that was not observed in the parenchymal cells, i.e., hepatocytes, and that did 
not correlate with the cDNA data for AAV5. This finding is of particular interest as 
currently clinical studies are underway which use liver-directed targeting with AAV5 
vectors (e.g. (D'Avola et al. 2016; Rangarajan et al. 2017)). From the data obtained 
AAV5 is not as efficient to translate its high gDNA content into transgene expression 
which leads to the question whether the best candidate was chosen. Ideally, the vector 
should exhibit high transgene expression with little gDNA content, i.e., less particles 
entering the cells, thereby reducing the overall vector dose. High numbers of particles 
pose the danger of immune responses as reaction to capsid fragments correlates with 
the dose (Crudele et al. 2015).  
Furthermore, the gDNA lead candidates identified in stellate cells were not restricted to 
this cell type but were also found in the other NPC fractions. Especially, Kupffer cells had 
the highest degree of agreement with stellate cells. Additionally, a high correlation of 
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cDNA and gDNA ranks was observed for hepatocytes and LSECs as many variants 
showed up at similar position on the two lists and this trend was confirmed upon linear 
regression analysis of a higher sample size. This implies that capsids which enter the 
cells (gDNA) efficiently transcribe RNA (cDNA) from their encapsidated genomes. This 
directly influences the selection strategy as a selection on DNA level will most likely yield 
promising variants which additionally express delivered transgenes well.  
In contrast, Kupffer cells and to a lesser extent stellate cells showed a low level of 
accordance between gDNA and cDNA which was confirmed further with the linear 
regression analysis. Here, high gDNA amounts do not translate into high expression 
levels. These findings are of great interest and relevance as they imply that the AAV 
vector-host interaction mechanisms appear to be different in stellate cells as well as in 
Kupffer cells compared to hepatocytes and LSECs. Consequently, a selection purely on 
the DNA level - as performed in the present pilot study - will not automatically lead to the 
identification of efficient, i.e., transcriptionally active vectors.  
We therefore propose an alternative selection strategy that is based on the RNA level 
and thus provides a much higher chance to enrich variants that successfully uncoat and 
express their genome. However, this is technically challenging due to the biology of 
AAVs. First of all, there is only minimal expression of the capsid gene in the absence of a 
helper virus (section 1.1.1.4). Furthermore, there are (at least) two transcripts for the VP 
proteins, and in order to recover the complete cap gene, the largest VP1 transcript is 
needed, which is less abundant (section 1.1.1.1). One approach in this direction was 
implemented by Deverman et al. who identified the AAV9-based peptide variant PHP.B 
by using their so-called CREATE system (Deverman et al. 2016). Here, the AAV cap 
gene is flanked by a floxed primer binding site that becomes reverted upon cell-type 
specific expression of Cre recombinase and can then be harnessed for a PCR rescue of 
enriched cap sequences.  
The second kind of analysis that is enabled by the data set is to compare the abundance 
of a given capsid variant in different cell types. Here, an alternative normalization 
strategy is pursued that considers the vector load in a given cell type. Hence, the 
proportions acquired are valid per cell and disregard the complex organization of the 
organ itself. Among the top 15 lead candidates on the cDNA level for stellate cells, the 
chimeras derived from an unrelated screen in muscle (JEA) were found to have an even 
distribution between the different cell types (Figure 2-20). However, this property is not 
optimal for a cell-type specific vector. Ideally, the capsid itself is already as specific as 
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possible or at least displays increased on-targeting. For this reason, the JEA chimeras, 
that exhibit high transgene expression, are not the best option.  
Most interesting in the context of this work was whether the in vivo HSC selected 
chimeras had become more specific for stellate cells during iterative selection. In fact, 
most chimeras exhibited a mixed phenotype with activity among different cell types, akin 
to the characteristics of the parental AAV7 and AAVrh10. This result is in accordance 
with the selection strategy, as variants were enriched that were efficient at entering 
stellate cells. However, such a positive on-target selection does not automatically also 
convey specificity. Ideally, the application of a negative selection pressure would be 
highly beneficial to remove variants entering other cell types than the target cell, i.e. 
stellate cells in this study. In an in vivo setting this will pose to be difficult due to the 
complex organ architecture. In an in vitro assay one could use the library to firstly infect 
the off-target cells and then transferring the medium containing the remaining AAV 
variants to the target cell population. 
Another curious observation was that the abundance of a given variant in stellate cells 
was highly comparable to that in Kupffer cells. This apparent connectivity between these 
two cell types was unexpected, but could possibly be explained by the Kupffer cell´s 
nature as a macrophage as they ingest pathogens. Possibly, some AAV variants escape 
the degradation pathways to express their transgenes which could explain the shallow 
slope in the cDNA and gDNA rank comparison, which indicates an uncoupling of vector 
DNA presence and transcription. Alternatively, considering the fact that stellate and 
Kupffer cells had comparable cDNA and gDNA profiles, it might be that certain aspects 
of virus-host interactions are common as well, thus enriching the same AAV capsid 
variants during selection. Last but not least, the purification method is relevant, too. If 
contaminating cell types were still present after stellate cell purification, AAV vectors 
infecting these will contaminate the PCR rescue reactions as well. Indeed, the formation 
of stellate cell/Kupffer cell doublets that could have been co-isolated has been reported 
(Bartneck et al. 2015). However, here, the purification of stellate cells occurred based on 
FACS sorting which is considered pure (>99% according to (Mederacke et al. 2015).  
The overall aim of the screen was the identification of AAVs specific for a certain liver 
cell type, and indeed, good candidates were identified that should be studied further. A 
most notable example is the chimera DJ that was originally selected in vitro in 
hepatocytes and that, remarkably, maintained its hepatocyte tropism in vivo (Figure 
2-21). The overall efficiency of targeting LSECs was low, and no preferred candidates 
have been identified yet, in line with reported challenges to transduce LSECs with AAVs 
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(Buchholz, Friedel, and Buning 2015). Here, a separate selection should be considered 
and based on the existing gDNA/cDNA correlation a selection on DNA level could be 
conducted. The selection in stellate cells yielded variants which efficiently entered the 
target cells and showed off-targeting from hepatocytes. This promising result is 
encouraging for subsequent selection steps and as the tested variants were not efficient 
a mixture of different libraries (shuffled, peptide insertions and combinations thereof) 
could lead to further diversification thereby increasing chances for the identification of 
promising variants.    
Initially, the variant 3-5 was the lead candidate due to its performance in stellate cells 
and Kupffer cells in the single-cell type experiment. The NGS screen showed that the 
efficiency is even slightly higher in Kupffer cells than in stellate cells. Accordingly, this 
capsid will be considered further for both cell types. Likewise, 4N1 will be validated as 
well as it exhibited a higher efficiency for stellate cells over Kupffer cells. One advantage 
of the two chimeras over the assigned parental wild-types AAV1 and AAV6 is the 
increase in production efficiency. Especially for experiments in mice or higher species, 
the ability to obtain high-titer stocks is critical as it will allow to reduce the injection 
volume. Moreover, the increase in production efficiency reduces work loads and costs as 
productions can be scaled down. 
The choice of capsid is the first important step for efficient target cell transduction. The 
NGS screen established that a very low proportion of hepatocytes were transduced in 
the biodistribution analysis by the lead candidates 3-5 and 4N1, but this will eventually 
translate into a higher hepatocyte number as they constitute the majority of the cells in 
the liver. In addition, the vector dose will be increased by over 10-fold for the actual 
experiments in comparison to the NGS screen. Therefore, additional levels of restriction 
were implemented by enhancing the specificity of the vector cassette itself and all 
generated constructs were tested in vitro with cell lines modeling the different cell 
populations, as described in the Results section. To achieve detargeting from 
hepatocytes, vectors were generated bearing miRNA-122 bs. This miRNA is abundantly 
and selectively expressed in hepatocytes and was shown to mediate AAV vector 
detargeting before (e.g. (Geisler et al. 2011; Xie et al. 2011)). As the capsids are not able 
to discriminate between Kupffer cells and stellate cells, binding sites for miRN-142-3p 
were additionally incorporated. This miRNA is abundant in cells from hematopoetic origin 
and was shown to mediate Kupffer cell-specific knockdown in vivo in a lentiviral vector 
(Merlin et al. 2017). In the in vitro setting, the VEC promoter restricted transgene 
expression to a specific cell line, namely HUVECs. Likewise, the VEC promoter and the 
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cd11b promoter were previously shown to being functional in mice in a cell-type specific 
manner (Merlin et al. 2017).  
Ultimately, we believe that a triple strategy needs to be pursued in order to achieve 
maximum specificity and efficiency (Figure 3-2). Already, good capsids were identified 
for hepatocytes (DJ), Kupffer cells (3-5) and stellate cells (3-5 and 4N1). In case of 
residual off-targeting, genes of interest can be transcribed from a cell-type specific 
promoter such as VEC or cd11b to further restrict the expression to the on-target cell. 
Analogously, expression can be turned off by the incorporation of cell-type specific 
miRNA binding sites as observed in the in vitro study by miRNA122 or 142-3p binding 
sites. In the future, these vectors will be validated in combination with the chosen 
capsids.  
 
FIGURE 3-2: TRIPLE STRATEGY TO MEDIATE SPECIFICITY      
A strategy is depicted for the generation of liver cell-type specific AAV vectors. There are several 
levels were specificity will be mediated: the chosen capsid (A), the choice of promoter (B) and the 
incorporation of miRNA binding sites to mediate mRNA degradation in off-target cells. 
 
3.4. OVERALL CONCLUSIONS 
In this study, we dissected and improved - where possible - different crucial steps in the 
protocol for AAV DNA family shuffling, with the overall aim to streamline and optimize 
this exciting technology and to thereby make it even more accessible to members of the 
biomedical community. Our key results include our demonstration that enzymatic 
digestion based on DNaseI is the more robust approach as compared to physical 
fragmentation, despite the predicted advantages of the latter. Additionally, we improved 
the methodology for purification of the cap DNA pool after the nested PCR step, by 
replacing gel extraction with direct column purification, which saves time, work and 
consumables.  
miRNA
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PhD thesis, Anne-Kathrin Herrmann 
83 
 
On top, through extensive and comprehensive trans-complementation studies, we 
relieved concerns about AAP impairment as an adverse by-product of shuffling of the 
cap gene, that were originally triggered when the overlap in ORFs of AAP and cap were 
discovered. While our data clearly show that chimeric AAPs mostly retain functionality, 
we also made a variety of surprising observations, such as the different susceptibility of 
AAV serotypes to complementation with ectopic AAP that is most pronounced for the 
least homologous AAV4 and AAV5. Concurrently, we uncovered possibilities for 
improvement in the future, including the addition of excess AAP during library production 
with the aim to boost library viability and/or to avoid the early loss of interesting clones 
whose own capsid and AAP may be incompatible. Similarly, we made highly relevant 
observations that will help to advance future selection strategies. To our best knowledge, 
our study is the first to perform an AAV capsid library selection in the liver at higher 
resolution, i.e., on the level of specialized cellular subtypes rather than on the level of the 
whole organ. Our approach to concomitantly study the distribution of different AAVs in 
hepatocytes, stellate cells, Kupffer cells and LSECs, is unique as it is the only so far that 
respects the distinct functions and receptor compositions of single specialized cells 
within the liver. Notably, our proof-of-concept selection in stellate cells succeeded as we 
were able to enrich chimeras that deliver substantial amounts of vector DNA to these 
cells.  
At the same time, we learned two vital additional lessons that can be harnessed in future 
reiterations of this selection scheme or in modifications thereof in other tissues. Firstly, 
we identified a discrepancy between the ranking of lead candidates on the gDNA versus 
the RNA level, i.e., the amounts of vector DNA that had entered the cells did not always 
correlate with the amount of transcripts. This observation of capsid- and cell type-specific 
gDNA/RNA uncoupling implies that future studies should aim to establish a rescue on 
the mRNA instead of the DNA level, to foster the enrichment of capsids that are 
transcriptionally most active. Secondly, albeit the in vivo selection in stellate cells 
enriched efficient capsid variants, it became clear that it may be difficult to solely convey 
specificity through the capsid itself. Therefore, to further restrict gene expression to a 
specific cell type, we developed new combinatorial vector cassettes that carried cell-
specific promoters and miRNA binding sites, and that can easily be adapted to mediate 
optimal specificity and efficiency in other target cells as well. 
In summary, we have identified a variety of possible improvements for future AAV capsid 
library generation and selection strategies, based on which we conclude with the 
following recommendations: (i) an AAP cocktail should be supplemented during 
production in cases where less homologous AAVs are present in the parental library; (ii) 
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to increase chances to enrich transcriptionally active capsids, a selection based on the 
mRNA level is preferred; (iii) a repertoire of cell-type specific promoters and miRNAs 
should be gathered and combined with transductional targeting mediated by the capsid; 
(iv) unique library-specific barcodes can be incorporated into the backbones to reduce 
the risk of cross-contamination during rescue steps and to concurrently enable 
multiplexed library screening; and, finally, (v) initial library quality and progress of the 
selection should be monitored by next-generation sequencing technology such as 
PacBio/SMRT, to cover a larger sample size and to thus reduce bias that is invariably 
introduced by conventional Sanger sequencing. Based on our cumulative experience 
from this work and from the past decade, we are highly optimistic that these and other 
improvements developed by our colleagues in the field will synergize and accelerate 
both, the wider application of molecular AAV evolution technology and the isolation of 
powerful new gene therapy vectors with unprecedented efficiency and specificity.          
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4. MATERIALS AND METHODS 
4.1. REAGENTS, BUFFERS AND DEVICES USED 
 
TABLE 4-1: LIST OF DEVICES 
Application Device Company 
 
Bacterial 
incubators 
 
Heraus function line incubator 
 
Thermo Fisher Scientific (Waltham, USA) 
  Shaking Incubator Multitron  INFORS HT (Basel, Switzerland) 
  Shaking Incubator Minitron  INFORS HT (Basel, Switzerland) 
Cell culture/  
sterile working 
Countess Thermo Fisher Scientific (Waltham, USA) 
  HERA safe sterile work bench Thermo Fisher Scientific (Waltham, USA) 
  HERA cell 150 incubator Thermo Fisher Scientific (Waltham, USA) 
Centrifugation Allegra X-12R centrifuge Beckman Coulter (Brea, USA) 
 Argos flexifuge Biozym Scientific GmbH (Hessisch 
Oldendorf, Germany) 
  Avanti J-26 XP centrifuge Beckman Coulter (Brea, USA) 
  Avanti J-25 centrifuge Beckman Coulter (Brea, USA) 
  Beckman tube sealer Beckman Coulter (Brea, USA) 
  Benchtop centrifuge 5415R Eppendorf (Hamburg, Germany) 
 Benchtop centrifuge 5417R Eppendorf (Hamburg, Germany) 
 500 ml centrifuge bottles Beckman Coulter (Brea, USA) 
 Fixed angle type 70 Ti rotor Beckman Coulter (Brea, USA) 
 Fixed angle type 70.1 Ti rotor Beckman Coulter (Brea, USA) 
  Galaxy minister VWR (Fenenay-sous-Bais, France) 
  Optima
TM
 L-90K 
Ultracentrifuge 
Beckman Coulter (Brea, USA) 
 Optima
TM 
Ultracentrifuge tubes 
(26x77 mm) 
Beckman Coulter (Brea, USA) 
  Ultracentrifuge tubes 16x76 
mm 
Seton Scientific (Petaluma, USA) 
Electroporation Gene Pulser Xcell Bio-Rad (Hercules, USA) 
Flow cytometry Cytomics FC500MPL analyzer  Beckman Coulter (Brea, USA) 
Gel 
electrophoresis 
Gel Doc XR Bio-Rad (Hercules, USA) 
  MINI-SUB CELL GT Bio-Rad (Hercules, USA) 
  Mitsubishi P93D Mitsubishi Electric (Cypress, USA) 
  SUB CELL GT Bio-Rad (Hercules, USA) 
  UV-Transilluminator Biostep GmbH (Jahnsdorf, Germany) 
Microscopy CKX 419F Olympus cooperation (Tokyo, Japan) 
 U-RPL-T  Olympus cooperation (Tokyo, Japan) 
other applications accujet pro BrandTech Scientific (Essex, UK) 
 Bunsen burner Carl Friedrich Usbeck KG 
(Radevormwald, Germany) 
 Covaris focused-ultrasonicator 
S2 
Covaris (Woburn, USA) 
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 Bio-Dot® SF Microfiltration 
Apparatus 
Bio-Rad (Hercules, USA) 
  Lauda Aqualine AL5 DJB Labcare (Buckinghamshire, UK)  
 Magnetic stirrer Thermo Fisher Scientific (Waltham, USA) 
  Microwave Sharp Electronics (Hamburg, Germany) 
  Mixing block MB-102 Biozym Scientific GmbH (Hessisch 
Oldendorf, Germany) 
 Nanodrop 2000 Thermo Fisher Scientific (Waltham, USA) 
  NanoVue Spectrophotometer Thermo Fisher Scientific (Waltham, USA) 
  pH meter PB-11 Sartorius (Göttingen, Germany) 
  Pipettes Gilson (Middleton, Germany) 
    Eppendorf (Hamburg, Germany) 
 Qubit fluorometer Thermo Fisher Scientific (Waltham, USA) 
 Refractometer Exacta Optech (San Prospero, Italy) 
  Shaker DRS-12 neoLab (Heidelberg, Germany) 
 Sonorex ultrasonic bath Bandelin (Berlin, Germany) 
  St5 cat shaker  M. Zipperer GmbH (Staufen, Germany) 
 Tissue lyser LT QIAGEN (Hilden, Germany) 
 Tube roller TRM-V neoLab (Heidelberg, Germany) 
  Vacuum pump Promega (madison, USA) 
  Vortex Genie2 Scientific Industries (Bohemia, USA) 
  Water bath TW12 Julabo Labortechnik (Seelbach, 
Germany) 
 Weighing scale KERN & SOHN GmbH (Balingen, 
Germany) 
PCR C1000 Touch thermal cycler Bio-Rad (Hercules, USA) 
  Corbett RG6000 QIAGEN (Hilden, Germany) 
  FlexCycler analyticjena (Jena, Germany) 
 QX200™ Droplet Generator Bio-Rad (Hercules, USA) 
 QX200™ Droplet Reader Bio-Rad (Hercules, USA) 
  vapo protect Eppendorf (Hamburg, Germany) 
Western Blot Film developing cassettes Dr. Goos-Suprema GmbH (Heidelberg,  
Germany) 
  Mini-PROTEAN Tetra cell 
chamber 
Bio-Rad (Hercules, USA) 
  PowerPac basic/ HV/ HC Bio-Rad (Hercules, USA) 
  Trans-Blot® SD Semi-Dry 
Electrophoretic  
Bio-Rad (Hercules, USA) 
 ChemoCam (ECL Imager) INTAS Science Imaging Instruments 
(Göttingen, Germany) 
  X-OMAT 2000 processor (film 
developer) 
KODAK (Rochester, USA) 
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TABLE 4-2: LIST OF CHEMICALS, REAGENTS AND KITS 
Reagent Name Company 
Chemicals Acetic acid VWR chemicals (Fenenay-sous-Bais, 
France) 
  Agarose Biozym Scientific GmbH (Hessisch 
Oldendorf, Germany) 
  Albumin Fraktion V (BSA) Roth (Karlsruhe, Germany) 
  Ammonium persulfate (APS) GRÜSSING GmbH (Filsum, Germany) 
  Bromophenol blue CHROMA (Bellows Falls, USA) 
 Calcium chloride (CaCl2) Roth (Karlsruhe, Germany) 
 Cesium chloride (CsCl) Roth (Karlsruhe, Germany) 
 DMSO Merck (Darmstadt, Germany) 
 Dodecylsulfate-Na-salt-pellets 
(SDS) 
SERVA Electrophoresis GmbH 
(Heidelberg, Germany) 
  Ethanol absolute SIGMA-ALDRICH (St. Louis, USA) 
  Ethidium bromide Roth (Karlsruhe, Germany) 
  Ethylendiamintetraacetate (EDTA) GRÜSSING GmbH (Filsum, Germany) 
  Glucose MERCK (Darmstadt, Germany) 
  Glycerol VWR chemicals (Fenenay-sous-Bais, 
France) 
 HEPES Roth (Karlsruhe, Germany) 
 Hydrochloric acid (HCl) SIGMA-ALDRICH (St. Louis, USA) 
  Iodixanol (Optiprep
TM
) Progen (Heidelberg, Germany) 
 Isopropanol SIGMA-ALDRICH (St. Louis, USA) 
  Magnesium chloride (MgCl2) Applichem (Darmstadt, Germany) 
 Magnesium sulphate (MgSO4) MERCK (Darmstadt, Germany) 
 Methanol SIGMA-ALDRICH (St. Louis, USA) 
  Milk powder Roth (Karlsruhe, Germany) 
 MOPS SERVA Electrophoresis GmbH 
(Heidelberg, Germany) 
  Nuclease-free water Ambion, Thermo Fisher Scientific 
(Waltham, USA) 
 PBS Dulbecco without Ca
2+
 MERCK (Darmstadt, Germany) 
 PEG8000 Promega (Madison, USA) 
  Phenol red MERCK (Darmstadt, Germany) 
 Polyethylenimine (PEI), linear Polysciences Inc. (Eppelheim, Germany) 
 PonceauS SIGMA-ALDRICH (St. Louis, USA) 
 Potassium acetate (KAc) GRÜSSING GmbH (Filsum, Germany) 
  Potassium chloride (KCl) GRÜSSING GmbH (Filsum, Germany) 
  Rotiphorese Gel 40 (19:1) Roth (Karlsruhe, Germany) 
  Sodium chloride (NaCl) GRÜSSING GmbH (Filsum, Germany) 
  Sodium hydroxide (NaOH) SIGMA-ALDRICH (St. Louis, USA) 
 TE buffer Thermo Fisher Scientific (Waltham, USA) 
  TGS (Tris/Glycine/SDS buffer) 10x Bio-Rad (Hercules, USA) 
  Tris-HCl/ Tris Roth (Karlsruhe, Germany) 
  Tween20 Roth (Karlsruhe, Germany) 
  UltraPure
TM
 TEMED Thermo Fisher Scientific (Waltham, USA) 
  β-Mercaptoethanol Roth (Karlsruhe, Germany) 
Enzymes Antarctic Phosphatase NEB (Ipswich, USA) 
4 Materials and methods 
88 
 
  Benzonase MERCK (Darmstadt, Germany) 
  DNase I Thermo Fisher Scientific (Waltham, USA) 
  HotStar Hifidelity Polymerase QIAGEN (Hilden, Germany) 
 OneTaq® 2X Master Mix with 
Standard Buffer 
NEB (Ipswich, USA) 
  Phusion Hot Start II DNA 
Polymerase 
Thermo Fisher Scientific (Waltham, USA) 
  Proteinase K Roche (Penzberg, Germany) 
 RNaseA QIAGEN (Hilden, Germany) 
 Restriction Enzymes NEB (Ipswich, USA) / 
Fermentas (St. Leon-Rot, Germany) 
  T4 DNA Ligase NEB (Ipswich, USA) 
Kits ddPCR™ Supermix for Probes (No 
dUTP) 
Bio-Rad (Hercules, USA) 
 DirectPCR Lysis Reagent Viagen Biotech Inc (Los Angeles, USA) 
 DNA clean & concentrator-5 zymo research (Irvine, USA) 
 DNeasy Blood & Tissue Kit QIAGEN (Hilden, Germany) 
  NucleoBond® Xtra Midi / Maxi Macherey-Nagel (Hœrdt, France) 
 PureYield
TM
 Plasmid Midiprep kit Promega (Madison, USA) 
 SensiMix
TM
II Probe Kit Bioline (London, UK) 
 QIAprep Spin Miniprep Kit QIAGEN (Hilden, Germany) 
  QIAquick Gel Extraction Kit QIAGEN (Hilden, Germany) 
  QIAquick PCR Purification Kit QIAGEN (Hilden, Germany) 
 Qubit dsDNA BR Assay Kit Thermo Fisher Scientific (Waltham, USA) 
  Western Lightning® PLUS-ECL PerkinElmer (Waltham, USA) 
Media  
(eukaryotic) 
DMEM GlutaMAX +4.5 g/ L D-
Glucose  
-pyrovat 
Gibco by Thermo Fisher Scientific 
(Waltham, USA) 
 Endothelial Cell Growth Medium Promocell (Heidelberg, Germany) 
 Endothelial Cell Growth Medium 
SupplementMix 
Promocell (Heidelberg, Germany) 
  1x DPBS Gibco by Thermo Fisher Scientific 
(Waltham, USA) 
  Fetal Bovine Serum Gold (FBS) Gibco by Thermo Fisher Scientific 
(Waltham, USA) 
 Minimum Essential Medium Non-
essential amino acids (100x) 
Gibco by Thermo Fisher Scientific 
(Waltham, USA) 
  Penicillin-Streptomycin Gibco by Thermo Fisher Scientific 
(Waltham, USA) 
  0.25% Trypsin/ EDTA Gibco by Thermo Fisher Scientific 
(Waltham, USA) 
Media  
(prokaryotic) 
Ampicillin Roth (Karlsruhe, Germany) 
  Bacto
TM
 Agar BD (Franklin Lakes, USA) 
  Bacto
TM
 Trypton BD (Franklin Lakes, USA) 
  Bacto
TM
 Yeast Extract BD (Franklin Lakes, USA) 
Standards 100 bp DNA ladder Thermo Fisher Scientific (Waltham, USA) 
  1 kb DNA ladder plus Thermo Fisher Scientific (Waltham, USA) 
  PageRuler
TM
 Plus Prestained 
Protein Ladder 
Fermentas (St. Leon-Rot, Germany) 
  Colorplus prestained protein 
ladder 
NEB (Ipswich, USA) 
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Oligonucleo- 
tides 
dNTPs (dATP, dCTP, dGTP, 
dTTP) 
NEB (Ipswich, USA) 
 
 
TABLE 4-3: BUFFER COMPOSITIONS 
Material Composition 
Ampicillin stock solution 5% (w/v) Ampicillin (50 mg/ ml) 
Benzonase buffer  50 mM Tris/HCl pH 8.5 
  150 mM NaCl 
 2 mM MgCl2 
10x DNA loading dye 50 mM Tris pH 7.6 
  60% glycerol 
  0.25% (w/v) bromophenol blue 
6x Purple loading dye NEB (Ipswich, USA) 
ddPCR™ Droplet Reader Oil Bio-Rad (Hercules, USA) 
Droplet Generation Oil for Probes Bio-Rad (Hercules, USA) 
Freezing medium 10% (v/v) DMSO 
 90% (v/v) FBS 
15% Iodixanol phase 25% (v/v) Iodixanol, 75% (v/v) PBS-MK-NaCl 
25% Iodixanol phase 41.66% (v/v) Iodixanol, 58.33% (v/v) PBS-MK, phenol red 
until it appears red 
40% Iodixanol phase 66.67% (v/v) Iodixanol, 33.33% (v/v) PBS-MK  
60% Iodixanol phase 100% Iodixanol (v/v), phenol red until it appears yellow 
LB medium  1% (w/v) Bacto Tryptone 
  0.5% (w/v) Bacto Yeast Extract 
  1% (w/v) NaCl 
LB Amp medium LB medium supplemented with 1 ml 5% Ampicillin per L 
LB plates LB medium plus 1.5% (w/v) Bacto Agar  
LB Amp plates LB plates supplemented with 1.5 ml 5% Ampicillin per L 
Miniprep P1 (pH 8.0) 50 mM Tris/HCl pH 8.0 
  100 µg/ml RNase A 
  10 mM EDTA 
Miniprep P2  200 mM NaOH 
  1% SDS 
Miniprep P3 (pH 5.1) 2.8 M KAc 
NaHEPES resuspension buffer 50 mM HEPES 
 150 mM NaCl 
 25 mM EDTA 
PBS-MK 1 mM MgCl2 
 2.5 mM KCl 
 in PBS 
PBS-MK-NaCl 1 mM MgCl2 
  2.5 mM KCl 
  1M Nacl 
  in PBS 
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40% PEG/ NaCl solution 40% (w/v) PEG8000 
 1.915 M NaCl 
Phenolred solution 0.5% (w/v) phenol red 
Protein sample buffer 2x 2 mM EDTA 
 100 mM Tris/ HCL pH 7.5 
 4% SDS 
 20% glycerol 
 10% β-mercaptoethanol 
 0.02% bromphenolblue 
Running gel buffer (pH 8.8) 1.5 M Tris 
 0.4% SDS [(v/v) from a 10% stock solution] 
SOB medium (pH 7.0) 2% Bacto Tryptone 
  0.5% (w/v) Bacto Yeast Extract 
  10 mM NaCl 
  2.5 mM KCl 
 10 mM MgSO4 (addition after autoclaving) 
  10 mM MgCl2 (addition after autoclaving) 
SOC medium SOB medium plus 20mM glucose 
Stacking gel buffer (pH 6.8) 500 mM Tris 
 0.4% SDS [(v/v) from a 10% stock solution] 
50x TAE  1M Acetic acid 
  50mM EDTA 
  2M Tris 
10x TBS  250 mM Tris/HCl, pH 7.4 
  1.25 M NaCl 
TBST 1x TBS 
 0.05% Tween20  
TFBI buffer (pH 5.8) 16 mM CaCl2 
 13.2 % (v/v) glycerol 
 30.6 mM KAc 
 100 mM KCl 
 80 mM MgCl2 
TFBII buffer (pH 8.0) 76 mM CaCl2 
 13.2 % (v/v) glycerol 
 10 mM KCl 
 4.8 mM MOPS 
10x TGS (Running buffer) Bio-Rad (Hercules, USA) 
Topping solution (RI= 1.3710) 3.27 M CsCl (0.55g/ ml) 
 In NaHEPES resuspension buffer 
Transferbuffer 1x TGS 
 20% Methanol 
 in H2O 
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TABLE 4-4: LIST OF MATERIALS USED 
Material Company 
Amicon Ultra-15 centrifugal filter units 
(100,000 NMWL) 
MERCK (Darmstadt, Germany) 
BD plastipak (syringe) BD (Franklin Lakes, US) 
BD microlance3 BD (Franklin Lakes, US) 
Cell culture flasks (75/ 175 cm2) Greiner bio-one (Frickenhausen, Germany) 
Cell culture plates (6/12/96 well) Greiner bio-one (Frickenhausen, Germany) 
Cell culture plates 15cm Nunc, Thermo Fisher Scientific (Waltham, USA) 
Cell lifter Corning (New York, USA) 
Centrifuge tube 500 ml Corning (New York, USA) 
Coster 50ml reagent reservoir Corning (New York, USA) 
Countess
TM
 cell counting chamber slides Thermo Fisher Scientific (Waltham, USA) 
Cuvettes (polystyrene) Sarstedt (Nümbrecht, Germany) 
Covaris reaction tubes (microTUBE AFA 
fibre Snap-Cap 6x16 mm) 
Covaris (Woburn, USA) 
Dialysis tubing /Type 20/32 inch, wall 
thickness 0.02 mm, MWCO 14,000) 
Roth (Karlsruhe, Germany) 
DG8™ Cartridges for QX200™/QX100™ 
Droplet Generator 
Bio-Rad (Hercules, USA) 
DG8™ Gaskets for QX200™/QX100™ 
Droplet Generator 
Bio-Rad (Hercules, USA) 
Electroporation Cuvettes (25x 1mm) peqlab (Erlangen, Germany) 
Erlenmeyer flasks Thermo Fisher Scientific (Waltham, USA) 
Filter tips Sarstedt (Nümbrecht, Germany), Mettler-Toledo 
(Columbus, USA) 
Glass bottles DURAN group (Wertheim, Germany) 
Glass culture tubes DURAN group (Wertheim, Germany) 
Microlance canules 21G 0.8x40mm, 19G 
1.1x40 mm 
BD (Franklin Lakes, USA) 
Nitrocellulose membrane  Whatman (Maidstone, UK), Ahlstrom (Helsinki, 
Finland) 
PCR tubes 0.2 ml 8-Strip STARLAB (Hamburg, Germany) 
Pasteur capillary pipettes (230 mm) neoLab (Heidelberg, Germany) 
Petri dishes Greiner bio-one (Frickenhausen, Germany) 
Pipette tips Greiner bio-one (Frickenhausen, Germany), Kisker 
(Steinfurt, Germany) 
qPCR tubes 0.1ml strips and lids QIAGEN (Hilden, Germany) 
Reaction tubes (0.5, 1, 2ml) SARSTEDT (Nümbrecht, Germany), Eppendorf 
(Hamburg, Germany) 
Reaction tubes 5ml Eppendorf (Hamburg, Germany) 
Reaction tubes 15 ml, 50 ml Greiner bio-one (Frickenhausen, Germany) 
Reaction tubes 50 ml BD (Franklin Lakes, US) 
Serological pipettes (5, 10, 25 ml) Greiner bio-one (Frickenhausen, Germany) 
Slide-A-Lyzer dialysis cassette (MWCO 
20,000) 
Thermo Fisher Scientific (Waltham, USA) 
Sterile filter (0.22 µM pore size) Greiner bio-one (Frickenhausen, Germany) 
Steritop filter (0.22 µM) MERCK (Darmstadt, Germany) 
twin.tec® PCR Plates semiskirted Eppendorf (Hamburg, Germany) 
VacConnectors QIAGEN (Hilden, Germany) 
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Whatman paper 3mm Whatman (Maidstone, UK) 
X-ray films Amersham HyperfilmTM ECL GE Healthcare (München, Germany) 
 
 
TABLE 4-5: LIST OF SOFTWARES APPLIED 
Application Program Vendor 
Alignment analysis tool Salanto Developed in close collaboration with 
Christian Bender (Schurmann et al. 2013; 
Große 2016) 
(https://bitbucket.org/benderc/salanto/wiki/H
ome) 
Alignments AlignX Thermo Fisher Scientific (Waltham, USA) 
 ClustalX2 (Larkin et al. 2007) 
Covaris SonoLite 2.07 Covaris (Woburn, USA) 
ddPCR QuantaSoft™ Software, 
Regulatory Edition 
Bio-Rad (Hercules, USA) 
Figure design MS office Microsoft Corporation (Redmond, USA) 
Flow cytometry  MXP software Beckmann Coulter (Brea, USA) 
Gel pictures Quantity One Bio-RAD (Hercules, USA) 
Graphical analysis GraphPad Prism GraphPad Software, Inc. (La Jolla, USA) 
qRT-PCR Rotor Gene 6000 Series QIAGEN (Hilden, Germany) 
Picture anaylsis Fiji (Schindelin et al. 2012) 
Running scripts Python 3.5 The Python Software Foundation 
(Walmington, USA) 
Sequence visualization Serial cloner 2.6 http://serialbasics.free.fr/Serial_Cloner.html 
 
TABLE 4-6: LIST OF OLIGONUCLEOTIDES 
Name with internal 
numbering 
Description Sequence 5´to 3´ 
#36 cap mid  binds in the middle of cap of all 
serotypes except 4, 5, 12 and po1; 
sequencing primer 
GAAATTGGCATTGCGATTCC 
#37 cap mid binds in the middle of cap of 
serotypes 4 , 5, 12 and po1; 
sequencing primer 
GATTGGCATTGCGATTCCAC 
#176 DJ rev rev primer, sequencing in whc 
background 
GTCGCAAAACACTCACGTG
ACCTC 
#459 SAfor cap amplification after first PCR GACTACAAGGACGACGATG
ACAAG 
#460 SArev cap amplification after first PCR CACTGAATTCTCATCAGGCG
AAG 
#822 LSeqFor sequencing/ cloning primer for 
shuffled libraries 
GATCTGGTCAATGTGGATTT
G 
#823 LSeqRev sequencing/ cloning primer for 
shuffled libraries 
GACCGCAGCCTTTCGAATG
TC 
#824 LSeqFor Nested Primer for nested PCR during 
selection 
ACTGCATCTTTGAACAATAA
AT 
#826 LSeqRev Nested Primer for nested PCR during 
selection 
GGTTTATTACTAGTGGCGCG 
#827 M13for for initial cap amplification GTAAAACGACGGCCAGTGA
G 
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#828 M13Rev for initial cap amplification GGAAACAGCTATGACCATG 
#833 Rep2For Binds Rep2 within native HindIII site AGACGCGGAAGCTTCGATC
AA 
#835 CMV for Binds at the end of the CMV 
promoter und was used to sequence 
transgenes 
CGCAAATGGGCGGTAGGCG
TG 
#983 AAP2 NotI For Cloning primer for AAP2 with NotI 
site 
ataagaatgcggccgcATGGAGAC
GCAGACTCAGTAC 
#984 AAP2 EcoRI Rev Cloning primer for AAP2 with EcoRI 
site (and AAP3) 
ccggaattcTCAGGGTGAGGTA
TCCATAC 
#985 AAP4 NotI For Cloning primer for AAP4 with NotI 
site 
ataagaatgcggccgcATGGAGCA
GGCGACGGACCC 
#986 AAP4 EcoRI Rev Cloning primer for AAP4 with EcoRI 
site 
ccggaattcTCACGTACGGCAG
TTCGTAC 
#987 AAP5 NotI For Cloning primer for AAP5 with NotI 
site 
ataagaatgcggccgcATGGACCC
AGCGGATCCCAGC 
#988 AAP5 EcoRI Rev Cloning primer for AAP5 with EcoRI 
site 
ccggaattcTCAGCGTCGCGTA
ACCGTAC 
#989 AAP8 NotI For Cloning primer for AAP8 with NotI 
site 
ataagaatgcggccgcATGGCGAC
TCAGAGTCAGTTC 
#990 AAP8 EcoRI Rev Cloning primer for AAP8 with EcoRI 
site (AAP1, 6) 
ccggaattcTCATGAACACGTC
CGCCGGG 
#991 AAP9 NotI For Cloning primer for AAP9 with NotI 
site 
ataagaatgcggccgcATGGCGAC
ACAGAGTCAGTCC 
#992 AAP9 EcoRI Rev Cloning primer for AAP9 with EcoRI 
site 
ccggaattcTCATGAAAACGTC
CGCTGG 
#1292 AAP1/3/6/7 NotI 
For 
Cloning primer for AAP1/3/6/7 with 
NotI site 
ataagaatgcggccgcATGGCGAC
TCAGAGTCAGTCC 
#1293 AAPrh10 NotI For Cloning primer for AAPrh10 with 
NotI site 
ataagaatgcggccgcATGGCGAC
TCAGAGTCAGTGC 
#1294 AAP7/ rh10 EcoRI 
Rev 
Cloning primer for AAP7/ rh10 with 
EcoRI site 
ccggaattcTCATGAAGACGTC
CGCCGGG 
#1295 pSSV9-YFP-for Cloning primer for eYFP via NheI  atgcagctagcgccgccaccATGGT 
GAGCAAGGGCGAGGA 
#1296 pSSV9-YFP-rev Cloning primer for eYFP via KpnI tgcatggtaccactagtggcgcgccTT
ACTTGTACAGCTCGTCCA 
#1297 pSSV9-p(A)-for Cloning primer for BGH poly(A) via 
KpnI 
atgcaggtaccTAGAGCTCGCTG
ATCAGCCT 
#1298 pSSV9-p(A)-rev Cloning primer for BGH poly(A) via 
NotI 
tgcatgcggccgcCTCCCCAGCA
TGCCTGCTAT 
#1314 spacer-for Insert spacer with additional SpeI/ 
AflII site with AscI and KpnI 
overhangs 
cgcgccatcattactagtagatagtactta
cttaagccaattggtac 
#1315 spacer-rev Insert spacer with additional SpeI/ 
AflII site with AscI and KpnI 
overhangs 
Caattggcttaagtaagtactatctactag
taatgatgg 
#1512 For_ccdbAscI Amplifies ccdb cassette with AscI 
site, for 
agactagtggcgcgccACTGGCTG
TGTATAAGGGAG 
#1513 rev_ccdbPacI 
Amplifies ccdb cassette with PacI 
site, binds REV 
agccttaattaaTCGCGTGGATC
CGGCTTACT 
#1515 miR122-for Clone miR122 binding sites via ClaI atgcaatcgatAGCGGCCGCAC
AAAC 
#1516 miR122-rev Clone miR122 binding sites via SalI tgcatgtcgacGCTCTAGATGGA
GTG 
#1538 periostinREV To clone the periostin promoter via 
NheI 
atcgatgctagcTTCAGCCCTGA
GCTCCG 
#1539 pSSV9-cd11b-for Cloning primer for the cd11b 
promoter via PacI  
atgcattaattaaTCGACGGTATC
GATAAGCTT 
#1540 pSSV9-cd11b-rev Cloning primer for the cd11b tgcatgctagcGGATCCCGAGAA
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promoter via NheI CCTGGAAG 
#1543 VEC-for Cloning primer for the VEC promoter 
via PacI 
atgcattaattaaTCGTCGACTCT
AGCTAGTAG 
#1544 VEC-rev Cloning primer for the VEC promoter 
via SpeI 
tgcatactagtACCGGTGGATCT
CGAGTCTG 
#1784 periostin-for Cloning primer for periostin via PacI atcgatttaattaaCCTCTGACTCA
TCTTC 
#1789 miR122-for Clone miR122 binding sites via AvrII atgcacctaggCGCACAAACACC
A 
#1790 miR122-rev Clone miR122 binding sites via SalI gctctagtcgacgctctttaattaaAGAT
GGAGTGTGACA 
#1791 miR142-3p-for Clone miR142-3p binding sites via 
PacI 
atgcattaattaaGCTTGCGGCCG
CTCC 
#1792 miR142-3p-rev Clone miR142-3p binding sites via 
SalI 
tgcatgtcgacCAGCGGCCTGTA
GTGTTTCC 
2/indet* for primer for AAPx02 as it started 
as AAP2 and shuffled to another 
parent 
ataagaatgcggccgcATGGAGAC
GCAGACTCAGTCCC 
AAP2ko_for 
 
Cloning primer for AAP knockout 
with NotI site 
ataagaatgcggccgcCGG 
AGACGCAGACTCAGTAC 
AAP8ko_fo
r  
 
Cloning primer for AAP knockout 
with NotI site 
ataagaatgcggccgcCCGGCGA
CTCAGAGTCAGTTC 
AAP9ko_fo
r 
 
Cloning primer for AAP knockout 
with NotI site 
ataagaatgcggccgcCCGGCGA
CACAGAGTCAGTCC 
rescueBCnew Binds rev, for PCR rescues with 
barcodes via NdeI 
atcgatcatatgCATATGGGAAG
GACAGGAGGTCACCT 
rescueBCori Binds rev, for PCR rescues with 
barcodes via NdeI 
atcgatcatatgAAGCCCGTGGA
GGCTTCTAG 
rescueBC289 Binds rev, for PCR rescues with 
barcodes via NdeI 
atcgatcatatgTTAGCCGGCAC
ACCTCTAGG 
rescueBC1 Binds rev, for PCR rescues with 
barcodes, contains SpeI site 
atcgatactagtTCACGACGTCG
ATGTGGAGC 
Underlined are sites for restriction enzymes, small letters indicate stuffers/ overhangs for enzymes, CAPITAL letters 
indicate sequence stretches complementary to the template  
 
TABLE 4-7: PLASMIDS USED 
Name with internal number Description Origin 
#68  
pIRES(blast) FLAG/HA-
hAgo2-GA 
CMV driven human Argonaute2 
expression plasmid including a 
FLAG/HA tag; acceptor for AAP 
expression 
Cloned by Nina Schürmann 
#182 WHc1(SpeI) Cap helper plasmid with rep2 and cap 1 Cloned by Eike Kienle 
#183 WHc2(SpeI) Cap helper plasmid with rep2 and cap 2 Cloned by Eike Kienle 
#184 WHc4(SpeI) Cap helper plasmid with rep2 and cap 4 Cloned by Eike Kienle 
#185 WHc5(SpeI) Cap helper plasmid with rep2 and cap 5 Cloned by Eike Kienle 
#186 WHc6(SpeI) Cap helper plasmid with rep2 and cap 6 Cloned by Eike Kienle 
#187 WHc7(SpeI) Cap helper plasmid with rep2 and cap 7 Cloned by Eike Kienle 
#188 WHc8(SpeI) Cap helper plasmid with rep2 and cap 8 Cloned by Eike Kienle 
#189 WHc9(SpeI) Cap helper plasmid with rep2 and cap 9 Cloned by Eike Kienle 
#190 WHcrh10(SpeI) Cap helper plasmid with rep2 and cap 
rh10 
Cloned by Eike Kienle 
#193 WHc-CapDJ Cap helper plasmid with rep2 and cap 
DJ 
Cloned by Eike Kienle 
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#545 pBS-sds-decoy-empty Self-complementary vector bearing 
ITRs with CMV-eGFP 
Cloned by Stefan 
Mockenhaupt 
#552 pBSUF3rev-YFP-sds Self-complementary vector bearing 
ITRs with CMV-eYFP with SV40 
enhancer 
Cloned by Eike Kienle 
#641 pDONR207 ccdb gene Thermo Fisher Scientific 
(Waltham, USA) 
#778 pSSV9_Pac_Asc Single-stranded replication competent 
vector with ITRs, rep2 and a stuffer for 
cap insertion 
Cloned by Stefanie Große 
 
#1080 pIRES(blast) FLAG-
AAP2 
 
AAP expression construct under control 
of CMV with HA/ FLAG tag (based on 
#68) 
Cloned by Stefanie Große 
 
#1081 pIRES(blast) FLAG-
AAP4 
 
AAP expression construct under control 
of CMV with HA/ FLAG tag (based on 
#68) 
Cloned by Stefanie Große 
 
#1082 pIRES(blast) FLAG-
AAP5 
 
AAP expression construct under control 
of CMV with HA/ FLAG tag (based on 
#68) 
Cloned by Stefanie Große 
 
#1109 pIRES(blast) FLAG-
AAP8 
 
AAP expression construct under control 
of CMV with HA/ FLAG tag (based on 
#68) 
Cloned by Stefanie Große 
 
#1110 pIRES(blast) FLAG-
AAP9 
 
AAP expression construct under control 
of CMV with HA/ FLAG tag (based on 
#68) 
Cloned by Stefanie Große 
 
#1111 Adeno helper plasmid 
 
Plasmid required for AAV production, 
expresses factor required from 
adenovirus 
(Matsushita et al. 1998) 
#1134 WHC2mutAAP 
 
Cap helper plasmid with rep2 and cap 2 
bearing a knockout in AAP 
Cloned by Stefanie Große 
 
#1183 pSSV9-CMV-Cas9 Single-stranded vector with Cas9 under 
control of a CMV promoter  
Cloned by Stefanie Große 
#1189 WHC4GA Cap helper plasmid with rep2 and cap 4 
(original version, sequenced optimized 
to cap2) with PacI site 
Cloned by Stefanie Große 
 
#1190 WHC5GA 
 
Cap helper plasmid with rep2 and cap 5 
(original version, sequenced optimized 
to cap2) 
Cloned by Stefanie Große 
 
#1194 WHc3(SpeI) Cap helper plasmid with rep2 and cap 3 Cloned by Eike Kienle 
#1290 WHC4GA_w/o PacI 
 
Cap helper plasmid with rep2 and cap 4 
(original version, sequenced optimized 
to cap2) without PacI site 
Cloned by Stefanie Große 
 
#1291 WHC4GA repaired 
 
During sequence optimization the AAP 
frame was not accounted for resulting 
in many mutations. Here, stop codons 
were removed and the start codon re-
installed. 
Cloned by Stefanie Große 
 
#1292 WHC5GA repaired 
 
During sequence optimization the AAP 
frame was not accounted for resulting 
in many mutations. Here, stop codons 
were removed and the start codon re-
installed. Additionally, rep was mutated 
as well and was fixed here. 
Cloned by Stefanie Große 
 
#1293 WHC5GA only 
repSTOP 
 
During sequence optimization the AAP 
frame was not accounted for resulting 
in many mutations. Here, only the 
mutation in rep was fixed (AAP is not 
fixed). 
Cloned by Stefanie Große 
 
#1326 WHC8mutAAP 
 
Cap helper plasmid with rep2 and cap 8 
bearing a knockout in AAP 
Cloned by Stefanie Große 
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#1327 WHC9mutAAP 
 
Cap helper plasmid with rep2 and cap 9 
bearing a knockout in AAP 
Cloned by Stefanie Große 
 
#1452 pBSc1 
 
Bluescript plasmid with cap 1 gene 
flanked by PacI/ AscI and oligo binding 
sites for DNA family shuffling 
Cloned by Eike Kienle 
#1453 pBSc2 
 
Bluescript plasmid with cap 2 gene 
flanked by PacI/ AscI and oligo binding 
sites for DNA family shuffling 
Cloned by Eike Kienle 
#1454 pBSc3 
 
Bluescript plasmid with cap 3 gene 
flanked by PacI/ AscI and oligo binding 
sites for DNA family shuffling 
Cloned by Eike Kienle 
#1455 pBSc4 
 
Bluescript plasmid with cap 4 gene 
flanked by PacI/ AscI and oligo binding 
sites for DNA family shuffling 
Cloned by Eike Kienle 
#1456 pBSc5 
 
Bluescript plasmid with cap 5 gene 
flanked by PacI/ AscI and oligo binding 
sites for DNA family shuffling 
Cloned by Eike Kienle 
#1457 pBSc6 
 
Bluescript plasmid with cap 6 gene 
flanked by PacI/ AscI and oligo binding 
sites for DNA family shuffling 
Cloned by Eike Kienle 
#1458 pBSc7 
 
Bluescript plasmid with cap 7 gene 
flanked by PacI/ AscI and oligo binding 
sites for DNA family shuffling 
Cloned by Eike Kienle 
#1459 pBSc8 
 
Bluescript plasmid with cap 8 gene 
flanked by PacI/ AscI and oligo binding 
sites for DNA family shuffling 
Cloned by Eike Kienle 
#1460 pBSc9 
 
Bluescript plasmid with cap 9 gene 
flanked by PacI/ AscI and oligo binding 
sites for DNA family shuffling 
Cloned by Eike Kienle 
#1461 pBScrh10 Bluescript plasmid with cap rh10 gene 
flanked by PacI/ AscI and oligo binding 
sites for DNA family shuffling 
Cloned by Eike Kienle 
#1494 pBSc4SO repaired 
 
Bluescript plasmid with cap 4 
sequence-optimized gene with repaired 
AAP flanked by PacI/ AscI and oligo 
binding sites for DNA family shuffling 
Cloned by Stefanie Große 
 
#1495 pBSc5SO repaired 
 
Bluescript plasmid with cap 5 
sequence-optimized gene with repaired 
AAP flanked by PacI/ AscI and oligo 
binding sites for DNA family shuffling 
Cloned by Stefanie Große 
 
#1500 WH_empty_Hind/Spe 
 
Cap helper plasmid with rep2 and a 
stuffer instead of cap allowing cloning 
(via HindIII/ SpeI) 
Cloned by Stefanie Große 
 
#1544 whc_ccdb_PacI_AscI 
 
Cap helper plasmid with rep2 and a 
ccdb cassette instead of cap allowing 
cloning (via PacI/ AscI) 
Cloned during this study 
#1608 
pSSV9_Pac_Asc_ccdB 
 
Comparable to #778 with a ccdb 
cassette instead of  a stuffer 
Cloned during this study 
#1661 WHC1mutAAP 
 
Cap helper plasmid with rep2 and cap 1 
bearing a knockout in AAP 
Cloned by Stefanie Große 
 
#1662 WHC3mutAAP 
 
Cap helper plasmid with rep2 and cap 3 
bearing a knockout in AAP 
Cloned by Stefanie Große 
 
#1663 WHC6mutAAP 
 
Cap helper plasmid with rep2 and cap 6 
bearing a knockout in AAP 
Cloned by Stefanie Große 
 
#1664 WHC7mutAAP 
 
Cap helper plasmid with rep2 and cap 7 
bearing a knockout in AAP 
Cloned by Stefanie Große 
 
#1665 WHCrh10mutAAP 
 
Cap helper plasmid with rep2 and cap 
rh10 bearing a knockout in AAP 
Cloned by Stefanie Große 
 
#1666 pIRES(blast) FLAG- AAP expression construct under control Cloned by Stefanie Große 
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AAP1 
 
of CMV with HA/ FLAG tag (based on 
#68) 
 
#1667 pIRES(blast) FLAG-
AAP3 
 
AAP expression construct under control 
of CMV with HA/ FLAG tag (based on 
#68) 
Cloned by Stefanie Große 
 
#1668 pIRES(blast) FLAG-
AAP6 
 
AAP expression construct under control 
of CMV with HA/ FLAG tag (based on 
#68) 
Cloned by Stefanie Große 
 
#1669 pIRES(blast) FLAG-
AAP7 
 
AAP expression construct under control 
of CMV with HA/ FLAG tag (based on 
#68) 
Cloned by Stefanie Große 
 
#1670 pIRES(blast) FLAG-
AAPrh10 
 
AAP expression construct under control 
of CMV with HA/ FLAG tag (based on 
#68) 
Cloned by Stefanie Große 
 
#1824 pIRES(blast) FLAG-
AAP DJ 
 
AAP expression construct under control 
of CMV with HA/ FLAG tag (based on 
#68) 
Cloned by Stefanie Große 
 
#1913 pSSV9-CMV-YFP-
spacer 
Single-stranded vector with an eYFP 
under the control of a CMV promoter 
bearing a spacer with additional 
restriction sites between the eYFP and 
the poly(A)  
Cloned during this study 
#1914 pSSV9-VEC-YFP Same as #1913 with the VEC promoter 
presumably mediating specificity in 
LSECs 
Cloned during this study 
#1915 pSSV9-cd11b-YFP Same as #1913 with the cd11b 
promoter presumably mediating 
specificity in Kupffer cells 
Cloned during this study 
#2006 sc-eYFP-miR122 Self-complementary eYFP driven by 
CMV promoter bearing 4x miR122 
binding sites 
Cloned during this study 
#2007 sc-eGFP-miR122 Based on #545 with 4x miR122 binding 
sites 
Cloned during this study 
#2008 sc-eGFP-miR122-
miR142-3p 
Based on #2008 bearing two additional 
miR142-3p binding sitesy 
Cloned during this study 
#2009 pSSV9-VEC-eGFP Single-stranded eGFP reporter vector 
driven by the supposedly LSEC specific 
promoter VEC 
Cloned during this study 
#2010 pSSV9-cd11b-eGFP Single-stranded eGFP reporter vector 
driven by the supposedly Kupffer cell-
specific promoter cd11b 
Cloned during this study 
#2022 pSSV9-periostin-
eGFP 
Single-stranded eGFP reporter vector 
driven by the supposedly stellate cell-
specific promoter periostin 
Cloned during this study 
Cd11b vector Construct bearing the cd11b promoter, 
kindly provided by Antonia Follenzi 
(Simard et al. 2006) 
pBK06 Luciferase vector with additional 
miR122 binding sites 
Cloned by Ben Kachel 
pBK76 Luciferase vector with additional 
miR142-3p binding sites 
Cloned by Ben Kachel 
1.2-kb peri-lacZ Construct bearing the truncated version 
of the periostin promoter, kindly 
provided by Holger Willenbring 
(Lindsley et al. 2007) 
VEC vector Construct bearing the VEC promoter, 
kindly provided by Antonia Follenzi 
(Gory et al. 1999) 
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4.2. METHODS 
 
4.2.1. MOLECULAR BIOLOGICAL METHODS 
 
4.2.1.1. POLYMERASE CHAIN REACTION (PCR)  
In order to amplify DNA for further subcloning the phusion HS II polymerase was used. In 
one reaction, 10 µl GC or HF buffer, 1 µl dNTPs (10 mM), 0.5 µl polymerase, 1.5 µl 
DMSO, 1.5 µl forward primer (10 µM), 1.5 µl reverse primer (10 µM) and 0.2 µl template 
plasmid were mixed and filled up to 50 µl with water. Usually, an initial heating step of 
5 min at 95°C was performed followed by 40 cycles of denaturation (95°C, 15 s), 
annealing (50-60°C, 15 s) and elongation (72°C, 30 s per 1 kb). The annealing 
temperature was usually set to 56°C and further modified by gradient PCRs if necessary. 
Finally, a 10 min elongation step at 72°C was included with indefinite hold at 4°C.  
A colony PCR was performed to test colonies after transformation for successful insert 
integration. Therefore, 25 µl Taq 2x mastermix were mixed with 0.2 µl forward primer 
(10 µM), 0.2 µl reverse primer (10 µM) and 4.6 µl water. A colony was picked from the 
plate with a pipet tip, streaked out on a new plate and used to stir within the PCR tube 
containing 10 µl of the mix. After an initial heating step of 95°C for 5 min, 30 cycles of 
heating (95°C, 15 s), annealing (50-60°C, 15 s) and elongation (68°C, 1 min per 1 kb) 
followed. The run was finalized by an elongation step for 10 min at 68°C and kept 
indefinitely on hold at 4 °C. 
In any case, the PCR product was separated on a 1% (w/v) agarose gel, at 80-120 V for 
30 to 50 min and DNA was visualized by intercalating ethidium bromide under UV light. If 
necessary, a 6x loading buffer was added to the DNA prior loading. PCR products 
required for further cloning procedures were excised from the gel using a scalpel and 
samples were stored at -20°C. 
 
4.2.1.2. RESTRICTION DIGESTION 
For subcloning purposes 20 µl plasmid backbone were digested with 2 µl of each 
appropriate restriction enzyme, 4 µl of 10x buffer and filled up to 40 µl with water. 
Digestion occurred depending on the enzymes´ requirements usually with 10x CutSmart 
buffer at 37°C either over day for a couple of hours or overnight. In case of PCR 
products, a similar strategy was applied concerning the volume but digestion took place 
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over night. For all reactions the amount of total enzyme did not exceed one tenth of the 
total volume. If the digest of the vector yielded two differently sized fragments they had to 
be separated on a 1% (w/v) agarose gel and the appropriate band was extracted.  
Test digestions were performed to either test the successful integration of an insert and/ 
or the integrity of the ITRs. For this, 1 µl 10x buffer was mixed with 0.25 µl of each 
required enzyme and 0.5-2 µl plasmid DNA was filled up to a total volume of 10 µl with 
water. Usually, 0.5 µl plasmid was used but if small digestion products or a low 
concentration was expected the amount was increased. After incubation for 1 h at the 
appropriate temperature the test digests were analyzed on a 1% (w/v) agarose gel. In 
order to test for insert integration the enzymes already used for cloning were used. In 
case of ITR integrity XmaI was used for ITR2 originating from AAV2 and PstI for ITR4 
originating from AAV4. The ITRs were regarded as intact if the in silico predicted 
patterns matched the real one. 
 
4.2.1.3. LIGATION 
For standard cloning purposes a ligation mix was set up containing 0.5 µl T4 ligase, 1 µl 
10x ligase buffer, insert, vector and water filled up to a total volume of 10 µl. Usually, an 
insert to vector ratio of 3:1 was used with a total DNA amount of 100 ng. In case of small 
fragments like miRNA binding sites or small oligonucleotides a 7:1 ratio was applied. The 
reaction occurred either over night at 16°C or over day for at least 3 h at room 
temperature. 
 
4.2.1.4. DNA ISOLATION  
DNA purification from a 1% (w/v) agarose gel was performed using the QIAquick Gel 
Extraction Kit according to manufacturer´s recommendation. The optional isopropanol 
step was always included as well as an additional washing step with buffer QG and a 
prolonged “empty” spin for 3 min instead of 1 min. For elution 30 µl water was used for 
PCR products and 50 µl for vectors. This was incubated 5 min at room temperature prior 
spinning. In case for the generation of initial and selected AAV libraries the QIAquick 
PCR purification kit was used. Again, instructions were followed with the prolonged 
empty spin and elution in 30 µl for 5 min at room temperature prior spinning. 
Usually, digested PCR products as well as digested vectors where only a small stuffer 
below 50 bp fell out were purified via the DNA clean & concentrator-5 kit according to 
4 Materials and methods 
100 
 
manufacturer´s instructions. Vectors were eluted in 40 µl water and PCR products in 
20 µl water. 
After subcloning colonies were inoculated to isolate plasmid DNA the next day. In most 
cases a so called “dirty” mini protocol was applied with lab-made buffers P1, P2 and P3. 
Buffers P1 and P3 were stored at 4°C whereas P2 stayed at room temperature. For this, 
2 ml of the culture were pelleted in a 2 ml tube at maximum speed for 2 min in a table top 
centrifuge. The supernatant was discarded and the pellet was resuspended in 300 µl 
resuspension buffer P1. Next, 300 µl lysis buffer P2 was added, tubes were gently 
inverted and incubated for 5 min at room temperature. For neutralization 300 µl 
neutralization buffer P3 was added and gently inverted. After an incubation time of 5 min 
at room temperature the samples were spun down at max speed for 10 min. Carefully 
800 µl of the clear supernatant was transferred to a new tube containing 600 µl 
isopropanol. The DNA was then pelleted at maximum speed for 15 min. The supernatant 
was discarded and an additional washing step with 70% ethanol was performed for 5 min 
at maximum speed. Again, the supernatant was discarded and remaining ethanol was 
removed carefully by pipetting. The pellet was dried and then eluted in 50 µl water. 
Sometimes, the cultures were inoculated in the early morning, vortexed and then DNA 
was isolated in the afternoon. In such cases elution occurred in 40 µl. Mini preps 
originating from the “dirty” prep protocol were used for sequencing purposes and for 
further subcloning. For small-scale transfections “clean” mini preps were prepared by 
using the QIAgen miniprep kit according to manufacturer´s instructions with elution in 
50 µl water. 
If larger plasmid DNA amounts were required a midi (80 ml) or maxi (300 ml) culture 
were inoculated and pelleted the next day at 4000 x g, 10 min at room temperature. For 
midi prep the DNA was isolated according to manufacturer´s instruction using the 
PureYieldTM Plasmid Midiprep kit. The recommended drying step of 30 s to 1 min was 
prolonged to 5 min in order to reduce ethanol contamination. Elution occurred for 5 min 
with 1 ml water. Similarly, for maxi prep the manual of the NucleoBond® Xtra Midi / Maxi 
kit was followed with the instructions for maxi preparations. Usually, 1.5 ml was used for 
elution. 
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4.2.2. PROKARYOTIC METHODS 
 
TABLE 4-8: ESCHERICHIA COLI STRAINS USED 
Strain Competence Vendor 
E. coli ccdb Survival
TM 
T1
R 
Chemically competent Thermo Fisher Scientific (Waltham, 
USA) 
E. coli MAX Efficiency 
DH5α
TM
 
Chemically competent Thermo Fisher Scientific (Waltham, 
USA) 
E. coli MegaX DH10B
TM
 T1
R
 Electrocompetent Thermo Fisher Scientific (Waltham, 
USA) 
 
 
4.2.2.1.CULTIVATION CONDITIONS 
Bacteria were usually cultured in LB medium carrying the respective antibiotic 
resistance. If bacteria were cultivated on LB plates, 1.5% (w/v) agar was added to the 
medium and the antibiotic was added shortly before pouring of the plates. All media and 
plates were stored at 4°C until usage. For liquid cultures, glass culture tubes were used 
for mini cultures, 250 ml flasks for midi culture and 2 l flasks for maxi preps. Mini cultures 
were usually inoculated in 3 ml medium by picking a clone from a plate with a pipet tip 
and the larger formats used a 1/1000 volume of a preculture. Incubation occurred at 
37°C shaking at 180 rpm. Bacteria plated out on plates were incubated at 37°C overnight 
in an incubator. In some cases a glycerol stock was prepared by mixing 800 µl bacteria 
from a fresh culture with 200 µl glycerol. After careful inversion the tube was frozen and 
stored at -80°C.  
 
4.2.2.2. ELECTROCOMPETENT BACTERIA: PRODUCTION AND 
ELECTROPORATION 
For the production of electrocompetent bacteria 30 ml LB medium without antibiotics 
were inoculated with MegaX DH10BTM T1R from the glycerol stock under sterile 
conditions with the help of a Bunsen burner. The next day four 2 L flasks with 400 ml 
antibiotic free medium were inoculated with 5 ml of the overnight culture. The bacteria 
were grown for 2-4 h until an OD600 of 0.5-0.55 was reached. Then they were transferred 
into centrifuge bottles and incubated on ice for 15 min. While the cells were pelleted for 
10 min at 4000 x g at 4°C four to five dialysis tubings were prepared. They were cut to a 
length of 20-25 cm and were put into a beaker containing enough water to cover them. 
They were cooked in the microwave until the water started boiling and were allowed to 
cool down again. After centrifugation the cell pellets were resuspended in a total volume 
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of 60 ml sterile water which was pre-cooled. The bacteria were transferred into the 
dialysis tubings, closed with clips and dialyzed overnight in pre-cooled water at 4°C 
slightly stirring. The next day the cells were transferred into 50 ml tubes and spun down 
for 10 min at 4000 x g at 4°C. All cells were resuspended in 900 µl 10% (v/v) glycerol 
and the OD600 was determined. The bacteria were diluted with 10% (v/v) glycerol until a 
theoretical OD600 of one was reached by calculating OD600 measured x 900 µl equals the end 
volume. The cells were aliquoted and snap-frozen in liquid nitrogen. To test the efficiency 
1.5 µl pUC19 vector were electroporated according to manufacturer´s instructions and 
efficiencies in the range of 5x108 colony forming units per µg DNA and higher were 
accepted for library productions. 
For one electroporation, 30 µl of electrocompetent bacteria were thawed on ice and 2 µl 
of the ligation reaction were added. This was then transferred into a pre-cooled 
electroporation cuvette and inserted into the device. A pulse was initiated with 1800 V, 
25 μF and 200 Ω. For recovery 1 ml of pre-warmed SOC medium without antibiotic was 
added to the cuvette, the bacteria were transferred into a 1.5 ml tube and shaken for 1 h 
at 600 rpm in a heating block. In case of regular cloning procedures, the bacteria were 
spun for 3 min at 4000 x g, the supernatant was poured off and the pellet was 
resuspended in the remaining liquid. This was then plated out. If a library was subcloned 
all electroporations of one library were pooled and 100 µl were plated out from each, 
undiluted, 1:10 diluted and 1:100 diluted sample, respectively. The remainder was used 
to inoculate a maxi culture. 
 
4.2.2.3. CHEMOCOMPETENT BACTERIA: PRODUCTION AND 
TRANSFORMATION 
The MAX Efficiency DH5αTM were streaked out on an LB-plate without antibiotic from the 
glycerol stock and one single colony was used to inoculate 6 ml LB medium. The day 
after, three flasks with 200 ml SOC medium were inoculated with 1 ml of the overnight 
culture and were grown until an OD600 of 0.5. The bacteria were pelleted for 15 min with 
1800 x g at 4°C and were resuspended in 40 ml TFBI buffer. After 10 min incubation on 
ice the cells were pelleted again and were resuspended in 10 ml TFBII buffer. Again, the 
bacteria were incubated on ice for 10 min and were then aliquoted into 50 µl portions, 
snap frozen in liquid nitrogen and stored at -80°C. 
For standard cloning purposes chemocompetent bacteria were thawed on ice and 50 µl 
bacteria were added to 10 µl of the ligation reaction. This mixture was left on ice for 
20 min followed by a heat shock at 42°C for 45 s and an incubation on ice for two more 
minutes. The complete reaction was plated out. If a plasmid containing a ccdb cassette 
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was to be transformed, the ccdb competent bacteria were used. In all other cases it was 
DH5α. 
4.2.3. CLONING OF NEW CONSTRUCTS 
 
4.2.3.1. Generation of ccdb containing plasmids  
To facilitate the transfer from a chimeric capsid from the replication competent backbone 
pSSV9 (Figure 4-1 A) into the helper context (Figure 4-1 B) a helper plasmid with PacI 
and AscI sites was generated. For this a chimeric variant was transferred via HindIII and 
SpeI from the pSSV9 backbone into a helper construct. As the PacI and AscI site flanked 
the chimeric cap they were transferred as well (Figure 4-1 C). In order to improve 
transformation, the chimeric cap gene was replaced by the suicide gene ccdb. This gene 
is toxic for regular E. coli and can only be propagated in special E. coli ccdb resistant 
strains e.g. E. coli ccdb SurvivalTM T1R strain. As a consequence bacteria who took up 
undigested or partially digested backbone will die. The ccdb cassette was PCR amplified 
using primers #1512 and #1513 on the template plasmid #641 and replaced the chimeric 
cap by cloning via PacI and AscI.  
 
FIGURE 4-1: CCDB CONSTRUCTS 
(A) The replication competent construct #778 is shown being characterized by the inverted 
terminal repeats (ITR) in combination with rep2 and cloning sites for cap transfer. (B) The helper 
construct #1500 is depicted. This backbone is used to subclone a chimeric capsid by SwaI and 
SpeI restriction sites to package transgenes into a chimeric capsid. (C) To facilitate cloning a 
chimeric capsid present in the replication competent context was subcloned using HindIII and 
SpeI sites thereby introducing PacI and AscI. (D, E) To reduce the amount of false positive clones 
a ccdb construct was first introduced into the helper context (D) and was then transferred to #778 
(E). Red boxes indicate stuffers between restriction enzymes. 
A
ITR ITRrep2
AscI
PacI SpeI
HindIII
B
rep2
SpeIHindIII
SwaI
rep2
HindIII
PacI
cap*
AscI
SpeI
C
rep2
HindIII
PacI
ccdb
AscI
SpeI
D E
ITR ITRrep2
AscI
PacI SpeI
HindIII
ccdb
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This generated construct #1544 (Figure 4-1 D). The ccdb cassette was transferred to the 
replication competent background as well by PacI and AscI digestion of both, the donor 
plasmid #1544 and the acceptor plasmid #778, thereby yielding construct #1608 (Figure 
4-1 E). 
 
4.2.3.2. CLONING OF AAP EXPRESSION PLASMIDS 
Usually, the AAP was PCR amplified from the capsid of interest by matching 
oligonucleotides.  Therefore, the N-terminal and C-terminal part was tested in silico for 
primer binding depending on the serotype origin. These regular AAP expression 
constructs applied primers #983 - #992, #1292 - #1294 and 2/indet* in the case were 
none of the primers fit. The resulting PCR product was subcloned via EcoRI and NotI 
restriction sites into the acceptor plasmid #68 (Figure 4-2 A). Note that the endogenous 
start codon “CTG” was changed to “ATG”. To confirm the successful knockout of AAP 
within the knockout constructs, mutated AAP was cloned out using primers AAP2ko_for / 
#984, AAP8ko_for / #990 and AAP9ko_for / #992 on plasmid #1134, #1326 and #1327, 
respectively (Figure 4-2 B). The PCR product was subcloned as described above. The 
knockout is based on a mutated start codon (CTG  CCG) and the introduction of an 
early stop codon (TGG  TAG). 
 
FIGURE 4-2: AAP EXPRESSION CONSTRUCT DESIGN 
AAP can be cloned via NotI / EcoRI restriction site under the control of a CMV promoter. In 
addition, AAP bears a FLAG (F)/ HA (H) tag. (A) The endogenous CTG start codon was altered to 
the conventional ATG. (B) In the AAP knockout construct the start codon was changed to CCG 
and a stop codon (TAG) was introduced as indicated by the red cross.  
 
4.2.3.3. BARCODE RESTRICTION DURING SELECTION 
The aim is to introduce so called barcodes into the replication competent backbone 
pSSV9 (#778) at two positions thereby being able to track a library and to optimize the 
PCR rescue further. The barcodes are 20 nucleotide stretches designed to already bear 
the corresponding sticky ends for ligation. At first, two matching oligonucleotides (Table 
4-9), 5 µl forward (100 µM) and 5 µl reverse (100 µM), were mixed with 40 µl H2O and 
incubated at 95°C for 5 min. The heat block was turned off and allowed to slowly cool 
A
CMV F H AAP
NotI EcoRI
ATG
B
CMV F H AAP
NotI EcoRI
CCG / TAG
x
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down to room temperature. A ligation mixture was set up as described 4.2.1.3 for 
standard cloning purposes with 1 µl digested acceptor backbone and 2 µl annealed 
oligos. Transformation occurred into chemocompetent bacteria (4.2.2.3). Clones were 
picked for “dirty” mini prep and assessed for ITR integrity (4.2.1.4, 4.2.1.2.). Positive 
clones were validated by sequencing using primer #822.  
 
TABLE 4-9: BARCODE ANNEALING 
Name For oligo 5´ to 3´ Rev oligo 5´ to 3´ 
introNdeI cgcgccgtactataagcatatgagatagtacttacta ctagtagtaagtactatctcatatgcttatagtacgg 
BC289 cgcgccCCTAGAGGTGTGCCGGCTAAca tatgTTAGCCGGCACACCTCTAGGgg 
BCori cgcgccCTAGAAGCCTCCACGGGCTTca tatgAAGCCCGTGGAGGCTTCTAGgg 
BCnew cgcgccGGTTGCGGTCGCATTATGCGca tatgCGCATAATGCGACCGCAACCgg 
BCred cgcgccGGCAATACTCGCAAGCCTGGca tatgCCAGGCTTGCGAGTATTGCCgg 
BC1 tatgGCTCCACATCGACGTCGTGAa ctagtTCACGACGTCGATGTGGAGCca 
Underlined are sites for restriction enzymes, small letters indicate stuffers/ overhangs for enzymes, CAPITAL letters 
indicate barcode sequence 
 
 
FIGURE 4-3: CONSTRUCTS FOR BARCODE SELECTION  
The schematic depicts the construct design for replication competent backbones where 
libraries as well as selection rounds can be tagged with a barcode.  (A, B) Into the initial 
#778 backbone (A) an NdeI site was integrated (B). (C) The stuffer between NdeI and 
SpeI can then be replaced by a barcode tagging the selection round.  (D) This construct 
can then be used to insert barcodes specific for a given library. Red squares indicate 
stuffers to separate restriction sites, the purple square (BC1) indicates the selection 
round barcode, the green square represents a library (lib) barcode.  ITR, inverted 
terminal repeats, 
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The cloning of the barcodes is based on an NdeI site which needed to be introduced into 
#778 first (Figure 4-3 A). The annealed oligos for “introNdeI” were ligated into AscI and 
SpeI digested #778 resulting in the vector depicted in Figure 4-3 B. Next, the annealed 
oligos for BC1 were introduced via NdeI and SpeI (Figure 4-3 C). This backbone bearing 
the BC1 barcode was used to insert four different library barcodes by using BC289, 
BCori, BCred and BCnew (Figure 4-3 D). 
 
4.2.3.4. CONSTRUCTS TO MEDIATE LIVER CELL-TYPE SPECIFICITY 
The details for all constructs mentioned in this paragraph are summarized in Table 4-10 
and are depicted in Figure 4-4 . The cell-type specific promoters used in this study do not 
fit into the self-complementary vectors due to their size. Therefore, a single-stranded 
acceptor backbone containing a CMV promoter with eYFP was cloned first. The eYFP 
was PCR amplified and cloned into the acceptor backbone via NheI and KpnI restriction 
sites, thus generating the intermediate pSSV9-CMV-eYFP. In a next step, a poly(A) tail 
was inserted via KpnI and NotI thereby creating the cloning intermediate pSSV9-CMV-
eYFP-bgh. At last, a spacer was inserted between the eYFP and the poly(A) tail by using 
the restriction enzymes AscI and KpnI bearing additional restriction sites which allow for 
insertion of miRNA binding sites. This plasmid (#1913) is now the acceptor for different 
promoters. Two promoters, cd11b and VEC, were PCR amplified and subcloned into 
#1913. The CMV was replaced by PacI and NheI in case for cd11b and due to an 
internal NheI site within VEC by PacI and SpeI for VEC, respectively. Note that the same 
digested backbone was used as the cohesive ends from SpeI and NheI are compatible 
to ligate to each other but the original NheI site gets thereby destroyed. At the end, a 
Kupffer cell-specific vector encoding for eYFP (#1914) and a LSEC specific vector 
encoding eYFP (#1915) were generated. To improve validation the reporter fluorophore 
was exchanged to eGFP. Complementary to the initial strategy with eYFP, eGFP was 
PCR amplified and got inserted by NheI and AscI in case of cd11b resulting in #2010. 
Since the NheI site got destroyed upon VEC insertion (#1915) AgeI was used as an 
alternative site thereby creating construct #2009. In addition, a promoter supposedly 
working well in stellate cells in vivo was acquired, PCR amplified and inserted into #2010 
by PacI and NheI digestion yielding construct #2022. As an alternative strategy a self-
complementary vector was prepared bearing miRNA binding sites to mediate 
degradation in a cell-type specific manner. As before, four miRNA122 binding sites were 
introduced into a self-complementary eYFP vector (#552) by PCR amplification and 
restriction by ClaI and SalI yielding plasmid #2006. For the same reason as above, the 
fluorophore for analysis should be eGFP. Therefore, the miR122 binding sites were 
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introduced into #545 by AvrI and SalI resulting in vector #2007. During that step a PacI 
site was introduced allowing insertion of two miR142-3p binding sites by PacI and SalI 
digestion creating construct #2008.   
 
FIGURE 4-4: CELL TYPE SPECIFC VECTOR DESIGN 
The construct design is depicted to mediate cell-type specificity. (A) The promoter of the single-
stranded vectors can be exchanged by PacI and NheI restriction sites. Between the fluorescent 
reporter eGFP and the poly(A) tail (p(A)) a variety of restriction enzymes is present to allow 
incorporation of miRNA binding sites. (B) The self-complementary vector bears a CMV driven 
eGFP. Two different miRNA binding sites namely for miR122 (red) and miR142-3p (light blue) 
were incorporated between the fluorophore and the poly(A) indicated by the narrow boxes.   
 
TABLE 4-10: CLONING STRATEGY FOR CELL-TYPE SPECIFIC CONSTRUCTS 
Final vector Insert source Acceptor backbone 
pSSV9-CMV-eYFP PCR on plasmid #552 with primers #1295/ 
#1296 
#1183 
pSSV9-CMV-eYFP-
bgh 
PCR on plasmid #552 with primers #1297/ 
#1298 
pSSV9_CMV_eYFP 
#1913 Spacer was created by oligo annealing of 
primers #1314/ #1315 
pSSV9-CMV-eYFP-
bgh 
#1914 PCR on VEC vector with primers #1539/ #1540 #1913 
#1915 PCR on Cd11b vector with primers #1543/ 
#1544 
#1913 
#2009  PCR on #545 with primers #835/ #1296 #1915 
#2010 PCR on #545 with primers #1295/ #1296 #1914 
#2022 PCR on 1.2-kb peri-lacZ with primers #1784/ 
#1538 
#2010 
#2006 PCR on pBK06 with primers #1515/ #1516 #552 
#2007 PCR on #2006 with primers #1789/ #1790 #545 
#2008 PCR on pBK76 with primers #1791/ #1792 #2006 
 
A
B
promoterITR eGFP p(A) ITR
PacI NheI
AscI
NotISpeI
AflII
KpnI
CMVITR eGFP p(A) ITR
PacIAvrII SalI AscI
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4.2.4. LIBRARY GENERATION BY DNA FAMILY SHUFFLING 
 
4.2.4.1. AMPLIFICATION OF CAPSID GENES 
In a very first step, the cap genes of the required serotypes were PCR amplified from a 
plasmid backbone. For this, 10 µl 5x Hifi buffer was mixed with 1 µl M13For primer 
(10 µM), 1 µl M13Rev primer (10 µM), 2 µl Hifi polymerase, 200 ng template and water to 
a final volume of 50 µl. After an initial step of 5 min at 95°C, 40 cycles of heating for 15 s 
at 94°C, annealing for 30 s at 57°C and elongation for 3 min at 68°C followed with a final 
elongation step at 72°C for 10 min. Finally, the cycler kept the samples at indefinite hold 
at 4°C. Usually, two to four reactions per cap gene were set up in parallel and were 
separated together in one well on a 1% (w/v) agarose gel and the resulting 2.5 kb band 
was excised, purified as described in 4.2.1.4 and eluted in 60 µl water. 
 
4.2.4.2. FRAGMENTATION BY DNASE I 
The DNA concentration was determined by the QuBit system which is based on a 
fluorophore intercalating into double-stranded DNA making it more accurate for this 
method compared to determination by spectrophotometric devices such as the 
nanodrop. For one reaction, 4 µg total DNA was required and equal amounts of each 
capsid DNA were mixed with 6 µl 10x DNase I buffer and water to a final volume of 
59.7 µl. Two heating blocks with 25°C and 75°C were prepared. After addition of 0.3 µl 
DNase I to the sample the tube was flicked until no glycerol smear was visible anymore 
followed by incubation at 25°C for 30 s to 2 min. The incubation time is dependent on the 
activity of the DNase I and was experimentally determined. In order to inactivate the 
enzyme, 6 µl EDTA (25 mM) was added, the sample was vigorously vortexed and 
incubated at 75°C for 10 min. After addition of loading dye, the sample was separated on 
a 1% (w/v) agarose gel and the resulting smear from 100 bp to 1 kb was excised, 
purified as described in 4.2.1.4. and eluted in 60 µl water. 
 
4.2.4.3. FRAGMENTATION BY COVARIS 
Similarly to DNase I-based fragmentation, 4 µg of capsid DNA was mixed and filled up 
with water to 60 µl. The DNA was transferred into a Covaris reaction tube and inserted 
into the Covaris focused-ultrasonicator S2. A program described previously ((Große 
2016), Table 4-11) was chosen to generate fragments of 150 bp, 300 bp and 800 bp in 
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size. The samples were separated on a 1% (w/v) agarose gel and corresponding sizes 
were excised and processed as described in the section above. 
 
TABLE 4-11: COVARIS FRAGMENTATION CONDITIONS 
Fragment size [bp] 150 300 800 
Time [s] 500 120 80 
Cycles per burst 200 200 200 
Duty cycle [%] 10 10 5 
Intensity 5 4 3 
 
4.2.4.4. RE-ASSEMBLY AND NESTED PCR 
In the first PCR 500 ng fragmented cap DNA was mixed with 10 µl 5x HF buffer, 1 µl 
dNTPs (10 nM), 0.5 µl phusion HS II polymerase, 1.5 µl DMSO and water to a final 
volume of 50 µl. This PCR is primerless as the cap fragments will partially re-anneal due 
to homology which can then be filled up by the polymerase. The PCR starts with an initial 
step at 98°C for 30 s which is then followed by 40 cycles of heating at 98°C for 10 s, 
annealing at 42°C for 30 s and elongation at 72°C for 45 s. Finally, an elongation step for 
10 min at 72°C occurs followed by indefinite hold at 4°C. For the second PCR nested 
primers were used. Here, 2 µl of the first PCR is used as input material together with 1 µl 
SaFor (10 µM), 1µl SaRev (10 µM), 0.5 µl 25 mM MgSO4, 2 µl Hifi polymerase, 10 µl 5x 
Hifibuffer and 33.5 µl water. The PCR was run at 95°C for 5 min followed by 40 cycles of 
a two-step protocol with 94°C heating for 15s and 68°C annealing/ elongation for 3 min 
finalized by 10 min 72°C and indefinite hold at 4°C. Usually, one test reaction was being 
run to see if reassembly was successful. If this was the case, the reaction was upscaled 
to 20 reactions which were either separated by a 1% (w/v) agarose gel followed by 
subsequent purification from the gel using one column only or by direct column 
purification. In either way, the samples were eluted in 30 µl water and 4 µl 10x CutSmart 
buffer, 2 µl H2O, 2 µl PacI and 2µl AscI were added for overnight digestion at 37°C. The 
next day, the digest was purified over a 1% (w/v) agarose gel as described earlier. In 
parallel, the replication competent acceptor backbone #778 or #1608 was digested 
along. In case of the comparison of different fragmentation methods the taqmix was used 
for the second PCR using 25 µl 2x taqmix, primers as above and filled up to a total 
volume of 50 µl. The cycling program run for 5 min at 95°C followed by 40 cycles of 
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heating for 15 s at 95°C, annealing for 15 s at 55°C and elongation for 3 min at 68°C. 
After a final elongation step for 10 min at 68°C the samples were kept on 4°C. 
 
4.2.4.5. GENERATION OF THE PLASMID LIBRARY 
A ligation mixture in a total volume of 40 µl with 10x ligase buffer, 4 µl T4 ligase, 861 ng 
vector and 1139 ng insert representing a 1:3 ratio was prepared and incubated overnight 
at 16°C. Electrocompetent bacteria were thawed on ice and electroporated as described 
in 4.2.2.2. Per library, 20 electroporations were performed. The next day, a glycerol stock 
was prepared and the remaining culture was pelleted for maxi prep. The number of 
colonies was counted on the plates bearing the 1:10 and 1:100 dilutions thereby 
determining the efficiency which gives an idea about the theoretical diversity. For this, 
the formula “number of colonies x dilution x number of electroporations x 10” was 
applied. Initial libraries usually yielded efficiencies in the range of 5x105 to 5x106. 
 
4.2.4.6. SEQUENCE ANALYSIS OF THE GENERATED LIBRARY BY 
“SALANTO” 
First, single colonies were screened by colony PCR using primers #822 and #823 to test 
for successful integration. If more than half of the clones had no integration the library 
would be repeated. Positive clones were then inoculated for a “dirty” mini prep and the 
resulting plasmid was sent for sequencing by mixing 500 ng DNA with 5 µM primer in a 
total volume of 10 µl. The sequencing of classical Sanger sequencing as well as PacBio 
sequencing was performed at GATC biotech (Konstanz, Germany). Due to the length of 
the cap gene of approximately 2.2 kb three sequencing reactions were prepared to cover 
the complete sequence: the forward part was covered by primer #822, the end by primer 
#823 and the middle by either primer #36 or primer #37 depending of the serotype origin 
at that position. With the help of either AlignX or SerialCloner the complete sequence 
was put together manually and inserted into a text file already containing the respective 
sequences of the parental serotypes with the formatting “>name” and the sequence in 
the line below. The document was saved as “.fasta” file and was opened either in 
ClustalX or AlignX to perform an alignment. The resulting fasta file containing the 
alignment was analysed in the Shuffling-ALignment ANalysis Tool (Salanto) (Schurmann 
et al. 2013). Of note, with the help of the chromatograms all sequences were corrected 
for “N/n” which were indetermined from the sequencing software and potential 
“MUT”ations resulting from either alignment errors or from sequencing errors in 
homopolymer stretches. In addition, real mutations were identified by this as well. In 
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Salanto one can regard the “Type assignment” which assigns sequence stretches to a 
given parent, a mutation or to “indet”ermined if the stretch originates from a parent where 
multiple possibilities exist. In order to generate the colored bars shown in this work the 
type assignment was copied into excel and a macro was run ((Große 2016), 6.2.1) to 
generate shortened and colored stretches which were then inserted into Powerpoint as a 
picture. Another feature allows regarding the homology between different variants by 
depicting the percentage of differing positions. This was used to generate the heatmaps 
showing homology. Furthermore, one can regard the library composition in terms of 
percentage of each parental sequence and the probability of a given serotype at a given 
position. The last analysis mentioned was depicted by line graphs. 
 
4.2.5. CELL CULTURE AND VIRUS PRODUCTION 
 
4.2.5.1. CELL CULTURE 
All cell lines were cultured at 37°C with 5% CO2 in their respective medium and were 
split upon reaching 80% confluency. For this purpose, the medium was removed and the 
cells were washed with PBS. To detach cells trypsin was added and the cells were 
incubated for 1-5 min in the incubator until they detached from the flask. The cells were 
then resuspended in 10 ml medium and either 1 ml of cell suspension was filled up with 
medium for further cultivation or cell number was determined automatically by the 
countess cell counter and the desired amount was seeded. Usually, DMEM Glutamax 
medium supplemented with 10% FBS and 5% Penicillin/ Streptomycin was used for most 
cell lines including HEK293T, LX-2, MCF-7 and SF539. Non-essential amino acids were 
additionally added for Huh7 cells. HUVECs were cultured in Endothelial Cell Growth 
Medium with supplements. 
TABLE 4-12: LIST OF CELL LINES USED 
Cell line Origin Tissue Reference 
HEK293T  Human Embryonic kidney (DuBridge et al. 1987) 
Huh7 Human  Hepatic carcinoma (Nakabayashi et al. 1982) 
HUVECs Human Umbilical Vein 
Endothelial Cells 
Provided by promocell (Heidelberg, Germany) 
LX-2 Human Hepatic stellate cells (Xu et al. 2005) 
MCF7 Human Mammary carcinoma (Soule et al. 1973) 
RAW264.7 Mouse Macrophage, tumour 
derived 
(Raschke et al. 1978; Ralph and Nakoinz 1977) 
SF539 Human Gliosarcoma (Rutka et al. 1986) 
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4.2.5.2. CRUDE LYSATE PRODUCTION (SMALL-SCALE) 
In order to produce AAVs in a small-scale HEK293T cells were seeded in 2 ml medium 
at a density of 0.5x106 cells per well of a 6-well plate. On the next day, two transfection 
mixes using a total of 2.6 µg DNA and 300 mM NaCl were prepared as listed in Table 
4-13. It was preferred to use DNA originating from kit isolation instead of the “dirty” mini 
protocol. For some AAP trans-complementation assays chimeric capsids were 
transferred from the replication competent context into the helper context (#1544) by 
HindIII and SpeI digestion beforehand. After combination of the two mixes they were 
vortexed and incubated at room temperature for 10 minutes. The mix was then added 
dropwise to the cells with a P200 pipette. Two days later, the medium was removed, the 
cells were rinsed once with PBS and were then transferred into a 1.5 ml tube by 
resuspension in 1 ml PBS. The samples were spun for 10 min at 4000 x g, the 
supernatant was removed and 500 µl PBS was added. In order to free AAVs from the 
cells they were lysed by five cycles of vortexing, freezing in liquid nitrogen and thawing in 
a 37°C water bath. Finally, the cell debris was spun down at 16100 x g for 10 min in a 
table top centrifuge and the supernatant which contained the AAV particles was 
transferred into a new tube. This lysate is referred to as a “crude lysate” and still contains 
cellular components and empty particles. It was stored at -20°C. 
 
TABLE 4-13: TRANSFECTION MIX FOR ONE WELL 
 H2O NaCl  PEI DNA (library) DNA (vectors) DNA (AAP rescue) 
Mix 1 49 µl 49 µl - 1.3 µg Adh, 
1.3 µg library 
866.66 ng of each:  
AAV helper, Adh,  
transgene 
690 ng of each: 
Adh, transgene, 
AAV helper and 
either 530 ng AAP 
or stuffer 
Mix 2 27 µl 49 µl 22 µl - - - 
Adh Adenohelper 
 
4.2.5.3. VIRUS PRODUCTION LARGE-SCALE 
For large-scale purification, HEK293T cells were expanded at a density of 7.5x106 cells 
per T175 flask. Approximately, four flasks were seeded for 30 plates. Two days later, the 
cells were harvested into one flask and the cell number was determined. Depending on 
the plate number a cell mix was prepared with 4x106 cells in 22 ml medium per plate. 
Then, the cells were seeded into 15 cm dishes and incubated two more days. For 
transfection, two mixes (Table 4-14) using 300 mM NaCl were prepared, combined, and 
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vortexed. After 10 min incubation at room temperature 3.2 ml of the transfection mix was 
added dropwise to a plate. Usually 44 µg DNA were transfected per plate with equal 
amounts of each construct with the exception of the library production in the presence or 
absence of an AAP mixture. Here, a total of 32.4 µg DNA was transfected and the 
constructs (Adh, library, AAP mix/ stuffer) were used in a 1.3:1.3:1 ratio. Within the AAP 
mixture all AAPs from the respective parental serotypes were present in equal amounts. 
Three days later, the cells were scraped off the plates, resuspended in their medium and 
transferred to appropriate vessels for centrifugation at 500 x g for 15 min. The 
supernatant was removed, the cells were washed in PBS and the cell pellet was 
resuspended in 0.5 ml benzonase buffer per plate. Comparable to the crude lysates five 
freeze/ thaw cycles were performed. In order to remove left-over plasmid DNA from 
transfection 75 U/ ml benzonase were added and incubated at 37°C for 1 h with 
inversion of the tube every 10 min. The samples were spun at 4000 x g for 15 min to 
remove cell debris. This is the starting material for the density centrifugation steps. 
 
 TABLE 4-14: TRANSFECTION MIX FOR ONE PLATE 
 H2O NaCl  PEI DNA (library) DNA (library AAP) DNA (vectors) 
Mix 1 * µl   790 µl - 22 µg Adh, 22 
µg library 
11.7 Adh, 11.7 µg 
library and 9 µg 
AAP mix or stuffer 
14.6 µg of each:  
AAV helper, Adh,  
transgene 
Mix 2 438 µl 790 µl 352 µl - - - 
* water is used to fill up the DNA to 790 µl therefore the amount varied 
 
4.2.5.4. PURIFICATION BY IODIXANOL DENSITY CENTRIFUGATION 
The samples underwent another spinning step at 4000 x g for 15 min to remove more 
debris. Then, the supernatant was transferred to a new tube and filled up to 7.5 ml with 
benzonase buffer. A Pasteur pipette was inserted into an ultracentrifuge tube (16x76 
mm) and the sample was applied. Now, the iodixanol phases in increasing density were 
loaded: the clear 15% phase followed by the red 25% phase, the clear 40% phase and 
finally the yellow 60% phase. Carefully, the Pasteur pipette was removed, air bubbles 
were removed and the tube was filled up to half of the neck with benzonase buffer. Next, 
the tubes were sealed and balanced with the help of different caps. The samples were 
inserted into the type 70.1 Ti rotor and they were run at 4°C for 2 h at 50000 rpm in a 
OptimaTM L-90K ultracentrifuge. After the run was completed, the vacuum was removed 
and the samples were extracted from the rotor. The tubes were fixed and first, a needle 
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was inserted at the top. Then, a needle was attached to a syringe and used to push 
through the 60% phase positioning the needle at the border of the 40% and 60% phase. 
The AAV containing 40% phase was pulled while taking care to avoid contamination 
from the 25% phase. The virus was aliquoted as required and stored at -80°C. 
 
4.2.5.5. PURIFICATION BY CESIUM CHLORIDE DENSITY CENTRIFUGATION 
A first precipitation step of protein debris was performed with 1/39 volume of 1 M CaCl2 
on ice for 1 h. The sample was spun for 15 min at 4°C at 10000 x g and the supernatant 
was transferred into a new tube. Now, ¼ volume 40 % PEG solution was added and 
incubated overnight on ice to precipitate the AAV particles. The particles were pelleted at 
2500 x g for 30 min at 4°C and the pellet was resuspended stepwise in a total of 10 ml 
NaHEPES buffer. The sample was spun again as before to clear the solution and the 
resulting supernatant was added to a prepared CsCl solution. Therefore, 13.2 g CsCl 
were mixed with 14 ml NaHEPES buffer. As this is an endothermic reaction the solution 
will turn cold and needs to be brought back to room temperature prior determination of 
the refractory index. With the help of a refractometer the refractory indices were 
determined and were adjusted to 1.3710 with NaHEPES buffer to lower the number or 
with CsCl to increase it again. The sample was transferred into OptimaTM ultracentrifuge 
tubes (26x77 mm) and filled up with topping solution bearing the same refractory index. 
A cap was used to close the tube and with the help of larger caps the samples were 
balanced. The gradients were run under vacuum in a type 70 Ti rotor at 45000 rpm for 
21-23 h at 20°C in OptimaTM L-90K ultracentrifuge. After the run was completed, the 
vacuum was removed, the tubes extracted and fixed. First, a needle was used to push 
through the tube at the bottom and then a second needle was inserted at the top. With 
the help of the upper needle the flow speed of the gradient cold be adjusted to a slow, 
dropwise manner and several fractions were collected: 3 ml, 3ml, 0.5 ml, 0.5 ml, 0.5 ml, 
5 ml, 0.5 ml, 0.5 ml, 0.5 ml, 3 ml. The refractory indices of several fractions were 
determined and the ones bearing an index between 1.3766 and 1.3711 were pooled. 
The virus containing fractions were inserted into a dialysis cassette which was then 
incubated standing for 30 min at room temperature in 1x PBS. After this time PBS was 
exchanged and then dialysis occurred at 4°C with continuous stirring. More buffer 
exchanges occurred after 1 h, overnight, 2 h and again 2 h. Per sample one amicon 
Ultra-15 centrifugal filter unit was washed twice with 15 ml PBS for 2 min at 1000 x g. 
Then the sample was applied and was carefully concentrated to 500-1000 µl at 400 x g. 
The virus was aliquoted as required and stored at -80°C. 
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4.2.5.6. TITRATION BY QPCR 
In order to determine the genome copy numbers per ml a titration was performed. 
Therefore, 10 µl virus was mixed with the same amount TE buffer (1 mM Tris-HCl) and 
for alkaline lysis 20 µl 2 M NaOH was added. After vortexing the sample incubated 
30 min at 56°C and was cooled down shortly on ice. For neutralization 38 µl 1 M HCl was 
added and vortexed. Finally, the sample was filled up to 1 ml with 922 µl water. This 
alkaline lysis breaks up the virus particles thereby freeing the viral/ vector genomes. 
Usually, water served as a negative control and a sample with known titer as a positive 
control. If the virus was purified via an iodixanol gradient the sample was additionally 
diluted 1:10. The qPCR was measured in triplicates and the mastermix for one triplex 
contained 17.5 µl 2x Sensimix II probe kit, 1.4 µl of 1:10 diluted forward primer, 1.4 µl of 
1:10 diluted reverse primer, 0.35 µl of 1:10 diluted probe and 9.35 µl water. In case of 
libraries the rep set was used for titration and for packaged eGFP and eYFP reporters 
the GFP set was applied as seen in Table 4-15. In a separate tube, 30 µl mastermix 
were mixed with 5 µl sample which was either originating from alkaline lysis or from a 
1:10 dilution row of the plasmid serving as standard. The samples were mixed well and 
10 µl were filled into one qPCR tube. The final concentration was 0.4 µM for each primer 
and 0.1 µM for the probe. The qPCR was run with an initial heating step of 10 min at 
95°C followed by 40 cycles of heating for 10 s at 95°C and combined annealing/ 
elongation for 20 s at 60°C. The titer of the sample was determined based on the 
standard curve which usually covered a range of 5x109 to 5x102 plasmid copies per 
reaction and multiplying the value with x 100 (factor to get from 10 µl virus to 1 ml vector 
prep) x100 (correct for dilution during alkaline lysis) x 7 (dilution of sample within tube) x 
dilution (in case of iodixanol based samples) x 2 (only in case of single-stranded vectors 
to correct for the double stranded standard).  
 
TABLE 4-15: PRIMER/ PROBE SETS USED 
Target For 5´to 3´ Rev  5´to 3´ Probe 5´to 3´ 
eGFP GAGCGCACCATCT
TCTTCAAG 
TGTCGCCCTCGAAC
TTCAC 
FAM-ACGACGGCAACTACA-BHQ1 
Rep AAGTCCTCGGCCC
AGATAGAC 
CAATCACGGCGCAC
ATGT 
FAM‐TGATCGTCACCTCCAACA‐BHQ1 
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4.2.5.7. TITRATION BY DDPCR 
Comparable to qPCR the virus particles were broken by alkaline lysis and the same 
primer/ probe sets were used. In addition to this the samples were diluted 1:8000 in a 
dilution row by using 5 µl for a 1:100 dilution followed by a 1:20 and a 1:4 dilution. 
Between dilution steps the samples were vortexed well. In parallel, a mastermix was 
prepared with 11 µl ddPCRmix for probes no dUTP, 1.1 µl forward primer, 1.1 µl reverse 
primer, 1.1 µl probe and 2.2 µl water. Primers were diluted 1:5.55 from the 100 µM stock 
and the probe was diluted 1:20 from the 100 µM stock. In a separate tube 16.5 µl 
mastermix were mixed with 5.5 µl sample. The final concentration for each primer was 
900 nM and for the probe 250 nM. After vortexing 20 µl of the reaction was applied to a 
cartridge into the appropriate well which already contained 70 µl oil for probes in its 
respective well. The cartridge was sealed with the casket and applied to the droplet 
generator. The droplets were transferred to a 96-well PCR plate and the plate was 
sealed at 105°C with tin foil. The PCR was run in a biorad cycler with an initial heating 
step of 10 min at 94°C followed by 40 cycles of heating 94°C 30 s and 60°C 1 min. After 
a final step for 10 min at 98°C the samples were kept at indefinite hold at 12°C. The 
droplets were evaluated with the droplet reader which gave absolute copy numbers per 
µl as an output. This value was then multiplied by x 100 (alkaline lysis) x 100 (correcting 
10 µl to 1 ml) x 5 (dilution in tube) x dilution (from dilution series). 
 
4.2.6. VIRUS VALIDATION: TRANSDUCTION ASSAYS AND CAPSID 
FORMATION 
 
4.2.6.1. TRANSDUCTION ASSAY 
The transduction efficiency of different capsids was assessed by packaging a fluorescent 
marker such as eYFP or eGFP as a surrogate marker for infection. The cell line of 
interest was seeded into 96-well plates in a volume of 100 µl per well. HEK293T cells 
were seeded at a density of 1.5×106 cells per 96-well plate and 0.5×106 cells per 96-well 
plate were seeded for MCF7 cells and SF539. The next day 10 µl virus was added and a 
serial dilution was performed by mixing a row and transferring 10 µl into the next one. In 
case of crude lysates, the mentioned volume was used and in case of purified virus a 
specific multiplicity of infection (MOI) as indicated was used. For the latter the required 
virus volume was mixed with medium to a final volume of 10 µl. Two days later the cells 
were prepared for FACS analysis by removal of the medium, washing with PBS and 
addition of 30 µl trypsin. The cells were incubated at 37°C for 5-10 min until the cells 
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detached from the plate and were resuspended in 170 µl 1% (w/v) BSA in PBS. The 
amount of positive cells was assessed in a flow cytometer using channels FL3 (mCherry) 
against FL4 (eGFP) or FL5 (eYFP). Debris was excluded by gating and only the cell 
population was measured until either 10000 events were detected or 60 s have passed. 
The results were exported into an Excel sheet by the accompanying MXP software and 
the values were sorted by a makro (6.2.2.) For evaluation the dilution was chosen were 
values were below 95% to avoid over saturation. Usually, a ratio to an appropriate 
control which was set to 1 was built in order to compare between experiments. 
 
4.2.6.2. WESTERN BLOT 
Protein samples were separated by reducing Tris-glycine sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE). Therefore, self-casted SDS gels were 
prepared by pouring first the resolving gel and putting a layer of isopropanol on top of it 
until it polymerized. In a next step, the isopropanol was removed, the stacking gel was 
poured on top and a comb was inserted (Table 4-16). For analysis of AAP expression 
HEK293T cells were transfected with 2.6 µg of the AAP expression plasmid as described 
in 4.2.5.2. Likewise, cells were harvested two days later and the cell pellet was taken up 
in 100 µl PBS. The samples were mixed with 2xSDS buffer and boiled for 5 min at 95°C. 
They were cooled down on ice, spun down shortly and 15 µl of a 1:5 dilution was loaded 
per well. For protein size determination, 5 µl of a protein ladder was loaded. The SDS gel 
was run at 90 V until the running front has entered the resolving gel and was then set to 
120 V until the running front has just run out. The proteins were transferred onto a 
nitrocellulose membrane by semi-dry blotting. Therefore, a stack of three Whatman 
paper sheets cut to size were soaked in blotting buffer and placed onto the blotting 
device. Soaking and placing was then performed for the membrane, the gel and three 
more Whatman paper sheets. Air bubbles were removed by rolling over the pile and 
blotting occurred at 4°C for 1 h at 100 mA per membrane. Then, the device was 
disassembled, the membrane was blocked in 5% milk in TBST for 1 h at room 
temperature and the primary antibody was incubated shaking at 4°C overnight. The next 
day the membrane was washed three times with TBST for 5 min each and the secondary 
HRP coupled antibody was added for 1 h at room temperature. As before, three washing 
steps were performed and the blot was developed by addition of the ECL developing kit 
reagent. Luminescence was detected by film and developed. AAP expression was 
detected by its HA-tag and for comparison actin was stained as a housekeeper (Table 4 
17). 
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TABLE 4-16: SDS GEL FOR WESTERN BLOT 
Resolving gel (5ml) 12% Stacking gel (2ml) 5% 
ddH2O 2.15 ml ddH2O 1.46 ml 
Acrylamide (19:1) 1.5 ml Acrylamide (19:1) 250 µl 
1.5 M Tris (pH 8.8)/  
0.4% SDS 
1.25 ml 0.5 M Tris (pH 6.8)/ 
0.4% SDS 
250 µl 
10% SDS 50 µl 10% SDS 20 µl 
1% APS 50 µl 1% APS 20 µl 
TEMED 2 µl TEMED 2 µl 
 
 
4.2.6.3. DOT BLOT 
In order to assess the capability of building intact particles a dot blot under native 
conditions was performed. A nitrocellulose membrane was cut to size, soaked 10 min in 
PBS and the Bio-Dot® SF Microfiltration Apparatus was assembled according to 
manufacturer´s instruction. Then, 15 µl of untreated crude lysate or 15 µl of heated crude 
lysate were applied to the membrane. The native crude lysate contained assembled 
particles which were thought to dissemble upon heating 100 µl for 5 min at 95°C. A 
vacuum was applied and the samples were soaked through the membrane. After two 
washing steps with 100 µl PBS the device was disassembled and the membrane was 
blocked for 1 h at room temperature with 5% milk in TBST. The primary antibody was 
incubated for 2-3 h at room temperature. Comparable to western blot the membrane was 
washed and incubated with the secondary antibody. The chemo luminescence was 
either detected by development with film or by digital imaging with the intas system.  
 
TABLE 4-17: LIST OF ANTIBODIES USED 
Antibody Species origin Dilution source Secondary 
antibody 
Adk1 mouse 1:10 (Kuck, Kern, and 
Kleinschmidt 2007) 
Goat anti-mouse 
A20 mouse 1:10 (Wistuba et al. 1995) Goat anti-mouse 
Adk4 mouse 1:10 (Kuck, Kern, and 
Kleinschmidt 2007) 
Goat anti-mouse 
Adk5 mouse 1:10 (Kuck, Kern, and 
Kleinschmidt 2007) 
Goat anti-mouse 
Adk6 mouse 1:10 (Sonntag et al. 2011) Goat anti-mouse 
Adk8 (3) mouse 1:10 (Sonntag et al. 2011) Goat anti-mouse 
Adk9 mouse 1:10 (Sonntag et al. 2011) Goat anti-mouse 
Anti-VP rabbit 1:200 61084, Progen 
Biotechnik GmbH 
(Heidelberg, Germany) 
Donkey anti-rabbit 
B1 mouse 1:10 (Wistuba et al. 1995) Goat anti-mouse 
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anti-HA mouse 1:200 sc-7392, Santa Cruz 
Biotechnology 
(Heidelberg, Germany) 
Goat anti-mouse 
anti-β-actin mouse 1:200 sc-47778, Santa Cruz 
Biotechnology 
(Heidelberg, Germany) 
Goat anti-mouse 
HRP coupled 
goat anti-
mouse 
goat 1:10000 115-035-003, Jackson 
ImmunoResearch 
Laboratories (West 
Grove, USA) 
- 
HRP coupled 
donkey anti-
rabbit 
donkey 1:10000 GE Healthcare 
(Chalfont St. Giles, 
UK) 
- 
All hybridoma supernatants detecting free VPs (B1) and assembled particles (Adk, A20) were a kind gift by 
Jürgen A. Kleinschmidt. 
 
4.2.7. IN VIVO SELECTION AND VALIDATION 
 
4.2.7.1. IN VIVO SELECTION ON STELLATE CELLS 
A viral capsid library encompassing serotypes 1, 2, 3b, 4SO, 5SO, 6, 7, 8, 9 and rh10 
was generated by DNA family shuffling. The plasmid library was transfected into 80 
plates and the virus was produced by CsCl gradient centrifugation (4.2.5.5). In 
collaboration with the laboratory of Holger Willenbring (University of California, San 
Francisco, USA) 5x1011 vector genomes were injected into one Lrat-Cre; ZsGreen 
mouse (Mederacke et al. 2013; Madisen et al. 2010). In this mouse model, the Cre 
recombinase is expressed under the stellate cell-specific lrat promoter. As a 
consequence, stellate cells will be ZsGreen positive. After 24 h, the mouse was perfused 
(Mederacke et al. 2015) and stellate cells were isolated based on FACS sorting. The 
cells which were double positive for ZsGreen and vitamin A were collected. Stellate cells 
store vitamin A which in turn can be excited by a violet laser. The sorted cells were 
processed for DNA isolation which then could be used to perform a PCR based rescue 
of the capsid genes. For this a test PCR was run initially to identify the optimal template 
volume. Therefore, 0.25 µl phusion HS II polymerase were mixed with 5 µl GC buffer, 
0.75 µl #822 primer (10 µM), 0.75 µl #823 primer (10 µM), 0.75 µl DMSO and 0.5 µl 
dNTPs (10 mM). The mix was filled up with water to 22.5 µl and 2.5 µl undiluted or 
diluted template were added. The condition which yielded the most prominent band was 
used for a large-scale PCR using five to ten times the mix described above. In case that 
the PCR product did not yield enough material a nested PCR under the same conditions 
was performed using primers #824 and #826 and a 1:10 dilution of the undigested PCR 
product as template. The samples were then purified, digested by PacI and AscI and 
cloned back into a replication competent backbone as seen in 4.2.4.5. In contrast to the 
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generation of an initial library only ten instead of 20 electroporations were performed. 
Accordingly, a ligation reaction with a total volume of 20 µl was set up with 569.5 ng 
insert and 430.5 ng insert, respectively. A secondary viral library was produced, injected 
and recovered. In total four rounds of selection were performed. After each round, single 
clones were sequenced and analysed with Salanto as described in 4.2.4.6. As the C-
terminal enrichment differed from round three to round four the fourth round was 
repeated with two more mice. For validation, the sequences were grouped and two 
chimeras were randomly chosen from each group for further subcloning into the helper 
context #1544 via PacI and AscI digestion. This allowed for packaging of an eYFP 
(#552) reporter by transfection of 15 plates per construct and purification via iodixanol 
gradient centrifugation (4.2.5.4). For validation 1x1011 vector genomes (vg) were injected 
per mouse with three mice per variant. Ten days later, the liver tissue was fixed in 10% 
formalin, slices were generated and stained for indicated markers. The animal work and 
stainings were performed in the Willenbring laboratory and PCR rescues, sequence 
analysis and virus production in the Grimm laboratory.  
The lead candidate AH3-5 was further validated in collaboration with the laboratory of 
Steven Dooley (University Hospital Mannheim, Germany). Four female BALB/cJRj mice 
18 weeks old were injected with 1x1011 and ten days later the livers were perfused. The 
four indicated cell types were isolated from each liver, cultivated and stained for YFP.  
 
4.2.7.2. BULK VALIDATION BY NEXT-GENERATION SEQUENCING 
In order to test more chimeric variants in parallel an approach based on next-generation 
sequencing (NGS) was chosen. This was done in close collaboration with a fellow PhD 
student in the Grimm Laboratory, Jonas Weinmann. In his work he already generated a 
library encompassing the twelve serotypes as well as various peptide insertion variants 
where each variant packaged an individual barcode. This library was injected into mice 
and organs of interest were extracted followed by DNA and RNA isolation. He 
established the protocols and scripts required for the NGS workflow and the subsequent 
analysis. In the screen presented in this study an extended library was generated 
encompassing published benchmarks, 28 chimeric variants selected on stellate cells and 
presented in this work (named AH) as well as chimeric variants selected on different 
muscle types (named JEA) from another colleague. Therefore, a barcoded YFP variant 
was packaged into 28 randomly chosen chimeric variants as described in section 
4.2.5.3. The barcode consisted of a 15 nucleotide stretch in the 3´ untranslated region of 
the YFP reporter. All variants were produced separately and at the end equal virus 
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amounts were pooled, concentrated and buffered to PBS. After titration of both, the initial 
library mentioned earlier, which already contained AH3-5, and the extended one, they 
were combined in such a manner that equal capsid amounts are represented. Six female 
C57BL/6J mice six weeks old were injected with 1.57x1012 vector genomes per mouse 
representing 1x1010 particles per variant with a total of 157 variants. These mice were 
used to regard the biodistribution. In addition, four female BALB/c mice 30 weeks old 
were injected with a comparable dose in collaboration with the Dooley laboratory. One 
week later the livers were perfused and different liver cell types were isolated (section 
4.2.7.3). The cell pellets were fed into the pipeline for NGS sequencing by J. Weinmann 
and the details about processing and normalization can be found in his PhD thesis.  
 
4.2.7.3. SINGLE CELL TYPE ISOLATION FROM ONE MOUSE LIVER 
The mice were anesthetized and perfused with a two-step collagenase perfusion 
technique through the vena cava (Mederacke et al. 2015). Hepatocytes were pelleted by 
a short centrifugation step at 50 x g for 2 min. The hepatocytes were loaded on a percoll 
gradient to separate live and dead cells. Live cells were recovered, counted and snap-
frozen. The non-parenchymal cells (NPC) were contained in the supernatant of the first 
spin to pellet hepatocytes. The initial slow spinning step was repeated to remove further 
hepatocytes. Then the NPC fraction was pelleted at 300 x g for 10 min and resuspended 
in 13 ml DMEM w/o phenol red. The cells were transferred into a 15 ml tube and pelleted 
as before. The pellet was then filled up to 1.2 ml with DMEM w/o phenol red and mixed 
with 4.8 ml 30% histodenz solution (15 g histodenz in 40 ml DPBS).  Carefully, 2 ml PBS 
were layered on top and the gradient was centrifuged at 1500 x g for 23 min without 
break and acceleration 4. The NPCs were collected at the histodenz/ PBS interface and 
added to 5 ml MACS buffer (0.5% BSA, 2 mM EDTA in PBS). The cells were pelleted as 
before and resuspended in 365 µl MACS buffer. After addition of 15 µl beads and 25 µl 
Fcblock the cells incubated for 15 min at 4°C with slight shaking every 5 min. The cells 
were washed by addition of 4 ml MACS buffer and pelleted as above. The resulting pellet 
was incubated with 20 µl secondary beads and 380 µl MACS buffer. After equilibration of 
the MS columns (Miltenyi Biotech, Germany) the sample was washed, resuspended in 
1 ml MACS buffer and was applied onto the column according to manufacturer´s 
instructions. The flow through was stained for the next marker and the eluate contained 
the targeted cell population. The Fcblock was added for the first staining only. 
Subsequently, stellate cells, Kupffer cells (CD11b) and LSECs (CD146) were isolated, 
counted and snap-frozen. The MACS based sorting for stellate cells occurred with an 
unpublished marker identified by the Dooley laboratory (manuscript in preparation). 
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4.2.8. PROOF OF PRINCIPLE FOR BARCODED LIBRARIES 
 
4.2.8.1. IN VITRO VALIDATION 
Libraries were generated by DNA family shuffling and were transferred into the standard 
pSSV9 backbone. The generated vectors from 4.2.3.3 were used to transfer three 
libraries by PacI and AscI digestion. The 289 library was tagged with BC289, the 1-10 
library was inserted into BCori and 1789rh10 was transferred into BCnew (see 4.2.3.3). 
The 289 library was previously generated (Herrmann 2014), the 1-10 library was created 
for the selection (see 4.2.7.1) and the 1789rh10 was generated during this study. All 
three libraries were transferred in parallel setting up the ligation in 10 µl using 215.3 ng 
backbone and 284.8 ng insert with two electroporations. The acceptor backbone was 
778-BC1 (4.2.3.3). The resulting plasmid library was recovered by mini prep using a 
commercial kit. As described in 4.2.5.2 crude lysates were produced for each individual 
library. For the in vitro validation 50 µl crude lysate were used to transduce HEK293T 
cells in one well of a 6-well plate. All libraries were individually transduced and 
additionally in combination with equal library amounts within 50 µl. After 24 h the cells 
were washed with PBS, resuspended in 1 ml PBS and transferred to a 1.5 ml reaction 
tube. The samples were spun at 1700 x g for 10 min, the supernatant was removed and 
the cell pellet was resuspended in 120 µl DirectPCR lysis reagent with proteinaseK being 
diluted 1:100 from a 20 mg/ ml stock solution. The cells were lysed overnight at 56°C 
shaking in 0.5 ml tubes. The next day, the samples were transferred into PCR tubes and 
proteinaseK was inactivated at 85°C for 45 min. This mixture was then used to perform a 
PCR rescue as described in 4.2.7.1 with #833 as forward primer and different 
combinations of reverse primer to either amplify the whole cap population (rescueBC1) 
or to recover caps from a single library (rescueBC289, rescueBCnew (1789rh10), 
rescueBCori). The PCR program was comparable except that annealing occurred at 
61°C. For subcloning a digestion with HindIII and NdeI was performed thereby 
subcloning cap with the respective library barcode back into an appropriate replication 
competent context. Note that a transfer by PacI and NdeI was unsuccessful due to a 
possible overlap of the sticky ends. For the ligation a 3:1 ratio was kept with 45 ng insert 
and 62.1 ng vector in a total volume of 10 µl. The next day 2 µl were electroporated and 
after the recovery period the bacteria were spun at 4000 x g for 5 min. The supernatant 
was poured off, the pellet was resuspended in the remaining liquid and plated out. 
Positive clones confirmed by colony PCR using primers #822 and #823 were sent for 
sequencing with #823. The present barcode was identified by sequencing with the help 
of two scripts (6.3) running on Python 3.5 and clones were analysed by Salanto as well.  
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4.2.8.2. IN VIVO VALIDATION 
In order to see if it is possible to track the library origin in vivo a total of four barcoded 
libraries were produced namely 289, 1-10 and two newly generated 1-10 libraries. The 
two newly generated 1-10 libraries were different as one was generated with the same 
conditions as the previous library (“new”) and the other one had reduced amounts of two 
serotypes (“red”). As the first 1-10 library had a bias towards AAV1 and AAV6 they were 
taken as one portion for the DNase I digest therefore every serotype encompassed 1/9 
of the total reaction instead of 1/10 as before. The libraries were transferred by PacI and 
AscI digestion into a backbone already containing BC1 as the general barcode and the 
respective library barcodes BC289, BCori, BCred and BCnew. For the ligation 645.9 ng 
vector and 854.4 ng insert in a total volume of 30 µl were mixed. In total, 15 
electroporations were performed per library. All four barcoded libraries were produced 
separately via CsCl gradient centrifugation and titrated (4.2.5.5, 4.2.5.7). Equal amounts 
of each library were mixed and 2.09x1011 vg were injected into two female NMRI mice six 
weeks of age. The mice were acquired from Janvier and all experiments were conducted 
by operators bearing a FELASA category B certificate according to European regulations 
at the “Klinisch Experimenteller Bereich (KEB)” at University Heidelberg. The 
experiments were approved by German authorities (35-9185.81/G-89/16, "Selektion 
neuer AAV-Kapside in adulten Mäusen"). After 48 h the mice were sacrificed and liver, 
kidney, muscle, lung and heart were extracted and snap-frozen in liquid nitrogen. The 
gDNA was isolated with the help of the DNeasy Blood & Tissue kit according to 
manufacturer´s instructions. The tissue was lysed in buffer ATL including the optional 
addition of 1:100 diluted reagentDX with the tissue lyser. Elution occurred in 150 µl 
elution buffer and different volumes were tested for cap recovery with the primer pair 
#833 and rescueBC1. As before, PCRs were run to rescue cap, digestion occurred with 
HindIII and NdeI and after ligation two electroporations for each organ were performed. 
For each organ 96 clones were sequenced and the barcode was determined with the 
help of the scripts (6.3). 
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6. SUPPLEMENTAL INFORMATION 
 
6.1. SUPPLEMENTAL FIGURES 
6.1.1. OPTIMIZATION OF DNA FAMILY SHUFFLING 
 
 
 
 
 
FIGURE 6-1: SALANTO ANALYSIS LIBRARIES C1 AND D1-3 
The complete analysis for 10 chimeric clones is depicted. (A) The average fragment length for 
each parental serotype of each library was determined and presented as a bar graph. (B) 
Accordingly, the sum of fragments is shown. The data set was adapted from (Herrmann et al. 
manuscript in preparation). 
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6.1.2. INADVERTENT SHUFFLING OF AAP 
 
 
 
FIGURE 6-2: SEQUENCE ANALYSIS OF THE CHIMERIC AAPS 
The distribution of all parental sequences of the chimeric AAPs was analyzed with Salanto. Each 
bar represents the nucleotide sequence of AAP for one clone and the parental stretches are 
colored accordingly. If several possibilities exist and no clear parent can be identified the 
sequence is assigned as indetermined (indet). Mutations (mut) are highlighted in white. The 
triangulars indicate chimeric AAPs which were not compatible with the AAV2 mutant. This data 
set was adapted (Herrmann, Grosse, et al. 2018). 
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TABLE 6-1: RESCUE OF DIFFERENT PARENTAL AAP KNOCKOUTS 
 AAVmut 
AAP
a
 1 3 4 5 6 7 8 9 rh10 
12 82.2±6.9 2.1±0.6 23.0±1.1 83.5±0.9 36.8±2.2 12.5±0.5 37.4±3.2 43.6±1.6 1.75±0.2 
16 - - 26.0±4.2 2.0±0.0 - - 0.0±0.0 0.0±0.0 - 
18 - - 22.0±8.8 2.5±0.7 - - 0.0±0.0 0.0±0.0 - 
19
b
 - - 
65.0±12.
7 
84.7±24.
9 
- - 72.7±8.1 87.7±7.1 - 
21 - - 
85.0±16.
9 
15±2.8 - - 0.0±0.0 0.0±0.0 - 
22 - - - 61.0±5.7 - - 5.0±0.7 2.3±0.2 - 
39
b
 
26.4±20.
3 
- - - - 10.0±5.0 
40.8±25.
6 
20.7±23.
8 
9.5±3.5 
45 89.5±2.5 - - - - 11.6±0.8 75.2±3.1 82.4±1.6 11.0±0.8 
51
b
 1.0±0.0 11.0±1.4 13.5±6.4 4.0±0.0 8.5±3.5 4.6±4.7 16.3±9.5 
17.3±18.
8 
- 
“Crude cell lysates were tested in MCF7 (AAV4) or SF539 cells (AAV1, 3, 5 to 9, rh10) (n ≥ 2). Positive cells were 
determined by flow cytometry and values (shown plus SD) were normalized to the respective AAV wild-type construct 
(always set to 100%). Grey, non-functional AAPs (< 5% activity); orange, intermediate performers (5 to 50%); green, high 
performers (≥ 50%).  
a
Numbers in this column refer to the labels of the chimeric AAP clones, not to AAV serotypes. 
b
These three clones were included since they barely crossed the 5% assay cutoff in Figure 2C.” 
 
This table was taken from (Herrmann, Grosse, et al. 2018). 
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6.1.3. AAV SELECTION ON STELLATE CELLS 
 
 
FIGURE 6-3: HOMOLOGY OF THE CAPSIDS 
The homology of the nucleotide sequence of ten different AAVs used in this study is depicted. An 
alignment was analyzed in Salanto and the difference in percentage (%) is depicted, i.e. the 
higher the homology, the brighter the color gets. (A) The alignment used the complete cap gene 
and the data is depicted as a heatmap. The scale is depicted below and is valid for all graphs. 
Orange boxes indicate the same combination. (B) The first 1100 bp of the cap gene were taken 
for the alignment. (C) The remaining nucleotides were analyzed likewise. (D) The scheme depicts 
the party used for the respective alignments. 
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FIGURE 6-4: AMINO ACID SEQUENCES SORTED BY SELECTION ROUND 
The amino acid sequences from the chimeras were monitored throughout the course of selection. 
Each bar represents the sequence of one clone and the parental distribution was colored 
according to the color scheme at the top. The fourth selection round was repeated with two more 
mice (B1 and B2).  
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FIGURE 6-5: THE VARIANTS TESTED IN THE NGS SCREEN 
The amino acid sequences of the variants tested within the NGS screen were assigned to their 
parental sequences. The numbers in front of the names indicate the position of the variant 
achieved in the ranking and the sequences were ranked accordingly. Variants which were newly 
sequenced to extent the repertoire are denoted with “N”.  
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FIGURE 6-6: GDNA PROFILES WITHOUT AAV5 
The graphs show the same dataset as in Figure 2-18 but for a better comparison AAV5 wild-type 
was removed from the analysis. 
6.1.4. OPTIMIZATION OF THE SELECTION PROCESS 
 
FIGURE 6-7: AMPLIFICATION WITH THE COMMON PRIMER  
PCR rescue using a common primer was performed on single-infected samples. Three different 
libraries were used to separately transduce HEK293T cells and the cap genes were recovered for 
further subcloning. The approximate last 800 bp were sequenced and the parental sequences 
were assigned according to the color code with Salanto. Adapted from (Herrmann et al. 
manuscript in preparation). 
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6.2.EXCEL MACROS APPLIED 
6.2.1. GENERATION OF COLORED TYPE ASSIGNMENTS 
After the type assignment was copied into Excel the following macro was run, column 
width was set to 0.5 and the resulting colored bars were copied and pasted into 
Powerpoint as a picture. The size was adjusted as seen in the figures. 
 
 
Dim Zelle As Range 
For Each Zelle In ActiveSheet.UsedRange 
If Zelle.Value = ">AAV1" Then 
Zelle.Interior.ColorIndex = 16 
End If 
If Zelle.Value = ">AAV1" Then 
Zelle.Interior.TintAndShade = 0.2 
End If 
If Zelle.Value = ">AAV2" Then 
Zelle.Interior.ColorIndex = 3 
End If 
If Zelle.Value = ">AAV2" Then 
Zelle.Interior.TintAndShade = 0.1 
End If 
If Zelle.Value = ">AAV3" Then 
Zelle.Interior.ColorIndex = 51 
End If 
If Zelle.Value = ">AAV3" Then 
Zelle.Interior.TintAndShade = 0.1 
End If 
If Zelle.Value = ">AAV4" Then 
Zelle.Interior.ColorIndex = 44 
End If 
If Zelle.Value = ">AAV5" Then 
Zelle.Interior.ColorIndex = 41 
End If 
If Zelle.Value = ">AAV5" Then 
Zelle.Interior.TintAndShade = 0.1 
End If 
If Zelle.Value = ">AAV6" Then 
Zelle.Interior.ColorIndex = 21 
End If 
If Zelle.Value = ">AAV6" Then 
Zelle.Interior.TintAndShade = 0.7 
End If 
If Zelle.Value = ">AAV7" Then 
Zelle.Interior.ColorIndex = 31 
End If 
If Zelle.Value = ">AAV7" Then 
Zelle.Interior.TintAndShade = 0.1 
End If 
If Zelle.Value = ">AAV8" Then 
Zelle.Interior.ColorIndex = 29 
End If 
If Zelle.Value = ">AAV8" Then 
Zelle.Interior.TintAndShade = 0.02 
End If 
If Zelle.Value = ">AAV9" Then 
Zelle.Interior.ColorIndex = 11 
End If 
If Zelle.Value = ">AAV9" Then 
Zelle.Interior.TintAndShade = 0.1 
End If 
 
 
If Zelle.Value = ">AAVrh10" Then 
Zelle.Interior.ColorIndex = 52 
End If 
If Zelle.Value = ">AAVrh10" Then 
Zelle.Interior.TintAndShade = 0.3 
End If 
If Zelle.Value = ">AAVpo.1" Then 
Zelle.Interior.ColorIndex = 10 
End If 
If Zelle.Value = ">AAVpo.1" Then 
Zelle.Interior.TintAndShade = 0.1 
End If 
If Zelle.Value = ">AAV12" Then 
Zelle.Interior.ColorIndex = 43 
End If 
If Zelle.Value = ">AAV12" Then 
Zelle.Interior.TintAndShade = 0.1 
End If 
If Zelle.Value = ">AAV4GA" Then 
Zelle.Interior.ColorIndex = 44 
End If 
If Zelle.Value = ">AAV4SO" Then 
Zelle.Interior.ColorIndex = 44 
End If 
If Zelle.Value = ">AAV4SO" Then 
Zelle.Interior.TintAndShade = 0.6 
End If 
If Zelle.Value = ">AAV4GA" Then 
Zelle.Interior.TintAndShade = 0.6 
End If 
If Zelle.Value = ">AAV5GA" Then 
Zelle.Interior.ColorIndex = 41 
End If 
If Zelle.Value = ">AAV5GA" Then 
Zelle.Interior.TintAndShade = 0.6 
End If 
If Zelle.Value = ">AAV5SO" Then 
Zelle.Interior.ColorIndex = 41 
End If 
If Zelle.Value = ">AAV5SO" Then 
Zelle.Interior.TintAndShade = 0.6 
End If 
If Zelle.Value = "indet" Then 
Zelle.Interior.ColorIndex = 15 
End If 
If Zelle.Value = "indet" Then 
Zelle.Interior.TintAndShade = 0.2 
End If 
If Zelle.Value = "MUT" Then 
Zelle.Interior.ColorIndex = 2 
End If 
Next Zelle 
  
End Sub 
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6.2.2. EXTRACTION OF TRANSDUCTION DATA 
 
To test for the transduction efficiency of AAVs having packaged a GFP reporter, FACS 
analysis was performed. After the run was complete the data was exported as an Excel 
sheet by the accompying MXP software. In the past, Joel Beaudouin designed a macro 
to extract different values such as “%gated” on the GFP channel or median intensity to 
simplify data analysis. 
 
Dim i As Integer 
Dim j As Integer 
 
    Sheets.Add 
    ActiveSheet.Name = "result" 
     
    For i = 1 To 12 
    For j = 1 To 8 
        Worksheets("result").Cells(j, i).Value = 
Worksheets("Result 1").Cells(9 + ((i - 1) + (j - 1) * 12) * 7, 
8) 
    Next 
    Next 
     
    Sheets.Add 
    ActiveSheet.Name = "result_positive cells" 
     
    For i = 1 To 96 
    'For j = 1 To 8 
        Worksheets("result_positive cells").Cells(i, 1).Value = 
Worksheets("Result 1").Cells(9 + ((i - 1)) * 7, 8) 
    'Next 
           
    Next 
Sheets.Add 
    ActiveSheet.Name = "result_x-mean" 
     
    For i = 1 To 96 
    For j = 1 To 8 
        Worksheets("result_x-mean").Cells(i, 1).Value = 
Worksheets("Result 1").Cells(9 + ((i - 1)) * 7, 10) 
    Next 
    Next 
     
    Sheets.Add 
    ActiveSheet.Name = "result_x-median" 
     
    For i = 1 To 96 
    For j = 1 To 8 
        Worksheets("result_x-median").Cells(i, 1).Value = 
Worksheets("Result 1").Cells(9 + ((i - 1)) * 7, 9) 
    Next 
    Next 
End Sub 
 
6.3. PYTHON SCRIPTS APPLIED 
 
6.3.1. REVERSE COMPLEMENTING SEQUENCING DATA 
In order to detect the library-specific barcode (section 4.2.3.3) the plasmids were 
sequenced with a reverse primer. As numerous sequencing files had to be regarded a 
code was kindly written by Mitja Kleider which extracted all sequences in a given folder 
to a separately saved text file in the reverse complemented orientation. 
#!/usr/bin/env python 
# coding: utf-8 
 
""" 
Merge all .seq files in a directory into one text file, ignore text behind ".seq" 
""" 
 
 
import glob 
import re 
import os 
 
try: 
    # Python2 
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    import tkFileDialog as fd 
except: 
    # Python3 
    import tkinter.filedialog as fd 
 
 
# which directory contains .seq files? 
directory = fd.askdirectory() 
 
result = [] 
for filename in glob.glob(os.path.join(directory, "*.seq")): 
    with open(filename) as f: 
        lines = f.readlines() 
        assert len(lines) == 2 
        result.append(">{}\n".format(os.path.basename(filename))) 
        reverse = lines[1].replace("\n","")[::-1] 
        complement = [] 
        for letter in reverse: 
            position =  "ACTGactgNn".find(letter) 
            if position == -1: 
                raise ValueError("unknown letter: {}".format(letter)) 
            complement.append("TGACtgacNn"[position]) 
        complement.append("\n") 
        result.append(''.join(complement)) 
    # empty line between files 
    result.append("\n") 
 
# write result to file 
with open(os.path.join(directory, "seqdata_reversecomplement.txt"), "w") as f: 
    f.writelines(result) 
 
 
 
6.3.2. BARCODE EXTRACTION FROM SEQUENCING DATA 
A second code by Mitja Kleider was written to sort the sequences into individual text files 
according to their barcode. Therefore, in an empty folder the text documents “patterns” 
and “source” were collected together with the code. “Patterns” contained the barcode 
name and sequence and “source” supplied the sequences to be analysed. After the 
script was run separate text files for each barcode where generated and in addition all 
sequences which could not be assigned where collected in “unknown”. These sequences 
were analyzed manually with the help of the chromatogram. 
#!/usr/bin/env python 
 
""" 
 
 
""" 
 
barcodes = {} 
 
# load patterns from patterns.txt 
with open("patterns.txt", "r") as f_patterns: 
    for line in f_patterns.readlines(): 
        # each line is one barcode, <name> <barcode> 
        name, code = line.split(" ") 
        # TODO check barcode for validity 
        barcodes[code.rstrip().upper()] = name 
 
output_files = {} 
for name in barcodes.values(): 
    output_files[name] = open(name+".txt", "w") 
output_files["unknown"] = open("unknown.txt", "w") 
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# load sequences from input.txt 
with open("input.txt", "r") as f_input: 
    for line in f_input.readlines(): 
        if line == "\n": 
            continue 
        if line[0] == ">": 
            sequence_name = line 
        else: 
            sequence = line.upper() 
 
            # look for patterns in sequence 
            num_found = 0 
            for code in barcodes.keys(): 
                if sequence.find(code) != -1: 
                    # write sequence to <name of pattern>.txt 
                    name = barcodes[code] 
                    output_files[name].write(sequence_name) 
                    output_files[name].write(sequence) 
                    output_files[name].write("\n") 
                    num_found += 1 
            assert num_found < 2, num_found 
            if num_found == 0: 
                # write unknown pattern to unknown.txt 
                output_files["unknown"].write(sequence_name) 
                output_files["unknown"].write(sequence) 
                output_files["unknown"].write("\n") 
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